- 1 Diversified Reporting Services, Inc.
- 2 RPTS NOBLEZA
- 3 HIF138000

4

5

- 6 MARKUP OF:
- 7 H.R. 7667, THE FOOD AND DRUG AMENDMENTS OF 2022;
- 8 H.R. 7666, THE RESTORING HOPE FOR MENTAL HEALTH AND
- 9 WELL-BEING ACT OF 2022;
- 10 H.R. 7233, THE KIDS CARES ACT;
- 11 H.R. 623, THE GABRIELLA MILLER KIDS FIRST RESEARCH ACT 2.0;
- 12 H.R. 3771, THE SOUTH ASIAN HEART HEALTH AWARENESS ACT OF
- 13 2021; AND
- 14 H.R. 5585, THE ARPA-H ACT
- 15 WEDNESDAY, MAY 18, 2022
- 16 House of Representatives,
- 17 Committee on Energy and Commerce,
- 18 Washington, D.C.

19

20

21

- The committee met, pursuant to call, at 10:07 a.m. in
- the John D. Dingell Room, Room 2123, Rayburn House Office
- 24 Building, Hon. Frank Pallone [chairman of the committee]
- 25 presiding.

26

27 Present: Representatives Pallone, Rush, Eshoo, DeGette,

Doyle, Schakowsky, Butterfield, Matsui, Castor, Sarbanes, 28 McNerney, Welch, Tonko, Clarke, Schrader, Cardenas, Ruiz, 29 Peters, Dingell, Veasey, Kuster, Kelly, Barragan, McEachin, 30 Blunt Rochester, Soto, O'Halleran, Rice, Craig, Schrier, 31 32 Trahan, Fletcher; Rodgers, Upton, Burgess, Latta, Guthrie, McKinley, Kinzinger, Griffith, Bilirakis, Johnson, Long, 33 Bucshon, Mullin, Hudson, Walberg, Carter, Duncan, Palmer, 34 Dunn, Curtis, Lesko, Pence, Crenshaw, Joyce, and Armstrong. 35 36 37 Staff Present: Lydia Abma, Policy Analyst; Vincent Amatrudo, FDA Detailee; Shana Beavin, Professional Staff 38 Member; Jesseca Boyer, Professional Staff Member; Hilary 39 Carruthers, HE Fellow; Waverly Gordon, Deputy Staff Director 40 and General Counsel; Jessica Grandberry, Staff Assistant; 41 Tiffany Guarascio, Staff Director; Perry Hamilton, Clerk; 42 Fabrizio Herrera, Staff Assistant; Stephen Holland, Senior 43 Health Counsel; Ed Kacsmarsk, Policy Analyst; Zach Kahan, 44 Deputy Director Outreach and Member Service; Saha Khaterzai, 45 Professional Staff Member; Mackenzie Kuhl, Digital Assistant; 46 47 Una Lee, Chief Health Counsel; Jerry Leverich, Chief Cunsel, Communic vations and Technology; Meghan Mullon, Senior Policy 48 Analyst; Juan Negrete, Junior Professional Staff Member; Joe 49 Orlando, Policy Analyst; Lino Pena-Martinez, Policy Analyst; 50 Kaitlyn Peel, Digital Director; Caroline Rinker, Press 51 Assistant; Chloe Rodriguez, Clerk; Kylea Rogers, Policy 52

- 53 Analyst; Andrew Souvall, Director of Communications,
- Outreach, and Member Services; Rick Van Buren, Senior Health
- 55 Counsel; Charlton Wilson, Fellow; Caroline Wood, Staff
- 56 Assistant; Alec Aramanda, Minority Professional Staff Member,
- 57 Health; Kate Arey, Minority Content Manager and Digital
- Assistant; Sarah Burke, Minority Deputy Staff Director; Seth
- 59 Gold, Minority Professional Staff Member, Health; Grace
- Graham, Minority Chief Counsel, Health; Nate Hodson, Minority
- Staff Director; Sean Kelly, Minority Press Secretary; Peter
- 62 Kielty, Minority General Counsel; Emily King, Minority Member
- 63 Services Director; Bijan Koohmaraie, Minority Chief Counsel,
- 0&I Chief Counsel; Clare Paoletta, Minority Policy Analyst,
- 65 Health; Kristin Seum, Minority Counsel, Health; Kristen
- 66 Shatynski, Minority Professional Staff Member, Health; and
- Olivia Shields, Minority Communications Director.

- *The Chairman. The Energy and Commerce Committee will
- 70 come to order.
- 71 We are meeting today to consider six bills.
- Due to the COVID-19 public health emergency members can
- 73 participate in today's markup either in person or remotely,
- 74 via online video conferencing.
- 75 For members participating remotely, your microphones
- 76 will be set on mute for the purpose of eliminating
- 77 inadvertent background noise. But members participating
- 78 remotely will need to unmute their microphone each time that
- 79 you wish to speak. So please note that, once you unmute your
- 80 microphone, anything that is said in Webex will be heard over
- 81 the loudspeaker in the committee room, and subject to be
- 82 heard by the livestream and C-SPAN.
- Additionally, I ask that members participating remotely
- use the "raise hand' 'feature of the software platform --
- *Voice. [Inaudible.]
- *The Chairman. What was that?
- *Voice. I think somebody unmuted themselves.
- *The Chairman. Oh, they unmuted themselves.
- [Laughter.]
- *The Chairman. Additionally, I ask that members
- participating remotely use the "raise hand' ' feature of the
- 92 software platform when you wish to be recognized, including
- 93 to give an opening statement or to offer an amendment.

- Now, during recorded votes you will need to unmute
- yourself to respond to the clerk once your name is called.
- 96 In responding to the clerk I ask that, instead of just saying
- 97 aye or no, that you respond with a phrase like, "Frank
- Pallone from New Jersey votes aye.' \ And this will provide
- 99 additional time for the voting member to be identified and
- 100 made visible on the platform.
- And since members are participating from different
- locations at today's markup, all recognition of members will
- 103 be in the order of full committee seniority.
- During this markup amendments will be sent to members
- 105 electronically. Members participating in person should not
- bring paper copies of their amendments to the clerk's desk.
- 107 If a member participating in person would like a paper copy
- of an amendment or bill, please alert staff during the
- 109 consideration of the amendment or the bill.
- 110 Amendments and motions should be sent to Chloe Rodriguez
- and Perry Hamilton, and documents for the record to Caroline
- 112 Wood at the email addresses we have provided to staff.
- 113 So I am now going to recognize myself for three minutes
- 114 for an opening statement. We will have opening statements,
- three minutes, from the full committee chair and ranking
- member and the Health Subcommittee. These are all health
- bills, so the subcommittee ranking member and chair on
- 118 Health, and then any other member can have an opening

- 119 statement for one minute, if they desire.
- So I will start with myself for three minutes, and say
- 121 that, as I said, we are marking up six bipartisan health
- bills including legislation to reauthorize and improve
- programs at the FDA, address the mental health and substance
- use disorder crisis, and establish President Biden's ARPA-H
- 125 initiative.
- We will begin today by taking up the food and drug
- amendments of 2022. This is comprehensive bipartisan
- legislation to reauthorize FDA's user fee program and improve
- 129 FDA's review of drugs, biologics, and medical devices.
- The bill will also reduce drug costs, improve program
- integrity and oversight in the accelerated approval program,
- 132 and improve diverse representation in clinical studies.
- With the ongoing infant formula shortage, I am pleased
- the amendment in the nature of a substitute will extend an
- authority first provided in the 21st Century Cures Act that
- will allow FDA to retain top scientists and high-level
- professionals not just for its drug, biologic, and medical
- device centers, but also the center for food safety and
- applied nutrition, and other product areas regulated by the
- 140 agency.
- While we certainly have more work to do in this area,
- including this provision today will improve the agency's
- 143 oversight of these products, including infant formula, and

- help avoid tragedies that led to the death of two infants due
- 145 to contaminated formula.
- Now, this bill has been crafted with consensus in mind
- from the start, as it is critical we pass this on time before
- 148 FDA funding runs out. We don't want them sending out the
- 149 pink slips.
- Next, after the FDA user fee bill, we will turn to the
- 151 consideration of the Restoring Hope for Mental Health and
- 152 Well-Being Act, which I introduced with Ranking Member
- Rodgers. This is a comprehensive, bipartisan package that
- includes provisions from members of the committee on both
- sides of the aisle. It reauthorizes more than 30 programs
- that aim to help Americans in need, providing access to
- 157 critical mental health and substance use disorder support and
- 158 care.
- 159 We will consider two amendments to the mental health
- 160 package that represents months of bipartisan negotiation on
- 161 two important bills: the MAT Act and the MATE Act. And
- 162 together, these policies will increase access to medication-
- 163 assisted treatment for opioid use disorder and substance use
- disorder treatment, as well as help address some of the
- 165 stigma associated with addiction. And I am glad that we are
- able to work together between our subcommittee markup and
- 167 today's markup on these two amendments, and I am hopeful they
- 168 will be included in our mental health package as it advanced

- 169 out of committee.
- 170 We will also consider another amendment that will help
- strengthen mental health parity by providing funding to
- states to implement and enforce parity. This is critical in
- illuminating disparities in insurance coverage and treatment.
- 174 And I must say that this committee has worked for years to
- try to address this parity issue, and we constantly have to,
- 176 you know, look back and see what else needs to be done. So
- 177 this is what we feel needs to be done.
- The committee will also vote on three bipartisan bills
- and the bipartisan Advanced Research Project Agency Health
- 180 Act, or ARPA-H, led by Chairwoman Eshoo. And this bill will
- 181 create an independent ARPA-H that accelerates biomedical
- innovation and makes transformative breakthroughs in the most
- 183 challenging diseases.
- So I look forward to advancing all six of the bipartisan
- 185 bills, and I really thank wholeheartedly our Ranking Member
- 186 Rodgers for her shared commitment to making this bipartisan
- 187 markup possible.
- Thank you, and I will yield to the ranking member.
- *Mrs. Rodgers. Thank you, Mr. Chairman, Health
- 190 Subcommittee Chair Eshoo, and Subcommittee Republican Leader
- 191 Guthrie, for your leadership on these solutions today.
- In the FDA Act we are taking action to lower health care
- 193 cost, spur more innovation, secure our supply chains, and

- 194 provide hope to patients who believe in the promise of
- 195 America: innovation for new cures, breakthrough drugs, and
- 196 access to treatments. For them we are committed to
- 197 delivering the user fee agreements on time.
- In addition, we are advancing the Restoring Hope for
- 199 Mental Health and Well-Being Act. This is the first major
- 200 effort to address the mental health crisis that has been
- 201 caused by government-driven lockdowns and school closures
- 202 during the pandemic.
- Like many other communities, Spokane, Washington is
- 204 recognizing May as Mental Health Awareness Month, and the
- 205 worsening mental health challenges we now face.
- 206 Children, especially, are more stressed, anxious, and
- 207 depressed than ever. Our message to them is that they
- 208 matter.
- 209 Our solutions will help communities make a difference in
- 210 people's lives, to turn despair into hope. This package
- includes reauthorizing programs like the Garrett Lee Smith
- 212 Memorial Act for youth suicide prevention, and programs to
- 213 help people with severe mental illness.
- It also helps moms by supporting care for maternal
- 215 health and substance use disorders, which are among the
- leading causes of death for pregnant and post-partum women.
- Our goal is to help save lives, and support women at every
- 218 stage of pregnancy and beyond.

- I want to personally thank Chairman Pallone,
- wholeheartedly, for helping lead this package which includes
- provisions by members on both sides of the aisle, and I am
- grateful for your leadership on mental health, and your
- 223 commitment to working with me.
- As we move forward there are improvements we are still
- working on, and I greatly appreciate the chairman's
- willingness to do so before the floor vote.
- Finally, regarding ARPA-H, because Congress already
- appropriated money for this, now is the time for us to
- 229 provide guardrails for the agency to be a success. After
- extensive negotiations with the majority, the amendment today
- 231 will put ARPA-H on the right path, with a targeted mission,
- increased accountability, and transparency, and a laser focus
- on promoting American innovators.
- Overall, we have a lot of meaningful, bipartisan bills
- 235 before us. This is the rich history of our committee, to
- 236 find solutions on the most pressing issues before us as a
- 237 nation.
- 238 Again, a big thank-you to Chairman Pallone, the
- committee members, and all of our committee staff, who have
- 240 worked tirelessly, especially over the last few weeks, to get
- us to this place today. Let's keep building on this on
- 242 behalf of those that we serve.
- 243 I yield back.

- *The Chairman. Thank you, Mrs. Rodgers. And I want to
- now recognize Ms. Eshoo, chairwoman of the Subcommittee on
- 246 Health for three minutes.
- And obviously, much of what we are doing today comes
- from both her and Ranking Member Guthrie. So thank you, and
- 249 I yield to the chairwoman.
- *Ms. Eshoo. Thank you, Mr. Chairman. Today our
- committee marks up, as has been stated, six bipartisan bills.
- 252 First, the Food and Drug Amendments of 2022, sponsored
- by myself and ranking member of the Health Subcommittee, Mr.
- Guthrie. It includes user fee agreements for both drugs and
- 255 medical devices. It also includes wider legislation to speed
- 256 the discovery of more cures, improve patient representation
- 257 in clinical trials, and enhance the FDA's ability to fulfill
- their vital mission of ensuring the safety, efficacy, and
- quality of America's drugs and medical devices.
- The next bill is the Restoring Hope for Mental Health
- 261 and Well-Being Act by Chairman Pallone and Ranking Member
- 262 McMorris Rodgers. This legislation reauthorizes more than 30
- 263 important programs, from SAMHSA to HRSA, to supplying more
- 264 resources and support for mental health care and substance
- use disorder across the country.
- We will also mark up the KIDS CARES Act from
- Representatives Hudson and Kuster to improve mental health
- 268 screening for at-risk youth in the criminal justice system

- and in schools, under the Medicaid programs.
- I support -- obviously, support these bipartisan mental
- health bills, but I want to caution that our work to address
- the mental health crisis in our country is not done yet,
- 273 because we do not have a comprehensive plan for children and
- adolescents.
- Today we are moving forward ARPA-H. This bipartisan
- bill has been a top legislative priority of mine, as everyone
- 277 knows, and would establish the Advanced Research Projects
- 278 Agency of Health as an independent agency within HHS.
- I thank the chairman of the full committee, and I thank
- the Republican Leader Rodgers for working with me on today's
- amendment in the nature of a substitute to ensure that the
- 282 legislation creates a responsible ARPA-H with strict
- 283 deliverables and clear lanes of authority to avoid
- 284 duplication in our research programs.
- 285 Finally, we are marking up two important bills focused
- on medical research.
- 287 And I would just close on this note, that the -- this
- 288 markup is the culmination of months of work by committee
- 289 members. I think that, together, we have crafted a set of
- 290 bills that are worthy of the American people.
- 291 And with that I yield back, Mr. Chairman.
- *The Chairman. Thank you, Chairwoman Eshoo, and I now
- 293 would recognize the ranking member of the subcommittee, Mr.

- 294 Guthrie, for three minutes.
- 295 *Mr. Guthrie. Thank you, Mr. Chair.
- Today we are considering six pieces of legislation that
- 297 passed the Health Subcommittee last week. Two of these bills
- 298 address crucial parts of our health care system, and are
- 299 designed to help address access to lifesaving health care
- 300 services for those in need.
- First, H.R. 7666, the Restoring Hope for Mental Health
- and Well-Being Act, introduced by the leaders of this
- 303 committee, would reauthorize key Federal programs and promote
- 304 access to this -- to behavioral health care and comprehensive
- 305 services for those seeking help overcoming substance use
- 306 disorder.
- We saw throughout the pandemic just how important access
- 308 to these services can be, especially in-person counseling
- 309 service and other wraparound services for those with mental
- 310 illness or substance use disorder. Onerous COVID-19
- 311 lockdowns created roadblocks for hundreds and thousands of
- 312 Americans to access these lifesaving services overnight.
- 313 We saw the highest number of recorded overdose deaths in
- a single calendar year in 2021. Most of these deaths could
- 315 be attributed to synthetic opioids, including fentanyl
- analogs, and are being trafficked into the United States
- 317 through our Southwest border, so we need to permanently --
- 318 act now to permanently schedule fentanyl-related substances

- 319 and get these poisons off our streets. The HALT Fentanyl
- 320 Act, championed by Mr. Latta and Griffith, would be -- would
- 321 permanently schedule fentanyl-related substances as schedule
- one drugs.
- Too bad we are not having that today, but we can act on
- 324 policies like the HALT Fentanyl Act, whilst also promoting
- ideas that help individuals with a substance use disorder
- gain access to comprehensive treatment and recovery services,
- and I am proud that legislation like my bill, the Substance
- 328 Use Prevention, Treatment, and Recovery Support Services
- 329 Block Grant Act of 2022, was included. This would
- reauthorize critical for -- programing designed to help
- 331 states address the unique needs of the communities with
- 332 substance use disorder.
- I want to thank Representative Tonko for leading on this
- 334 bill, as well as Representative McKinley for his support on
- 335 this important bill.
- We are also voting to reauthorize the FDA user fee
- 337 agreements in this -- from that this committee and,
- 338 ultimately, the entire House and Senate are charged with
- reauthorizing every five years. It is critically important
- that Congress conduct oversight and, ultimately, allows the
- FDA to collect fees from industry in exchange for timely
- review of drug and device applications, which, in turn, helps
- 343 patients access new medical products as quickly and safely as

- possible.
- The FDA Act of 2022, which passed the Health
- 346 Subcommittee unanimously last week, will preserve access to
- lifesaving therapies, incentivize innovation in our medical
- 348 supply chains.
- I urge my colleagues to support these bills, and I yield
- 350 back.
- *The Chairman. Thank you, Mr. Guthrie.
- Now, do any other members want to give an opening
- 353 statement for a minute?
- I will -- yes, Mr. Doyle is recognized.
- 355 *Mr. Doyle. Thank you, Mr. Chairman. I want to bring
- up an important issue that, while we are not focused on
- today, I hope we can make progress on passing this Congress,
- and that is H.R. 3932, the PASTEUR Act.
- 359 This bipartisan legislation ensures that new antibiotics
- 360 are developed as antibiotic resistant infections rise. Drug-
- 361 resistant infections already kill more people than HIV or
- 362 malaria each year, including over 35,000 Americans, with a
- 363 cost of 21 to 34 billion to the U.S. health care system.
- Despite this, few new antibiotic drugs are coming to market.
- 365 The way the pharmaceutical market is structured discourages
- 366 research and development because of the small profit margin
- on antibiotics. In fact, many pharmaceutical companies have
- 368 halted their antibiotic divisions altogether.

- The PASTEUR Act would establish a subscription style
 model offering antibiotic developers an upfront payment in
 exchange for access to their antibiotics. Public health
 experts and pharmaceutical industry agree that we need to
 make these investments today to prevent future crisis. I
 look forward to working with you, Mr. Chairman, and all of my
 colleagues, to ensure that the PASTEUR Act is passed this
- 377 I yield back.

session.

376

- *The Chairman. Thank you, and I agree this is important, and, you know, we will work on it. Thank you.
- On the Republican side? Dr. Burgess.
- *Mr. Burgess. Thank you, Mr. Chairman. And I just want to take a moment to express my support and gratitude to the members of staff who have dedicated time to working on bills that are included in today's markup. This is one of the most important things we do every five years: reauthorize the Food and Drug Administration.
- I will say that I am a little concerned about some bills
 that seem to be -- have been added to the markup that we
 really haven't had time for adequate discussion.
- Look, I pointed out the other day President Trump

 declared a public health emergency for opiate deaths. This

 committee responded with the SUPPORT Act. And we actually

 saw overdose deaths tick down briefly in 2019. Then came the

- 394 pandemic. And today we have a much bigger problem. The
- problem is fentanyl, and the rise of overdose deaths, it is,
- I am feeling, a large part of the mental health problem in
- 397 this country.
- In addition, fentanyl and opioid use disorder is a
- 399 multifaceted and complex condition. Individuals with this
- 400 have multiple other difficult health issues, and have
- 401 behavioral conditions that make it difficult for providers to
- 402 manage. I have personal experience in dealing with these
- individuals, and it could be sad and stressful for both the
- 404 patient, their family, and the provider. So we should be
- developing a more personalized care plan for individuals
- 406 struggling with this.
- I plan to support several of the packages, but I am
- 408 concerned about the addition of some of the provisions that I
- don't think give adequate representation to the seriousness
- 410 of this problem.
- 411 And I yield back.
- *The Chairman. Thank you, Dr. Burgess.
- On the Democratic side, anyone?
- Mr. Peters, the gentleman from Vermont, is recognized
- for one minute. Oh, oh, Scott, oh, I am sorry. Mr. Peters
- 416 from San Diego is recognized for one minute.
- 417 [Pause.]
- *The Chairman. He is on remote?

- 419 *Voice. He is in front of the camera.
- *The Chairman. Mr. Peters?
- *Mr. Peters. Oh, sorry, Mr. Chairman. Thank you very
- much. Thank you for holding the markup today. We are going
- 423 to do some terrific work here toward bipartisan consensus on
- these critical pieces of legislation to strengthen the FDA,
- support medical innovation, and address the behavioral health
- 426 crisis.
- And I just want to amplify my colleagues' ongoing
- 428 conversations around the Clarifying Remanufacturing to
- Protect Patient Safety Act. And I know we can't do
- everything today, but this would be a very important thing to
- get at, because medical device remanufacturing, if it is not
- 432 handled right, can reduce patient safety, including resulting
- 433 in patient death.
- So I am committed to work with you, Mr. Chairman, to
- 435 solve this problem. I look forward to our work today, and
- hope we can also get to this [inaudible].
- *The Chairman. Thank you, and we will work together.
- On the Republican side, anybody want to give an opening
- 439 statement?
- Anybody remotely?
- No? All right. Then how about on the Democratic side?
- No? All right. Anybody else remotely or otherwise?
- All right. Oh, wow, we are going to move fast here.

Pursuant to committee rules, members' written opening 445 statements shall be made part of the record. Please submit 446 written opening statements electronically to the email 447 448 address that we provided. So we are going to go to the FDA user fee. We will 449 begin consideration. The chair calls up H.R. 7667, the Food 450 451 and Drug Amendments of 2022, as forwarded by the Subcommittee on Health, and the clerk will report the title of the bill. 452 453 *The Clerk. Committee print to H.R. 7667 to amend the 454 Federal --*The Chairman. Madam Clerk, without objection, the 455 first reading of the bill will be dispensed with. The bill 456 is now considered as read. 457 And without objection, the bill is considered as read 458 and open for amendment at any point. 459 [The bill follows:] 460 461 ****************************** 462

Okay, let us -- so that concludes opening statements.

444

463

- *The Chairman. Well, I guess we could start. Are there
- any members who seek recognition to speak on the underlying
- bill before we get to amendments?
- 467 Okay, no?
- *Mr. Latta. Mr. Chairman?
- *The Chairman. Yes, Mr. Latta.
- *Mr. Latta. Strike the last word.
- *The Chairman. The gentleman is recognized.
- *Mr. Latta. Well, thank you very much, Mr. Chairman.
- Thanks very much for holding today's hearing.
- Let me just say that I am concerned that, over the past
- few years, while the FDA's Center for Drug Evaluation,
- 476 Research, or CDER, has announced a draft guidance titled,
- "Innovative Approach for Nonprescription Drug Products,' \ no
- 478 further action was taken to date. Potential changes were
- first prescribed back in 2012. While some progress has been
- 480 made, we are years later still waiting for a rule. Without
- this rule, consumers will further be denied the cost savings
- 482 from Rx to the OTC switches and convenience of the
- 483 availability of these medicines over the counter.
- And with that, Mr. Chairman, I yield back the balance of
- 485 my time. Thank you.
- *The Chairman. Thank you. Anyone else on the
- 487 underlying bill?
- 488 Otherwise, we are going to move to -- yes, the ranking

- 489 member, Mrs. Rodgers, you are recognized.
- 490 *Mrs. Rodgers. Thank you, Mr. Chairman. I move to
- 491 strike the last word, and I will be --
- *The Chairman. The gentlewoman is recognized.
- 493 *Mrs. Rodgers. I will be brief with my remarks today.
- But I would again like to thank Chairman -- or Chairwoman
- 495 Eshoo, Chairman Pallone, Ranking Member Guthrie, all of my
- 496 colleagues on the Energy and Commerce Committee for working
- 497 to get this critically important legislative package before
- 498 the full committee today.
- Over the last year this committee has carried out our
- tradition of reauthorizing these FDA user fee programs on
- 501 time and in -- with bipartisan support. I would like to
- 502 recognize the FDA and the industry's roles in delivering the
- agreements, and the commitment letters to Congress, and for
- your continued engagement as our committee considered your
- 505 proposals.
- The package before us today reflects the same patient-
- 507 centered and pro-innovation proposals we unanimously
- forwarded out of the subcommittee last week, as well as
- several policies we have continued to work together on in
- 510 preparation for today's full committee markup. The
- 511 provisions included in this package will promote the use of
- novel drug manufacturing technologies, address shortfalls in
- 513 FDA's drug inspections program, and facilitate the use of

- 514 decentralized clinical trials. These enhancements will
- ensure Americans are able to have timely and dependable
- access to future cures, essential medicines, and cutting-edge
- 517 health technologies.
- Other bipartisan provisions included in this package
- 519 will incentivize domestic manufacturing and secure our supply
- 520 chains.
- As parents across the country face dangerous shortfalls
- of infant formula, we have a renewed responsibility to the
- 523 American people to ensure our public health agencies are
- responding effectively to disruptions in our medical and
- 525 nutritional supply chains. The FDA Act may be a timely
- opportunity to demonstrate our commitment to meaningfully
- 527 addressing failures of our Federal scientific agencies in
- 528 their program integrity and oversight responsibilities.
- Trust needs to be rebuilt in public health, and my hope
- is reauthorizing these user fee programs will be a step in
- 531 that direction. I look forward to considering the bills
- before us today alongside my colleagues, and advancing these
- 533 critical pieces of legislation to the floor.
- Thank you. I yield back.
- *Mr. Tonko. Mr. Chair?
- *The Chairman. I thank the ranking member --
- *Voice. Mr. O'Halleran, Mr. O'Halleran, Mr. O'Halleran.
- *The Chairman. Oh, Mr. O'Halleran would like to strike

- 539 the last word? Recognized for five minutes.
- *Mr. O'Halleran. Oh, thank you, Mr. Chairman. I thank
- 541 the chairman and --
- *The Chairman. Remote.
- *Mr. O'Halleran. -- continuing to work in a bipartisan
- 544 manner to move important health-related legislation, the FDA
- user legislative package that we will be considering today.
- [Inaudible] authorization [inaudible] that we will be
- 547 considering today makes significant investments in
- 548 modernizing the FDA [inaudible] for patients by lowering
- costs, and bringing a path to innovators, and address
- longstanding shortages.
- I also want to thank my colleague from Arizona,
- 552 Congresswoman Lesko, for her work with me on reauthorizing
- 553 the [inaudible] public-private [inaudible] 2027. This will
- allow the FDA to continue its public-private partnerships
- 555 with universities and non-profit organizations. We have one
- based out of Tucson, and it has been integral in helping to
- work with the regulators, with industry to accelerate the
- development of medical products.
- This is an excellent example of how government can
- partner with the private sector to improve and assess
- critical drugs and medical devices, and accelerate the
- development of lifesaving treatments, while promoting
- important safety and efficiency standards.

- One last item I would like to finally speak to and
- 565 highlight. I have been working on language to the
- 566 predetermined change controls plans. As medical devices have
- become more advanced, I believe that this will be important
- 568 to the future of streamlining FDA resources, and ensure the
- devices are as safe and effective as possible.
- 570 And I yield back.
- *The Chairman. Thank you, Mr. O'Halleran. I like that
- 572 picture. It looks like the Grand Canyon in the back there.
- 573 *Mr. O'Halleran. Mr. Chairman, that is the Grand
- 574 Canyon.
- *The Chairman. It is? Okay.
- On the Republican side, is there any -- Dr. Joyce is
- 577 recognized.
- *Mr. Joyce. Mr. Chair, I wish to strike the last word.
- *The Chairman. The gentleman is recognized.
- 580 *Mr. Joyce. Thank you, Mr. Chair. I wish to briefly
- touch on three issues within the user fee bill, and urge
- adoption of this agreement by the full committee.
- First, I would like to thank Representative Matsui and
- Representative Griffith for working with me to introduce H.R.
- 7649, which will require the FDA to open up public docket on
- 586 what factors should be taken into consideration when they
- reviewed proposed changes to a third-party vendor, aiding in
- 588 the implementation of an existing Risk Evaluation and

- 589 Mitigation Strategy, or REMS, for a particular drug. This is
- 590 specifically important to address the issues of vendor
- 591 switches because in the past we have seen instances where
- 592 patient data does not transfer from vendor to vendor,
- 593 creating a myriad of problems for both the doctor and the
- 594 patient.
- 595 While we are very pleased to see this specific bill
- included in this agreement, this is only a first step in
- addressing problems many of us have heard with the REMS
- 598 process, and making sure that patient and provider input is
- 599 heard so that the continued access to medications will not be
- 600 interrupted.
- And second, I would like to thank committee leadership
- for including H.R. 6988, the Drug Manufacturing Innovation
- Act, which builds on the FDA's emerging technology program
- 604 which seeks to speed the approval of drugs made using novel
- 605 manufacturing technologies by providing more regulatory
- 606 certainty for drug sponsors. The use of these new
- 607 technologies will ultimately lower costs for patients and
- 608 address future supply chain issues.
- I would also like to thank Representative Levin for
- 610 working with me on this issue.
- And then, finally, I would like to touch on the issue of
- remanufacturing of medical devices, and I would like to echo
- 613 comments made by my colleagues, Representative Peters, Dr.

- 614 Schrier regarding the remanufacturing of complex medical
- devices. I want to be clear that this is an issue of patient
- safety, and I want to distinctly state that this legislation
- is not designed to target routine servicing and maintenance.
- And we remain open to working with my colleagues to reach
- 619 consensus on language that achieves both of these important
- 620 goals. Again, we are only seeking to define remanufacturing
- where devices are being fundamentally altered, resulting in
- adverse patient outcomes.
- I look forward to continuing our work on this matter,
- and I yield back.
- *The Chairman. Thank you, Dr. Joyce. So on our side we
- 626 have Doyle, Tonko, Schakowsky, Kuster. So let's see. Where
- do we start, with Doyle?
- Mr. Doyle.
- 629 *Mr. Doyle. Thank you, Mr. Chairman. I move to strike
- 630 the last word.
- *The Chairman. The gentleman is recognized.
- *Mr. Doyle. I think we can all agree on the importance
- of our committee approving the FDA user fee programs today to
- ensure the safety and efficacy of prescription drugs and
- 635 medical devices that Americans rely on.
- I want to express my support for section 701 of the
- 637 bill. This section would advance FDA medical and
- 638 pharmaceutical testing by allowing for alternative methods to

- 639 be used when appropriate. We should take advantage of any
- advancements in research technologies that can avoid
- 641 unnecessary harm to animals. I look forward to passing this
- 642 bill out of the committee today, and ensuring that we are
- developing the best pharmaceuticals in the world in the most
- humane way possible.
- I yield back, Mr. Chairman.
- *The Chairman. Thank you, Mr. Doyle.
- Do we have a Republican member who wants to speak on the
- 648 underlying bill?
- All right, so Ms. Schakowsky is next.
- *Ms. Schakowsky. Thank you, Mr. Chairman. I move to
- 651 strike the last word.
- *The Chairman. The gentlewoman is recognized.
- *Ms. Schakowsky. So I am grateful to the chairman and
- ranking member to see provisions included in this bill to
- improve FDA and its program -- and its programs, including
- 656 work to improve the treatment of rare diseases and
- 657 conditions.
- This week I met with ALS advocates who continue to face
- 659 barriers to treatment and cures, even though there are drugs
- that have shown they are both safe and effective.
- [Inaudible] was an enormous and hope-giving first step.
- 662 However -- the legislation that we passed.
- However, the FDA has yet to use their 2019 guideline for

- 664 regulating -- what does that say? Oh, I am sorry, for
- regulatory flexibility in the case of ALS treatment.
- I urge the FDA to use the 2019 guidelines, and to move
- forward on ALS treatments that have made their safety and
- 668 efficacy available.
- So I am also very grateful to see improvements in the
- accelerated approval program, particularly around
- 671 post-approval studies and programs -- and program integrity
- 672 action -- I am sorry, you know my reading is bad, but program
- 673 integrity for accelerated approval of drugs.
- I urge my colleagues to consider further strengthening
- 675 the program with a -- with a modest proposal to require that
- all drugs or biologics considered for accelerated approval
- first be evaluated by external expert advisory committees.
- We know that recent research published by Health Affairs
- indicated that advisory committees, committee meeting users
- 680 -- that advisory committee meeting used by the FDA in the --
- are now in the decline. That is dangerous. In 2010
- [inaudible] percent of drug approvals went through an
- advisory committee. As of 2021, only 6 percent of drug
- approvals benefited from such careful pre-marketing review.
- Again, we must ensure that drugs and treatments are not
- only fast, and available fast, but safe and effective. And I
- 687 think the committee -- and I thank the committee for their
- 688 work on this. But I think that we have to see that these

- advisory committees are considered in more cases.
- Thank you. I yield back.
- *The Chairman. Thank you, Ms. Schakowsky.
- The Republican side? No?
- I am just going to go back to seniority. I know some
- 694 people had their hands up earlier, but we will just do it
- 695 based on seniority. So next is Ms. DeGette.
- *Ms. DeGette. Thank you, Mr. Chairman. I move to
- 697 strike the last word.
- *The Chairman. The gentlewoman is recognized.
- *Ms. DeGette. Thank you. Mr. Chairman, if there is one
- 700 thing we have learned as a result of the COVID-19 pandemic,
- 701 it is the importance of having accurate and reliable
- 702 diagnostic testing.
- Every day, health care providers and patients across
- 704 this country use and rely on diagnostic tests to make
- 705 important and sometimes difficult decisions about their
- 706 health. The accuracy and reliability of these tests can
- 707 literally mean the difference between life and death for some
- 708 patients.
- For years, public health officials have been calling for
- 710 greater oversight of these important tools to ensure that
- 711 patients and health care providers are relying on is as
- 712 accurate as possible (sic). And so, for nearly a decade,
- 713 Representative Bucshon and I have been working together on

- 714 legislation to do exactly that.
- 715 The VALID Act, which we introduced last summer with
- 716 Senators Bennet and Burr, would establish a framework at FDA
- 717 to regulate diagnostic tests, and it would give FDA the tools
- necessary to help ensure that these tests are both safe and
- 719 effective. We were pleased to see the Senate take action to
- 720 include the VALID Act as part of the FDA user fee
- 721 reauthorization package. And yesterday we were pleased to
- 722 see that Senator Burr and Senator Murray have expressed their
- 723 strong support for the VALID Act as part of the user fee
- 724 package, and also their commitment to keeping it in.
- And so, even though we thought about doing it as an
- amendment to this bill, but we would prefer to really work
- 727 with our staff and with you, Mr. Chairman, as this VALID Act
- moves through the Senate process to make sure, as we move
- 729 forward, that we put this important regulation of diagnostic
- 730 testing into the bill.
- I have got three minutes left. I would be happy to
- 732 yield to Mr. Bucshon.
- 733 *Mr. Bucshon. I am going to speak on the AINS a little
- 734 later, so --
- 735 *Ms. DeGette. Okay. Then I will yield back, Mr.
- 736 Chairman.
- 737 *The Chairman. Thank you. Whenever the Senate takes
- 738 action on anything, we have to take notice because --

- 739 [Laughter.]
- 740 *Ms. DeGette. You are so right, Mr. Chairman.
- 741 *The Chairman. It is very difficult for them to take
- 742 action.
- 743 *Ms. DeGette. Right.
- *The Chairman. Anyone on the Republican side?
- 745 We will go next to -- Ms. Matsui is recognized.
- 746 *Ms. Matsui. Thank you, Mr. Chairman. I move to strike
- 747 the last word.
- 748 *The Chairman. The gentlewoman is recognized.
- 749 *Ms. Matsui. Thank you. I would like to quickly
- 750 express my support for section 809 of the underlying bill,
- 751 establishing a public docket on proposed changes to third-
- 752 party vendors for the REMS program.
- 753 This provision would create a critical opportunity for
- 754 stakeholders to provide the FDA with important feedback on
- 755 what to consider when making changes to platforms that
- 756 implement and manage Risk Evaluation and Mitigation
- 757 Strategies, REMS. We must address the lack of communication
- 758 in oversight of the REMS process by working together with
- 759 providers and pharmacies who operate REMS platforms. FDA can
- 760 protect against potential disruptions in patient access and
- 761 delays in care.
- 762 Since I first raised these REMS issues with the FDA at
- our hearing in February, I appreciate the efforts of my

- 764 colleague, Representative Joyce, and our work together
- 765 towards a meaningful solution. I also thank the committee
- for working towards a compromise that could be included in
- 767 today's markup.
- I think the opportunity to establish in this section
- 769 will be valuable, and I hope the comment period can be
- implemented quickly to improve the REMS modification process
- as it relates to third-party vendors.
- 772 That said, I view the agreement we got to today on REMS
- 773 modifications as just the starting point. We have more work
- to do to fully address stakeholder concerns, particularly
- around managing data and ensuring that providers can continue
- 776 to access the information they need to support patient care.
- 777 I look forward to continuing these discussions, and our work
- 778 to improve the REMS process.
- 779 And thank you, and I yield back.
- 780 *The Chairman. Thank you, Ms. Matsui. Next we go to --
- 781 Mr. Tonko is recognized for five minutes.
- 782 *Mr. Tonko. Thank you, Mr. Chair. I move to strike the
- 783 last word.
- *The Chairman. The gentleman is recognized.
- 785 *Mr. Tonko. I thank you, Mr. Chair and Ranking Member
- 786 Rodgers, Chair Eshoo, and Ranking Member Guthrie for your
- 787 work on this important bipartisan legislation to help fund
- 788 critical programs at FDA, ensuring the safety of our nation's

- 789 drugs and medical devices. I am indeed pleased to see this
- 790 critical initiative advancing on a timely and bipartisan
- 791 basis.
- In particular, I would like to highlight section 703 of
- 793 this legislation, which is based on the HEART Act that I
- introduced earlier this year with my good friend and
- 795 colleague, Representative David McKinley. The idea for this
- 196 legislation was brought to us by a constituent, Melissa
- 797 Goetz, who is the co-founder of the FCS Foundation, and a
- 798 parent of a child with familial chylomicronemia syndrome.
- The HEART Act aims to improve the FDA review process for
- 800 treatments for rare and ultra-rare diseases by shining a
- 801 light on current FDA review practices when it comes to
- 802 treatment for rare diseases, and ensuring that the patient
- voice is heard when the FDA makes its decisions about patient
- 804 safety.
- The legislation will also ensure that the FDA can
- maintain lists of experts in small population studies, who
- 807 can then consult with -- on rare disease issues. These
- 808 experts are critical, as many rare disease treatments involve
- 809 extremely small clinical trials, which can be difficult for
- regulators used to bigger drugs to assess.
- 811 I would like to thank the FCS Foundation and the
- 812 Haystack Project, in particular, for its advocacy on this
- 813 bill, and reiterate my commitment to getting this done in a

- 814 meaningful way.
- While I am pleased that we are making progress on this
- issue today with the provisions included in H.R. 7667, I am
- 817 hopeful we can continue to strengthen the HEART Act
- 818 provisions to amplify the patient voice as we move forward in
- 819 conversations with our Senate partners.
- Additionally, as we are discussing FDA regulation, I
- would like to bring up the issue of cosmetic animal testing,
- which I have been concerned about for many years. Today
- 823 cosmetic animal testing no longer represents the best
- 824 possible science for protecting consumer safety, nor is it
- often necessary. The Humane Cosmetics Act, led by a
- 826 bipartisan group of members, including Congressmembers Beyer,
- 827 Buchanan, Calvert, and myself, prohibits the production and
- 828 sale of cosmetics that have been newly tested on animals in
- 829 the U.S. It has been carefully developed to ensure that any
- 830 exceptions necessary for safety are allowed, and has strong
- 831 corporate support, including from the Personal Care Products
- 832 Council, which represents some 90 percent of the U.S.
- 833 cosmetic industry. It is also consistent with FDA's public
- 834 statements supporting replacement of animal tests with new
- 835 non-animal methods.
- Our legislation would bring the Federal Government in
- line with 8 states and 41 countries that have passed laws to
- 838 end or limit cosmetic animal testing, and would be a great

- opportunity to update animal testing practices, while
- ensuring consumer safety.
- 841 So Mr. Chair, reducing the use of animal testing is a
- priority for me, and I would ask if you would be willing to
- continue to work with me under the important issue of
- 844 reducing the use of animal testing in cosmetics.
- *The Chairman. Yes, sir, I certainly will. And again,
- taking notice of rare action by the Senate, they have
- included cosmetics, from what I understand, in their bill
- 848 that is similar to us. So --
- *Mr. Tonko. Well, that is good news. So thank you, Mr.
- 850 Chair. I appreciate your commitment on this. And I know you
- 851 are a longtime advocate for animal welfare for some of the
- 852 work that we have done together on horse racing and other
- 853 issues. So I look forward to working with you on this.
- And with that, I yield back the balance of my time.
- *The Chairman. Thank you, Mr. Tonko. Next we go to --
- 856 Ms. Kuster is recognized for five minutes.
- *Ms. Kuster. Thank you, Mr. Chairman. I move to strike
- 858 the last word.
- *The Chairman. The gentlewoman is recognized.
- *Ms. Kuster. I am pleased to see this committee come
- 861 together across party lines to advance comprehensive
- legislation to ensure that the Food and Drug Administration
- 863 has the resources it needs to ensure the safety and efficacy

- 864 of drugs and medical devices.
- The Food and Drug Amendments Act also includes my
- legislation in section 601 to lower drug costs for Granite
- 867 Staters and folks all across this country by removing
- 868 barriers in generic drug approvals. My bill, the Increasing
- 869 Transparency in Generic Drug Applications Act, introduced
- with Dr. Schrier, will bring lower-cost drugs to market
- faster, and boost competition so that Americans will pay less
- for their prescriptions at the pharmacy counter. Families
- 873 should have lower-cost alternatives to lifesaving medication
- 874 so that they don't have to make the impossible decision
- between paying the rent or getting the medicine they need.
- I thank the chairman, Mr. Pallone, and chairwoman of the
- 877 Health Subcommittee, Ms. Eshoo, and our staff for working to
- include these critical bills that will expand access to
- 879 lower-cost prescription medication, as well as the other
- 880 bills in this package on mental health and substance use
- 881 disorder treatment. I look forward to advancing these
- 882 proposals today.
- And with that I yield back the balance of my time.
- *The Chairman. I thank the gentlewoman. And next we go
- 885 to the vice chair of the full committee, Ms. Kelly.
- *Ms. Kelly. Thank you, Mr. Chair. I would like to
- 887 strike the last word. Thank you --
- *The Chairman. The gentlewoman is recognized.

- *Ms. Kelly. Thank you, Chairman Pallone and Ranking
 Member McMorris Rodgers. Thank you, Chairwoman Eshoo and
 Ranking Member Guthrie, for your leadership in the effort to
 diversify clinical trials.
- 893 A review of FDA data from 2020 shows that Black individuals are severely under-represented in clinical trial 894 data, even when the disease burden is high. For example, the 895 896 death rate for Black men with prostate cancer is twice as high as for White men, yet the clinical trial representation 897 898 of Black men in FDA-approved drug targeting prostate cancer was only two to five percent. The lack of adequate 899 representation of Black populations in clinical trial 900 research means the science we rely on for medical treatment 901 of diseases has not been fully vetted across diverse 902 903 populations.
- That is why I am thrilled that provisions from the 904 DEPICT Act, which I co-led with my colleagues, Chairwoman 905 Eshoo and Representative Fitzpatrick, have been included in 906 907 the Food and Drug Amendments of 2022. These provisions would 908 require FDA applicants to establish specific enrollment targets based on race, ethnicity, age, and sex, and to 909 910 develop diversity action plans. This would ensure that diverse populations are represented in clinical trial 911 912 research so that these communities can trust that new,

innovative therapies are safe and effective.

- I look forward to continuing to work with my committee
- and my colleagues in a bipartisan manner on this important
- 916 issue.
- Thank you, and I yield back.
- *The Chairman. Thank you. Mr. Cardenas had his hand
- 919 up.
- 920 *Mr. Cardenas. Yes. Thank you, Mr. Chairman. I move
- 921 to strike the last word.
- *The Chairman. The gentleman is recognized.
- 923 *Mr. Cardenas. Thank you. There are a lot of good
- 924 things in this bill. I am especially excited to see
- 925 provisions that will support the development of biosimilars
- and generics, as well as language to improve clinical trial
- 927 diversity.
- 928 But as we deliberate this user fee bill and discuss the
- 929 future of biomedical innovation, I want to also urge my
- 930 colleagues to support efforts to move away from a reliance on
- 931 animal testing. One area that I believe we have the
- 932 capability to transition away from animal testing is in the
- 933 cosmetics market. Our status quo vetting cosmetic products
- is inhumane, and thus unnecessary to ensure consumer safety.
- Animals are subject to harsh treatment when undergoing
- 936 these types of tests. They are smeared with or otherwise
- forced to ingest potentially dangerous chemicals, and often
- 938 times are put down at the conclusion of the process. What is

- 939 worse is that this cruel type of treatment does not even
- provide reliable results that will ensure human safety.
- There are viable alternatives to forcing animals to undergo
- 942 these types of trials that will also yield more relevant
- 943 results for people. Even the FDA has expressed an interest
- in "reducing the need for animal testing,' calling it a "top
- 945 priority.'\
- For these reasons I want to voice my support for
- legislation such as the Humane Cosmetics Act, which I am
- 948 proud to support. Mr. Chairman, I hope we can work together
- on this issue for the sake of animals, and to help people
- like our constituents that we are trying to do the best job
- 951 we can for.
- 952 With that, I yield back.
- *The Chairman. Thank you, Mr. Cardenas.
- 954 Do we have -- Mr. Ruiz has his hand up.
- 955 You are recognized for five minutes.
- 956 *Mr. Ruiz. Thank you. I move to strike the last word.
- 957 Thank you for holding this important markup today. I
- 958 will keep my remarks brief, because I know we have a lot to
- 959 go through, but I would be remiss if I didn't once again
- 960 raise the issue of the importance of diverse representation
- 961 in clinical trials.
- I am thrilled that so many members of this committee are
- 963 committed to addressing the current disparity that exists in

- our clinical trial system. As we know, gender, race,
- ethnicity, age, and lifestyle play an important role in how
- our bodies respond to medications, diagnostics, or medical
- 967 technology. It is, therefore, imperative that a wide array
- of individuals are included when we are studying the safety
- and efficacy of new therapies. If we want to address health
- 970 equity, we must address this issue.
- My bill, the Diverse Trials Act, will help do just that.
- 972 One of the barriers that potential trial participants face is
- 973 that they might not have access to or the ability to travel
- 974 to a clinical site. We can help reduce that barrier by
- increasing the ability for patients to participate remotely,
- 976 which is why my bill calls on the FDA to issue further
- 977 guidance on decentralized clinical trials.
- 978 I thank Chairman Pallone for including that policy in
- 979 the FDA bill that is being marked up today.
- 980 I also look forward to continuing to work with the
- ommittee to advance the rest of the bill, which gives trial
- 982 sponsors statutory authority to pay for some of the ancillary
- 983 costs of trial participation, such as transportation,
- lodging, and meals. This part is key to making sure that
- these trials are not exclusively accessible to people with
- 986 means.
- I would also like to thank my friend, Dr. Bucshon, for
- 988 working with me on this important piece of legislation.

```
Thank you, and I yield back.
989
           *The Chairman. Thank you, Dr. Ruiz.
990
           Anyone else who wants to make a statement on the
991
992
      underlying bill?
993
           Hearing none, we will go to amendments. I understand
      Mr. Guthrie has --
994
           *Mr. Guthrie. Mr. Chair, I have an amendment at the
995
996
      desk, an amendment in the nature of a substitute.
997
           *The Chairman. Okay. Well, I recognize -- well, I
998
      think the clerk has to report the amendment, so --
           *The Clerk. Amendment in the nature of a substitute to
999
      committee print of H.R. 7667 --
1000
           *The Chairman. And without objection, Madam Clerk, the
1001
      reading of the amendment will be dispensed with.
1002
1003
           [The amendment of Mr. Guthrie follows:]
1004
      ************************************
1005
```

- *The Chairman. And Mr. Guthrie is recognized for five
- 1008 minutes.
- 1009 *Mr. Guthrie. Thank you, Mr. Chair. I would like to
- 1010 speak in support of the amendment.
- 1011 User fees allow Food and Drug Administration to collect
- 1012 fees from industry in exchange for timely review of their
- 1013 drug or device applications. This was originally authorized
- 1014 by Congress in the early 1990s to address lengthy drug review
- 1015 times at the Food and Drug Administration for prescription
- 1016 medications.
- 1017 Today the agreement --
- *The Chairman. Do I have any ability to deal with that?
- [Laughter.]
- 1020 *The Chairman. So you just --
- 1021 *Mr. Guthrie. Yes, I don't know --
- *Mr. Upton. I have the Michigan marching band out in
- 1023 the hall. They are going to come in next.
- *Mr. Guthrie. Yes, people online probably realize
- 1025 something is pounding under us right now.
- 1026 Anyway, so I will get back to it. So every -- I don't
- 1027 know how to answer the Michigan fight song. I got to come up
- 1028 with -- I am not as quick as Billy Long. All hail to all
- 1029 Michigan.
- 1030 Every five years Congress has the unique ability to
- 1031 reauthorize these critical user fee programs. This process

represents an important opportunity for Congress, and
specifically members of this committee, to build on past
successes, conduct appropriate oversight over previously
authorized agreements, improve FDA programing, and establish
new policies that help promote access to new, lifesaving

therapies and medications.

- The fees paid by the FDA -- paid to the FDA by industry 1038 can be used for hiring personnel to oversee timely drug 1039 reviews and approvals, or to establish new programing aimed 1040 1041 to address emergent marketplace innovations. Importantly, these fees not only permit the FDA to carry out drug or 1042 device application reviews, but also represent significant 1043 percentages of the FDA's total operating budget without 1044 requiring significant taxpayer funding. 1045
- In fact, these agreements may yield a significant return on investment -- they have yielded a significant return on investment since they were originally authorized.
- Most of the world's innovative drug and device approvals 1049 originate in the United States as a result of this -- these 1050 1051 agreements. In 2021, 30 out of 50 of the world's novel drugs that were approved first were first approved in the United 1052 This was made possible by the FDA Amendments of 1053 States. This was most recently reauthorized user fee 1054 1055 agreements, which passed the House under suspension of the 1056 rules, and passed the Senate by a vote of 94 to 1.

- 1057 H.R. 7667, the FDA Act, which unanimously passed the
- 1058 Health Subcommittee last week by a vote of 30 to 0, would
- 1059 protect access to lifesaving cures, promote innovation,
- 1060 secure our medical supply chains, and lower costs for
- 1061 patients.
- I am proud to say the legislation includes my bill, the
- 1063 Approval Exchange -- Information Exchange Act. It includes -
- 1064 provide guidance on a collection of Real-World Evidence for
- 1065 companies with products authorized under emergency use
- 1066 authorizations during the COVID-19 public health emergency.
- The FDA Act also incentivizes investment in advanced
- 1068 pharmaceutical manufacturing technologies that can build a
- 1069 more resilient and secure medical supply chain.
- 1070 And finally, the FDA Act of 2022 preserves access to
- 1071 lifesaving therapies approved under the accelerated approval
- 1072 pathway, which I know has been an important priority of
- 1073 Ranking Member Rodgers through this process. By preserving
- 1074 this pathway, we are giving patients hope to one day find
- 1075 cures for incurable diseases such as Alzheimer's disease or
- 1076 terminal cancers, as we heard Ms. Schakowsky this morning
- 1077 talk about ALS.
- I urge my colleagues to support this legislation, and I
- 1079 yield back.
- *The Chairman. Thank you, Mr. Guthrie.
- 1081 *Voice. Mr. Chairman?

- *The Chairman. Yes, so we are going to have members now
- 1083 speak on the AINS, starting with -- Chairwoman Eshoo is
- 1084 recognized.
- 1085 *Ms. Eshoo. Thank you, Mr. Chairman. I move to strike
- 1086 the last word --
- *The Chairman. The gentlewoman is recognized.
- 1088 *Ms. Eshoo. -- to speak on the amendment in the nature
- 1089 of a substitute to the bill.
- I am proud, along with Representatives Guthrie, you, Mr.
- 1091 Chairman, and the ranking member of the full committee, Mrs.
- 1092 McMorris Rodgers, to sponsor the strong bipartisan FDA user
- 1093 fee bill. With today's markup we are on track to pass this
- 1094 bill through the House with plenty of time before the
- 1095 September 30th user fee deadline.
- The user fee agreements included in the bill, in total,
- 1097 is going to provide the FDA with billions -- that is with a B
- 1098 -- dollars over the next five years, allowing the FDA to hire
- 1099 hundreds of new, full-time employees.
- Beyond the user fee agreements, the bill also includes
- 1101 several important legislative riders, key portions of my
- 1102 DEPICT Act, which I introduced with Representatives Kelly and
- 1103 Fitzpatrick earlier this week.
- The National Academies released a report that found the
- 1105 lack of equitable representations in clinical trials
- 1106 compounds health disparities, and will cost the United States

- 1107 hundreds of billions of dollars due to sickness and loss of
- 1108 productivity. So we are on the mark by passing legislation
- 1109 that addresses this problem.
- And the National Academies recommended a policy very
- 1111 similar to the DEPICT Act. That Act, which is included in
- the bill, which statutorily require drug companies to show
- 1113 how they will include diverse populations in their clinical
- 1114 trials by reporting to FDA a diversity action plan with
- 1115 targets by demographic subgroups. This is -- these diverse
- 1116 clinical trials are not only fair and really desperately
- 1117 needed, it is also good science.
- H.R. 7667 also includes important reforms to the FDA's
- inspections program, based on bills introduced by
- 1120 Representatives Griffith and Welch, as well as by myself and
- 1121 Representative Hudson. And I thank him for all the work that
- 1122 he has done. These provisions are going to help the FDA
- 1123 catch up from a two-year inspection backlog due to the
- 1124 pandemic, and conduct a pilot program of unannounced foreign
- inspections, something that I have called for, and other
- 1126 members have, as well.
- Today's amendment also includes an important policy to
- improve the FDA's ability to hire and retain highly-qualified
- 1129 staff, including for the regulation of food. This authority
- is clearly needed after we have seen FDA's challenges in its
- 1131 food and infant formula division.

- So overall, I think I am preaching to the choir, but it
- is worth restating this is a strong bill with many worthy
- 1134 reforms, and I encourage every member of the full committee
- 1135 to move to move it forward -- to vote to move it forward to
- 1136 the full House.
- 1137 And with that I yield back, Mr. Chairman.
- *The Chairman. Thank you, Chairwoman.
- Dr. Bucshon is recognized for five minutes.
- *Mr. Bucshon. Thank you, Mr. Chairman. I move to
- 1141 strike the last word and speak on the AINS.
- *The Chairman. The gentleman is recognized.
- *Mr. Bucshon. I want to thank the chair and ranking
- 1144 member for working with me on a clarification in this AINS
- 1145 surrounding the implementation of the new accelerated
- 1146 approval provisions in this FDA user fee reauthorization
- 1147 package.
- 1148 This clarity will ensure sponsors of pending
- applications won't have to worry about the FDA changing the
- 1150 rules of their application in the middle of the game. The
- 1151 accelerated approval pathway is key to innovation and making
- 1152 sure innovators have certainty in their application process,
- 1153 and is a good policy.
- I also want to thank the committee for including a
- 1155 policy I helped author to promote diverse participation in
- 1156 clinical trials. This has long been an issue that has needed

- to be addressed, and one that the COVID-19 pandemic helped to emphasize. I want to thank my friend, Dr. Ruiz, for working together with me on this provision.
- 1160 This policy will be key to helping promote diverse 1161 participation, increasing -- and increasing innovation.
- Speaking of innovation, I look forward to continuing to work with the chair and the ranking member on finding a path forward for diagnostic testing reform. I want to associate myself with the statement of Congresswoman DeGette.
- 1166 Yesterday Senate HELP introduced their user fee discussion draft, which included the VALID Act, legislation 1167 that I have been working on for many years with my good 1168 1169 friend, Representative DeGette. This legislation would modernize the regulatory framework of diagnostic tests by 1170 establishing a risk-based framework that allows for leading-1171 edge development and innovation to thrive, while assuring 1172 doctors and patients have the certainty that their test 1173 results are analytically and clinically valid. 1174
- While I remain disappointed this committee didn't
 address the diagnostic testing reform in the user fee
 agreement we are considering today, it is my hope that, as we
 continue through the user fee process with the Senate, Energy
 and Commerce grabs a seat at the table and shows leadership
 on this critical issue that directly impacts patient safety.

 The time is now to answer the call and address the pitfalls

- 1182 that exist in the current regulatory framework surrounding
- 1183 laboratory-developed tests.
- I yield back the balance of my time.
- *The Chairman. Thank you, Dr. Bucshon, and I recognize
- 1186 myself to strike the last word, and speak in favor of the
- 1187 AINS.
- The FDA Amendments of 2022, basically, is a very strong
- 1189 bipartisan agreement that would reauthorize FDA's user fee
- 1190 programs, which are obviously important to ensure the agency
- 1191 has the funding it needs so that Americans can continue to
- 1192 trust that the drugs and medical devices they use are safe
- 1193 and effective.
- 1194 Further, FDA 2022 will serve as a critical asset in our
- 1195 nation's fight against COVID-19, improve post-market safety,
- increase diversity in clinical trials, and promote the
- 1197 development of novel therapeutics that will treat the
- 1198 diseases of today and tomorrow.
- So again, I want to thank members on both sides of the
- 1200 aisle for working together to advance this critically
- 1201 important legislation. But let me just talk a little bit
- 1202 about some aspects of the bill.
- 1203 First, the accelerated approval pathway. This includes
- important provisions from my bill to build program integrity
- into the accelerated approval pathway at FDA. We have heard
- 1206 from FDA officials that some drugs take years just to begin

- 1207 their required confirmatory studies after being approved
- 1208 under accelerated approval. And if the sponsors fail to show
- 1209 that the drug provides clinical benefit, it may take even
- 1210 more time to remove these drugs from the markets.
- 1211 And I think patients deserve to have confidence that the
- 1212 drugs they are taking are safe and effective, so that is why
- 1213 FDA 2022 aims to fix these issues by allowing the agency to
- 1214 require sponsors to begin their phase 4 studies before the
- 1215 approval is granted, and streamlines the process for
- 1216 withdrawing a drug if no clinical benefit is found, or if the
- 1217 sponsor fails to complete a study with due diligence, as FDA
- 1218 requires.
- I also wanted to talk about the -- well, let me also say
- 1220 this. It also helps ensure that patients have access to
- drugs they need, while providing them with the assurance that
- they are safe and effective. So I am glad that we have that
- 1223 provision.
- In addition, FDA 2022 improves the accuracy of clinical
- trials by ensuring that they are both representative and
- 1226 inclusive. It requires sponsors to submit diversity action
- 1227 plans as part of their applications. It requires FDA and
- 1228 stakeholders to examine how best we can increase the
- 1229 enrollment of historically under-represented populations in
- 1230 clinical studies. The -- our vice chair mentioned that.
- 1231 And as we have learned during the COVID-19 pandemic, the

- 1232 expansion of remote clinical trials helps ensure that we are
- 1233 reaching a diverse and representative sample of patients.
- 1234 Our bill will help expand the use of decentralized trials by
- 1235 requiring FDA to issue new guidance on trial design.
- 1236 And also, I know that Mrs. Rodgers mentioned the
- 1237 generics. The bill continues this committee's efforts to
- 1238 bring down drug costs by increasing competition from generic
- 1239 drugs, including by improving communications about regulatory
- 1240 requirements before generic drug sponsors and the FDA.
- 1241 And after our Health Subcommittee markup last week I
- worked with Ranking Member Rodgers and her members to clarify
- the scope of generic drug sponsors that can seek this
- information from FDA. And I am glad we were able to come to
- 1245 agreement on this provision to ensure it has bipartisan
- 1246 support.
- 1247 And also in the AINS today our committee is taking
- 1248 action to improve the workforce infrastructure at FDA,
- including for those that support the agency's work to
- 1250 regulate infant formula and the food supply chain:
- obviously, important issues. The AINS includes new language
- 1252 strengthening a provision first included in the 21st Century
- 1253 Cures Act -- again, thank you, Ms. DeGette and Mr. Upton --
- which would allow the agency to more quickly hire highly
- 1255 qualified scientists and other professionals at competitive
- 1256 wages and with less red tape.

- 1257 Currently, FDA's authorities from the Cures Act are
- 1258 limited to medical products. So this provision would expand
- these authorities to other centers at FDA, ensuring that the
- agency is able to hire highly qualified staff across the
- board, as recommended by GAO. It also requires the FDA to
- use this authority to develop an agency-wide workforce
- 1263 strategy.
- So FDA 2022 is a significant accomplishment for this
- 1265 committee, and a win for the American people. All members
- should be proud of the product we are advancing today. I
- look forward to seeing the bill pass on the floor of the
- 1268 House, and advancing -- well, we will see what the Senate
- 1269 does, but they are -- they issued a draft today, so that was
- 1270 certainly progress. And I just want to thank everyone for
- their work on the legislation, and yield back.
- Now, is there anyone else who wants to speak on the AINS
- 1273 on either side of the aisle?
- 1274 No?
- *Mr. Butterfield. Mr. Chairman, I have an amendment at
- 1276 the appropriate time.
- *The Chairman. Okay, we will move to your amendment.
- 1278 *Mr. Butterfield. Thank you, Mr. Chairman. I have an
- 1279 amendment at the desk. It is Butterfield [inaudible].
- *The Chairman. All right. And you have it, Madam
- 1281 Clerk?

1282	So the clerk will report Mr. Butterfield's amendment.
1283	*The Clerk. Amendment to the amendment in the nature of
1284	a substitute to H.R. 7667
1285	*The Chairman. And, Madam Clerk, without objection, the
1286	reading of the Butterfield amendment will be dispensed with.
1287	[The amendment of Mr. Butterfield follows:]
1288	
1289	**************************************

- *The Chairman. And the gentleman from North Carolina is recognized for five minutes.
- *Mr. Butterfield. Thank you so much, Mr. Chairman. And to the ranking member, thank you for this very important
- 1295 markup today. I attended many markups over the years, and
- let me tell you, this is the spirit in which we need to
- 1297 conduct our business. And so thank you to the leadership on
- 1298 both sides of the aisle.
- Mr. Chairman, my amendment is based on H.R. 6972, the
- 1300 Give Kids A Chance Act, which I introduced with my friend and
- 1301 Childhood Cancer Caucus co-chair, Mike McCaul. My amendment
- 1302 gives the FDA the authority to direct companies developing
- 1303 new cancer drugs for adults to study those drugs in
- 1304 combinations -- in combinations -- for children with cancer.
- 1305 My colleagues on this committee know very well that a
- 1306 significant portion of my time here in Congress has been
- spent promoting policies that bring focus to the forgotten
- 1308 and support for the vulnerable, including children with
- 1309 cancer and other rare diseases. This focus is the reason I
- 1310 became involved in the bipartisan Childhood Cancer Caucus.
- 1311 Congress has already passed three laws. We have passed
- three laws which have provided hope to families across the
- 1313 country suffering from pediatric cancer. We passed the
- 1314 Creating Hope Act; we passed the RACE for Children Act; and
- 1315 the Childhood Cancer Star Act. Today, Mr. Chairman, we have

- 1316 a chance to further support these families and provide more
- 1317 hope for them in their dark and difficult days. It is my
- 1318 sincere hope that my colleagues will support my amendment
- 1319 today, so that we can build upon the progress we have already
- 1320 made to spur innovation and create more cures for children
- 1321 with cancer.
- 1322 I would like to sincerely thank the chairman and the
- 1323 ranking member and their staff, especially their staffs, for
- their tireless work to find agreement on the policy.
- I would also like to thank our industry partners, whom
- we have talked with daily, for providing my staff with
- 1327 feedback to improve my bill and this amendment -- including
- 1328 this amendment, Mr. Chairman -- shows kids and families
- 1329 across our country that we see them, we hear their stories,
- and are taking action to bring them hope, treatments, and
- 1331 cures.
- 1332 Thank you, Mr. Chairman. I urge the adoption of my
- 1333 amendment.
- *The Chairman. Thank you, Mr. Butterfield.
- Does anyone want to -- on the Republican side want to
- 1336 comment on this?
- *Ms. Eshoo. I just want to say something --
- *The Chairman. Yes, Ms. Eshoo is recognized.
- 1339 *Ms. Eshoo. Mr. Butterfield, I think that I speak for
- 1340 everyone on the committee. Thank you, thank you, thank you

- 1341 for your superb advocacy. This is a legacy, your legacy, and
- 1342 really an extraordinary contribution when it becomes law for
- 1343 children with cancer in our country. So bravo.
- *The Chairman. Would the gentlewoman yield to me?
- 1345 *Mr. Butterfield. Thank you.
- *Ms. Eshoo. I would be happy to.
- *The Chairman. Thank you. I just wanted to say that
- 1348 throughout his career, Representative Butterfield has been
- working tirelessly to make advances in treatments and cures,
- 1350 particularly for pediatric cancers. And whether it be his
- 1351 Creating Hope Act or the RACE for Children Act, both of which
- have been signed into law, he has remained focused on
- 1353 supporting R&D into these terrible diseases that strike our
- 1354 most vulnerable young Americans.
- 1355 And while members on both sides of the aisle are
- 1356 definitely sad to see him retire later this year, and I
- 1357 certainly am, he is showing us all that he is not done
- 1358 working on behalf of children and families.
- So with this amendment today, a modified version of the
- 1360 Give Kids a Chance Act, Congressman Butterfield is expanding
- on the RACE for Children Act by allowing FDA to require drug
- sponsors to conduct molecularly targeted investigations of
- 1363 combination drugs, where there is a promise that studying
- these combinations could deal clinically meaningful pediatric
- 1365 study data regarding dosing safety, preliminary efficacy to

- inform potential pediatric labeling of the drug.
- So in other words, the bill will advance our
- 1368 understanding of pediatric cancers in a meaningful way that
- 1369 could lead -- probably will lead to new treatments for
- 1370 children. So I am just glad we were able to come to a
- 1371 bipartisan agreement on this, and encourage members to vote
- 1372 in favor.
- 1373 *Mr. Upton. Will the gentleman yield?
- *The Chairman. Yes, I yield to -- well, you want your
- 1375 own time?
- *Mr. Upton. No, no, I don't need --
- *The Chairman. All right. Well, it is Ms. Eshoo's
- 1378 time.
- Do you yield to Mr. Upton?
- *Ms. Eshoo. I am happy to.
- *Mr. Upton. I just want to thank my colleague, Mr.
- 1382 Butterfield. He has been a very helpful leader on this. I
- 1383 am sorry he is not present. We have got to watch his face on
- 1384 the Zoom.
- But this is an important amendment, and a lot of us have
- 1386 been dealing with the FDA over the last couple of weeks. And
- 1387 I know that this is something that I believe the
- 1388 Administration supports. But as we solve these awful
- 1389 diseases, this is an important tool in the toolbox that we
- 1390 need to have, and certainly I am glad to support it. I am

- 1391 glad that it is part of this legislation.
- 1392 And I yield back to my friend.
- 1393 *The Chairman. Thank you --
- *Mr. Butterfield. Mr. Chairman, if I could say very,
- 1395 very briefly, Mr. Chairman, I would be there today, but I
- lost four friends over the weekend. One of the funerals is
- 1397 today, so thank you, and --
- *The Chairman. Oh, my God.
- *Mr. Butterfield. -- [inaudible]. Yes.
- *The Chairman. Well, thank you. Unbelievable.
- 1401 Ms. Eshoo, you yield back?
- 1402 *Ms. Eshoo. I do.
- 1403 *The Chairman. Okay, the gentlewoman yields back.
- 1404 Does -- anyone on either side would like to comment on
- 1405 the Butterfield amendment?
- 1406 If not, we will go to a voice vote. Okay. If there are
- 1407 no -- if there is no further debate, we will proceed to a
- 1408 vote on the amendment.
- 1409 All those in favor of the amendment will signify by
- 1410 saying aye.
- 1411 All those opposed will say no.
- In the opinion of the chair, the ayes have it. The
- 1413 amendment is agreed to.
- 1414 Are there any further amendments to the amendment in the
- 1415 nature of a substitute?

- I don't think so. Okay, so then we will go to the AINS.
- 1417 If there is no further discussion, we will proceed to a vote
- on the amendment in the nature of a substitute.
- 1419 Is this a voice vote? Voice vote?
- 1420 *Voice. A voice vote on the AINS.
- *The Chairman. Okay, all those in favor of the
- 1422 amendment, Mr. Guthrie's amendment in the nature of a
- substitute to H.R. 7667, as amended, will signify by saying
- 1424 aye.
- 1425 All those opposed, say no.
- In the opinion of the chair, the ayes have it, and the
- amendment in the nature of a substitute to H.R. 7667, as
- 1428 amended, is agreed to.
- 1429 The question now occurs on favorably reporting --
- 1430 *Voice. This is a recorded vote.
- *The Chairman. Oh, this is recorded, okay. All right.
- 1432 With that -- well, I still have to announce what it is.
- So the question now occurs on favorably reporting H.R.
- 1434 7667, as amended, to the House. A recorded vote has been
- 1435 ordered.
- Those in favor of reporting H.R. 7667, as amended, to
- the House will say aye, those opposed will say no, and the
- 1438 clerk shall call the roll.
- 1439 *The Clerk. Mr. Rush?
- [No response.]

- *The Clerk. Ms. Eshoo?
- *Ms. Eshoo. [Inaudible.]
- *The Clerk. Ms. Eshoo votes aye.
- 1444 Ms. DeGette?
- 1445 *Ms. DeGette. Aye.
- *The Clerk. Ms. DeGette votes aye.
- 1447 Mr. Doyle?
- 1448 *Mr. Doyle. Yes.
- *The Clerk. Mr. Doyle votes aye.
- 1450 Ms. Schakowsky?
- [No response.]
- *The Clerk. Ms. Schakowsky?
- 1453 [Pause.]
- 1454 *Voice. She is muted.
- 1455 *Ms. Schakowsky. Schakowsky votes aye.
- *The Clerk. Ms. Schakowsky votes aye.
- 1457 Mr. Butterfield?
- 1458 *Mr. Butterfield. Votes aye.
- *The Clerk. Mr. Butterfield votes aye.
- 1460 Ms. Matsui?
- *Ms. Matsui. Matsui votes aye.
- *The Clerk. Ms. Matsui votes aye.
- 1463 Ms. Castor?
- *Ms. Castor. Ms. Castor votes aye.
- *The Clerk. Ms. Castor votes aye.

- 1466 Mr. Sarbanes?
- *Mr. Sarbanes. Sarbanes votes aye.
- *The Clerk. Mr. Sarbanes votes aye.
- 1469 Mr. McNerney?
- 1470 *Mr. McNerney. McNerney votes aye.
- *The Clerk. Mr. McNerney votes aye.
- 1472 Mr. Welch?
- [No response.]
- 1474 *The Clerk. Mr. Tonko?
- 1475 *Mr. Tonko. Mr. Tonko from New York votes aye.
- *The Clerk. Mr. Tonko votes aye.
- 1477 Ms. Clarke?
- 1478 *Ms. Clarke. Ms. Clarke from New York votes aye.
- *The Clerk. Ms. Clarke votes aye.
- 1480 Mr. Schrader?
- *Mr. Schrader. Schrader votes aye.
- 1482 *The Clerk. Mr. Schrader votes aye.
- 1483 Mr. Cardenas?
- 1484 *Mr. Cardenas. Cardenas from California votes aye.
- *The Clerk. Mr. Cardenas votes aye.
- 1486 Mr. Ruiz?
- *Mr. Ruiz. Ruiz votes aye.
- *The Clerk. Mr. Ruiz votes aye.
- 1489 Mr. Peters?
- 1490 *Mr. Peters. Peters votes aye.

- *The Clerk. Mr. Peters votes aye.
- 1492 Mrs. Dingell?
- 1493 *Mrs. Dingell. Dingell votes aye.
- *The Clerk. Mrs. Dingell votes aye.
- 1495 Mr. Veasey?
- [No response.]
- 1497 *The Clerk. Ms. Kuster?
- 1498 *Ms. Kuster. Kuster votes aye.
- *The Clerk. Ms. Kuster votes aye.
- 1500 Ms. Kelly?
- *Ms. Kelly. Kelly votes aye.
- *The Clerk. Ms. Kelly votes aye.
- 1503 Ms. Barragan?
- *Ms. Barragan. Barragan votes aye.
- *The Clerk. Ms. Barragan votes aye.
- 1506 Mr. McEachin?
- [No response.]
- *The Clerk. Ms. Blunt Rochester?
- *Ms. Blunt Rochester. Blunt Rochester votes aye.
- *The Clerk. Ms. Blunt Rochester votes aye.
- 1511 Mr. Soto?
- 1512 *Mr. Soto. Aye.
- *The Clerk. Mr. Soto votes aye.
- 1514 Mr. O'Halleran?
- *Mr. O'Halleran. O'Halleran votes aye.

- 1516 *Voice. Sablan votes aye.
- *Voice. Mr. Sablan votes aye.
- 1518 Ms. Kuster?
- *Voice. Kuster votes aye.
- *Voice. Ms. Kuster votes aye.
- 1521 Ms. Bustos?
- *Mr. O'Halleran. O'Halleran votes aye.
- 1523 [Laughter.]
- *Voice. What are they doing?
- *The Clerk. Mr. O'Halleran?
- 1526 *Mr. O'Halleran. O'Halleran votes aye.
- 1527 *Voice. Mr. Maloney?
- 1528 [Laughter.]
- *The Clerk. Mr. O'Halleran, I can't see you.
- 1530 [Pause.]
- *Mr. O'Halleran. Mr. O'Halleran votes aye.
- 1532 *Voice. Mr. Chairman, how am I recorded?
- *The Clerk. Mr. O'Halleran votes aye.
- 1534 Miss Rice?
- *Voice. Mr. Maloney, you are not recorded.
- *Miss Rice. Rice votes aye.
- *The Clerk. Miss Rice votes aye.
- 1538 Ms. Craig?
- 1539 *Ms. Craig. Craig of Minnesota votes aye.
- *The Clerk. Ms. Craig votes aye.

```
1541
           Ms. Schrier?
            *Ms. Schrier.
1542
                           Schrier votes aye.
            *The Clerk. Ms. Schrier votes aye.
1543
           Mrs. Trahan?
1544
1545
            *Mrs. Trahan.
                           Trahan votes aye.
            *The Clerk. Mrs. Trahan votes aye.
1546
           Mrs. Fletcher?
1547
1548
            [No response.]
1549
            *The Clerk. Mrs. Rodgers?
1550
            *Mrs. Rodgers. [Inaudible.]
1551
            *The Clerk. Mrs. Rodgers votes aye.
           Mr. Upton?
1552
           *Mr. Upton. Votes aye.
1553
1554
            *The Clerk. Mr. Upton votes aye.
1555
           Mr. Burgess?
1556
            *Mr. Burgess. [Inaudible.]
            *The Clerk. Mr. Burgess votes aye.
1557
           Mr. Scalise?
1558
1559
            [No response.]
1560
           *The Clerk. Mr. Latta?
           *Mr. Latta.
1561
                        [Inaudible.]
1562
           *The Clerk. Mr. Latta votes aye.
```

Mr. Guthrie?

*Mr. Guthrie. Aye.

*The Clerk. Mr. Guthrie votes aye.

1563

1564

- 1566 Mr. McKinley?
- *Mr. McKinley. Aye.
- *The Clerk. Mr. McKinley votes aye.
- 1569 Mr. Kinzinger?
- 1570 *Mr. Kinzinger. Aye.
- *The Clerk. Mr. Kinzinger votes aye.
- 1572 Mr. Griffith?
- 1573 *Mr. Griffith. Aye.
- *The Clerk. Mr. Griffith votes aye.
- 1575 Mr. Bilirakis?
- 1576 *Mr. Bilirakis. Aye.
- *The Clerk. Mr. Bilirakis votes aye.
- 1578 Mr. Johnson?
- 1579 *Mr. Johnson. Aye.
- *The Clerk. Mr. Johnson votes aye.
- 1581 Mr. Long?
- 1582 *Mr. Long. The only Long in Congress votes aye.
- *The Clerk. Mr. Long votes aye.
- 1584 Mr. Bucshon?
- 1585 *Mr. Bucshon. Aye.
- *The Clerk. Mr. Bucshon votes aye.
- 1587 Mr. Mullin?
- 1588 *Mr. Mullin. Aye.
- *The Clerk. Mr. Mullin votes aye.
- 1590 Mr. Hudson?

- 1591 *Mr. Hudson. Aye.
- *The Clerk. Mr. Hudson votes aye.
- 1593 Mr. Walberg?
- 1594 *Mr. Walberg. Aye.
- *The Clerk. Mr. Walberg votes aye.
- 1596 Mr. Carter?
- 1597 *Mr. Carter. Aye.
- *The Clerk. Mr. Carter votes aye.
- 1599 Mr. Duncan?
- 1600 *Mr. Duncan. Aye.
- *The Clerk. Mr. Duncan votes aye.
- 1602 Mr. Palmer?
- 1603 *Mr. Palmer. Aye.
- *The Clerk. Mr. Palmer votes aye.
- 1605 Mr. Dunn?
- 1606 *Mr. Dunn. Dunn votes aye.
- *The Clerk. Mr. Dunn votes aye.
- 1608 Mr. Curtis?
- 1609 *Mr. Curtis. Aye.
- *The Clerk. Mr. Curtis votes aye.
- 1611 Mrs. Lesko?
- 1612 *Mrs. Lesko. Aye.
- *The Clerk. Mrs. Lesko votes aye.
- 1614 Mr. Pence?
- 1615 *Mr. Pence. Aye.

- *The Clerk. Mr. Pence votes aye.
- 1617 Mr. Crenshaw?
- 1618 *Mr. Crenshaw. Aye.
- *The Clerk. Mr. Crenshaw votes aye.
- 1620 Mr. Joyce?
- *Mr. Joyce. Joyce votes aye.
- *The Clerk. Mr. Joyce votes aye.
- Mr. Armstrong?
- *Mr. Armstrong. [Inaudible.]
- *The Clerk. Mr. Armstrong votes aye.
- 1626 Chairman Pallone?
- *The Chairman. Pallone votes aye.
- *The Clerk. Chairman Pallone votes aye.
- 1629 *The Chairman. Members who are not recorded?
- 1630 Mr. Veasey?
- *Mr. Veasey. Mr. Chairman, I vote aye.
- 1632 *Mr. Rush. Mr. Chairman --
- *The Clerk. Mr. Veasey votes aye.
- 1634 *Mr. Rush. Mr. Chairman, how am I --
- 1635 *The Chairman. Mr. Rush?
- 1636 *Mr. Rush. Rush votes aye.
- *The Clerk. Mr. Rush votes aye.
- 1638 *The Chairman. Mrs. Fletcher?
- *Mrs. Fletcher. Fletcher votes aye.
- *The Clerk. Mrs. Fletcher votes aye.

- *The Chairman. Anyone else who is not recorded?
- 1642 That is it?
- 1643 All right, the clerk will report the tally.
- *The Clerk. On that vote, Mr. Chairman, the yeas are 55
- and the nays are 0.
- *The Chairman. Give me that again.
- *The Clerk. The yeas are 55 and the nays are 0.
- *The Chairman. Wow, I forgot that we had so many
- members.
- 1650 All right, the vote is 55 ayes to 0 noes, and so H.R.
- 1651 7667, as amended, is reported to the full House. Thank you,
- 1652 everyone.
- So now we are going to go to H.R. 7666. The chair calls
- up H.R. 7666, the Restoring Hope for Mental Health and
- 1655 Well-Being Act of 2022.
- 1656 And the clerk will report the title of the bill.
- *The Clerk. H.R. 7666, a bill to amend the Public
- 1658 Health Service Act to reauthorize certain programs relating
- 1659 to mental health and substance --
- *The Chairman. And without objection, Madam Clerk,
- 1661 without objection, the first reading of the bill would be
- dispensed with, and the bill is now considered as read.
- Does there -- anyone -- I am sorry.
- 1664 Without objection, the bill is considered as read and
- open for amendment at any point.

1666	[The bill follows:]
1667	
1668	**************************************
1669	

- *The Chairman. But why don't we start with those who
- 1671 would like to speak on the underlying bill?
- 1672 The Ranking Member, Mrs. Rodgers, is recognized.
- 1673 *Mrs. Rodgers. Thank you, Mr. Chairman. I move to
- 1674 strike the last word.
- *The Chairman. The gentlewoman is recognized.
- 1676 *Mrs. Rodgers. Mr. Chairman, I want to thank you again
- 1677 for working with us on this legislation, for your leadership
- on improving people's mental health.
- I know we have a commitment to keep working on some of
- 1680 the provisions.
- I also wanted to quickly make a note about the spending
- in this package. Many of the bills in this markup authorize
- 1683 discretionary spending, and often at currently appropriated
- 1684 levels. A few provisions and bills that we have included in
- this package, however, will have mandatory spending
- 1686 implications. I want to commit to my colleagues that, when
- 1687 the mental health package from Energy and Commerce is on the
- 1688 floor, that any mandatory spending will be fully offset.
- 1689 This has been the case for a number of bipartisan bills with
- 1690 mandatory spending that have moved through this committee in
- 1691 the past, including the SUPPORT Act.
- Mr. Chairman, just as you did last week in the Health
- 1693 Subcommittee, will you commit to working with me on mandatory
- spending in the mental health package before consideration on

- 1695 the floor?
- *The Chairman. Absolutely. And that has been our
- 1697 policy in general, that we will -- you know, this will be
- 1698 offset. Thank you.
- 1699 *Mrs. Rodgers. Thank you. I appreciate that
- 1700 commitment, as well as your partnership in working on this
- 1701 legislation.
- 1702 I yield.
- 1703 *The Chairman. Thank you.
- 1704 Anyone -- Ms. -- oh, okay. We are -- again, we are
- 1705 going to do this in order of seniority. So Ms. Clarke is
- 1706 recognized on the underlying bill.
- 1707 *Ms. Clarke. Thank you, Mr. Chairman. Mr. Chairman, I
- 1708 move to strike the last word.
- 1709 *The Chairman. The gentlewoman from Brooklyn is
- 1710 recognized. I say that because I like Brooklyn.
- 1711 *Ms. Clarke. Thank you, Mr. Chairman. A lot of folks
- 1712 are liking Brooklyn these days. But let me move forward with
- my statement.
- 1714 The need to invest more towards supporting mothers
- 1715 suffering from mental health issues and substance use
- 1716 disorders is extremely critical. It is astounding that -- to
- 1717 know that about 800,000 new moms in the United States each
- 1718 year experience a maternity-related mental health issue.
- 1719 Mental and emotional support and the access to mental

- 1720 health care has long been overlooked, yet it is critical to
- the overall health of both women, mothers, and their
- 1722 newborns.
- But the gift of life that it brings -- pregnancy can be
- a precious and blessed time in the lives of mothers who are
- 1725 experiencing it. Tragically, though, pregnancy also carries
- 1726 countless dangers to both mothers and their children that can
- 1727 persist long past birth. That is why I am proud to be
- 1728 co-leading the bipartisan, bicameral legislation, Into the
- 1729 Light for Mental -- Maternal Mental Health and Substance Use
- 1730 Disorder Act, along with my colleagues, Representatives
- 1731 Katherine Clark, Jaime Herrera Beutler, Doris Matsui, Michael
- 1732 Burgess, and Young Kim.
- This legislation is not only a necessary step towards
- 1734 providing new and expectant mothers and their children with
- the resources they need to stay healthy, both physically and
- 1736 mentally, but it reaffirms our commitment to support mothers
- 1737 through whatever difficulties they may face. Furthermore, it
- is an opportunity to protect and serve American mothers by
- 1739 providing them with the proper resources to lead a safe and
- 1740 healthy postpartum life. That is why I am proud to stand
- 1741 with my colleagues in this noble pursuit, and believe passing
- this legislation is an important step in ensuring no mother
- 1743 will suffer alone.
- 1744 I thank you, Mr. Chairman and Chairwoman Eshoo, for

- 1745 bringing up and supporting the mental health and well-being
- 1746 of communities in need. With that, I yield back the balance
- 1747 of my time.
- 1748 *The Chairman. Thank you.
- So now we -- these are statements on the underlying
- 1750 bill. Anyone on the -- Mr. Guthrie?
- 1751 *Mr. Guthrie. Thank you, Mr. Chair. I move to strike
- 1752 the last word.
- 1753 *The Chairman. The gentleman is recognized.
- 1754 *Mr. Guthrie. Thank you, Mr. Chair.
- 1755 H.R. 7666, the Restoring Hope for Mental Health and
- 1756 Well-Being Act, provides resources for building our
- 1757 behavioral health care workforce, treatment, and substance
- 1758 use disorder recovery resources, and access to mental health
- 1759 care services for those with mental illness.
- 1760 Recent Centers for Disease Control Prevention survey
- data underscores the stark toll school closures and lockdowns
- 1762 had on our youth throughout the pandemic. The data shows
- that nearly one in three of high school students surveyed
- 1764 experienced poor mental health during the pandemic, and
- 1765 nearly half the students felt persistently sad or hopeless.
- 1766 Some students even reported an experience of emotional abuse
- in the home, and more than 10 percent reported physical abuse
- 1768 in their home.
- 1769 The lockdown measures around the COVID-19 pandemic only

- 1770 compounded the substance use disorder issues impacting
- 1771 communities across the country, with my home state of
- 1772 Kentucky seeing one of the highest rises of drug annual
- overdoses between 2020 and 2021 in the country. Nationally,
- 1774 the CDC reported last week that the number of drug overdoses
- in 2021 is estimated to exceed 107,000 deaths.
- 1776 Ultimately, fighting the drug overdose epidemic will
- 1777 require a two-pronged approach. We need to equip our law
- 1778 enforcement with the tools they need to get these deadly
- 1779 poisons off the street, while making treatment and recovery
- 1780 resources available to those seeking help, especially
- 1781 vulnerable populations.
- 1782 Importantly, the proposals in the bill before us today
- 1783 will help to achieve these objectives, while helping us build
- our behavioral health care workforce to meet future needs.
- 1785 H.R. 7666 includes proposals designed to provide targeted
- 1786 resources to communities in need for the next several years.
- 1787 This bill unanimously passed the House subcommittee last
- 1788 week.
- 1789 Some specific highlights include the reauthorization of
- 1790 the Garrett Lee Smith Memorial Reauthorization Act. I would
- 1791 like to thank Ranking Member Rodgers and Representatives
- 1792 Trahan and Young Kim for leading on this issue.
- 1793 Representative Bucshon is also leading legislation
- 1794 alongside Representative Miller-Meeks, Axne, and Pappas to

- 1795 remove regulatory barriers to help those with opioid use
- 1796 disorder seek the care they need as quickly as possible.
- 1797 This is the Timely Treatment for Opioid Use Disorder Act.
- 1798 Representatives Curtis and Tonko are leading the Helping
- 1799 Enable Access to Lifesaving Services Act.
- 1800 And I am proud that my bill, the Substance Use
- 1801 Prevention, Treatment, and Recovery Support Services Block
- 1802 Grant, which I co-led with Representatives Tonko, McKinley,
- 1803 and Wild, is also included.
- I urge my colleagues to vote yes on Restoring the Hope
- 1805 for Mental Health and Well-Being, and I yield back.
- *The Chairman. Thank you, Mr. Guthrie. Next we have --
- 1807 Mr. Tonko is recognized for five minutes.
- 1808 *Mr. Tonko. Thank you, Mr. Chair. I move to strike the
- 1809 last word.
- 1810 *The Chairman. The gentleman is recognized.
- 1811 *Mr. Tonko. Thank you. I am proud to have worked on
- 1812 the bipartisan Substance Use Prevention, Treatment and
- 1813 Recovery Services Block Grant, which is incorporated as
- 1814 subtitle D of this bill, with my colleagues and friends,
- 1815 Representatives Guthrie, Wild, and McKinley.
- 1816 Thank you to Chair Eshoo and Ranking Member Guthrie and
- 1817 Chair Pallone and Ranking Member McMorris Rodgers and their
- 1818 staff for the focus on this legislation.
- 1819 Across our nation, millions of Americans are struggling

- 1820 with the disease of addiction, a crisis that has become even
- more dire during this pandemic. A staggering 101,306 people
- died of drug overdoses between April 2020 and April 2021, as
- 1823 -- 3 times more deaths than from traffic accidents. There is
- 1824 no corner of the country that has escaped the effects of this
- 1825 crisis.
- During my time in Congress I have fought hard to support
- 1827 programs that address this worsening crisis, and deliver
- 1828 critical resources to our communities. Last year I fought
- 1829 successfully to deliver funding to the Substance Abuse
- 1830 Prevention and Treatment Block Grant Program through our
- 1831 American Rescue Plan. And this reauthorization underscores
- 1832 our continuing commitment to ensuring we provide hope and,
- indeed, a path forward for our neighbors and loved ones who
- 1834 need it most.
- One of the best ways we can lessen the impacts of this
- 1836 epidemic is by strengthening and supporting state substance
- 1837 use prevention, treatment, and recovery efforts through the
- 1838 Substance Use Prevention, Treatment, and Recovery Services
- 1839 Block Grant reauthorization. The legislation will
- 1840 reauthorize this crucial block grant for another five years,
- 1841 guaranteeing sustained investment in evidence-based programs
- 1842 that support states, communities, and families battling the
- 1843 disease of addiction.
- 1844 It also updates services provided under the block grant

- 1845 to include screening and referral for treatment of viral
- 1846 hepatitis, in addition to existing services related to HIV
- 1847 and tuberculosis, and eliminates stigmatizing language
- 1848 related to substance use.
- This funding stream serves as the cornerstone of state
- substance use, treatment, prevention, and recovery systems.
- 1851 Block grant funds, which are distributed by formula to all
- 1852 states and territories, provide lifesaving treatment services
- 1853 to approximately one -- four million individuals per year.
- 1854 In some states, the block grant investment accounts for 100
- 1855 percent of substance use prevention dollars.
- 1856 While the overdose crisis predates the COVID-19
- 1857 pandemic, it has further impacted individuals struggling with
- 1858 or at risk for substance use disorders. So I think it is
- 1859 incredibly important that we did include this into our
- 1860 legislation.
- 1861 And with that, Mr. Chair, I yield back.
- 1862 *The Chairman. Thank you, Mr. Tonko.
- Does anyone else want to speak on the underlying bill?
- 1864 Anybody on the Republican side?
- 1865 If not, we will go to Chairwoman Eshoo.
- 1866 *Ms. Eshoo. Mr. Chairman, I move to strike the last
- 1867 word --
- 1868 *The Chairman. The gentlewoman is recognized.
- 1869 *Ms. Eshoo. -- [inaudible] amendment. I want to thank

- our colleague, Paul Tonko, for offering this amendment.
- 1871 Your years-long work expanding access to addiction
- 1872 treatment we all appreciate.
- 1873 Last year -- this is a terrible statistic. Oh, I see.
- 1874 Oh, I am -- yes, I am speaking on the amendment. So this is
- 1875 the AINS, so I will.
- *The Chairman. No, you can speak on it now, if you want
- 1877 to.
- 1878 *Ms. Eshoo. Okay, great. I will continue on this very
- 1879 well drawn remark. I know everyone is listening with bated
- 1880 breath.
- But this statistic -- and everyone on this committee
- 1882 cares about this -- last year, more than 106,000 Americans
- 1883 died from an overdose. And this is a record high. And one
- of the contributing factors to this overdose rate is how
- 1885 nearly impossible it is to find treatment. According to
- 1886 SAMHSA, in 2020 only 11 percent of people with an opioid
- 1887 addiction received medication-assisted treatment.
- 1888 There is an outdated Federal regulation known as the X
- 1889 waiver -- sounds like a movie -- puts unnecessary
- 1890 bureaucratic requirements on evidence-based care for opioid
- 1891 use disorder. This is not how we should be managing care in
- 1892 the midst of an epidemic that only continues to grow. The
- 1893 best way to treat the opioid crisis is to give patients
- 1894 evidence-based medications that are known to reduce the risk

- of overdose death, and help get long-term recovery.
- 1896 And Representative Tonko's amendment does just that. It
- 1897 removes the Federal restrictions on effective medical
- 1898 treatments by ending the stigmatizing X waiver, and it allows
- 1899 clinicians to prescribe the evidence-based care that is
- 1900 needed to save lives. So this is a very good bill. I think
- 1901 it is one of the best things we can do to prevent overdose
- 1902 deaths, and I urge everyone to vote for it.
- 1903 I yield back.
- 1904 *The Chairman. Thank you, Chairwoman.
- 1905 So we are going to do -- finish with the underlying bill
- 1906 statements. Then we are going to go to the AINS, and then we
- 1907 will have the Tonko amendment to the AINS.
- 1908 Anyone else on the underlying bill?
- 1909 Ms. -- on the Republican side now?
- 1910 All right. The gentlewoman from Michigan, Mrs. Dingell.
- 1911 *Mrs. Dingell. Thank you, Mr. Chairman. I move to
- 1912 strike the last word.
- 1913 I want to thank you and Ranking Member McMorris Rodgers
- 1914 for your efforts to build consensus in this important
- 1915 legislation to reauthorize and strengthen critical mental and
- 1916 behavioral health programs that will help address public
- 1917 health issues like the opioid epidemic, which claimed over
- 1918 107,000 lives in the United States last year alone.
- 1919 As was discussed last week in the subcommittee markup,

the mental health package before us contains strong mental
health parity provisions my colleague, Congresswoman Katie
Porter, and I led, which closes a critical gap in health care
coverage for mental health and substance abuse treatment for

thousands of frontline workers across the country.

1924

1935

I would also like to thank the chairman and ranking 1925 member for including a provision in today's AINS based off 1926 the Preventing Overdoses and Saving Lives Act 2.0, which I 1927 co-led with my friend and colleague, Congressman French Hill. 1928 1929 This provision provides incentives for co-prescribing when a doctor pairs an opioid prescription with a prescription of an 1930 opioid overdose reversal drug like naloxone. As was noted 1931 during a hearing before this committee with the Office of 1932 National Drug Control Policy, co-prescribing is a proven 1933 intervention that helps save lives, and must be part of a 1934

comprehensive effort to address the opioid crisis.

- Additionally, we have seen bipartisan adoption of coprescribing policies in states across the country. Inclusion
 of a co-prescribing provision in today's legislation
 strengthens the underlying package and our response to the
 opioid crisis.
- I appreciate the chairman, ranking member, as well as
 both Democratic and Republican committee staffs for the
 constructive efforts to engage on this issue with Congressman
 Hill and myself, and to incorporate it in today's

- 1945 legislation. This is a strong package that will improve our
- 1946 national response to some of the most pressing public health
- 1947 challenges facing Americans across the country, and it
- 1948 deserves our support.
- 1949 Thank you, Mr. Chairman, and I yield back.
- 1950 *The Chairman. Thank you, Mrs. Dingell.
- 1951 Anyone else on the underlying bill?
- 1952 Ms. Barragan is recognized.
- 1953 *Ms. Barragan. Thank you, Mr. Chairman, ad I move to
- 1954 strike the last word.
- 1955 *The Chairman. The gentlewoman is recognized for five
- 1956 minutes.
- 1957 *Ms. Barragan. Thank you, Mr. Chairman.
- 1958 I support provisions of this bill, H.R. 766 (sic), but I
- 1959 want to point out and talk about one section, 301, of this
- 1960 bill. It makes important investments in the collaborative
- 1961 care model to increase access to primary and behavioral
- 1962 health care.
- 1963 These integrated models of care hold a lot of potential
- 1964 for expanding access to behavioral health services for
- 1965 under-served communities. However, I believe we should also
- 1966 invest in other evidence-based models of integrated care,
- 1967 such as the primary care behavioral health model, to ensure
- 1968 no communities get left behind.
- 1969 I would note that Dr. Sandy Chung, president-elect of

- 1970 the American Academy of Pediatrics, testified that Congress
- 1971 should support both models of integrated care during last
- 1972 month's Health Subcommittee hearing on mental health.
- 1973 I have also heard from constituents in my district that
- 1974 this model has helped them access much-needed behavioral
- 1975 health services.
- 1976 I am proud of the work the committee has done to support
- 1977 and invest in mental health care, but I believe there is more
- 1978 that we can do. Increasing access to mental health care is
- 1979 important to me, and I hope we can look at this a little more
- 1980 closely.
- I want to emphasize that I support this bill, and I
- 1982 encourage my colleagues to do the same.
- 1983 Thank you, and I yield back.
- 1984 *The Chairman. Thank you, Ms. Barragan.
- 1985 Anyone else on the underlying bill?
- 1986 *Mr. O'Halleran. Mr. Chairman?
- 1987 *The Chairman. Mr. O'Halleran is recognized.
- 1988 *Mr. O'Halleran. Mr. Chairman, I move to strike the
- 1989 last word.
- 1990 *The Chairman. The gentleman is recognized for five
- 1991 minutes.
- 1992 *Mr. O'Halleran. I want to thank the chair and ranking
- 1993 member for today's bipartisan markup of a significant and
- 1994 comprehensive mental health package and substance abuse

- 1995 package.
- 1996 Now, through my time on this committee, I have -- we
- 1997 have worked in a bipartisan manner on bills to address
- 1998 substance abuse, including opioid and alcohol dependency and
- 1999 mental health bills to improve access to much-needed mental
- 2000 health care for all Americans. I am pleased to see that work
- 2001 continued today.
- 2002 And I also want to thank the staff and the leadership of
- 2003 the committee on both sides of the aisle.
- 2004 More than five people die every day of opioid overdoses
- 2005 in Arizona. The influx of counterfeit opioids like fentanyl
- 2006 are highly addictive and very deadly. I rise in -- the rise
- 2007 in fentanyl deaths is tearing our communities apart. I see
- 2008 this in many of the tribal communities that I represent.
- 2009 We know the date of drug -- rate of overdose deaths
- 2010 involving opioids is higher among Native American natives and
- 2011 also Alaska natives. We also know that it is higher in rural
- 2012 communities than the national average. This is in part
- 2013 because those of us in rural communities and in the tribal
- 2014 communities that I represent lack access to the most basic
- 2015 health care services that many take for granted.
- 2016 The storage of mental health providers is -- shortage of
- 2017 mental health providers is especially evident in our schools,
- 2018 where children struggle for access, and in our communities,
- 2019 where many patients are forced to travel long distances just

- to see a provider. Access to mental health services via
 telehealth has been particularly important, but we still are
 suffering from a lack of access to these services, and so are
 the families that are undergoing these tremendous, tragic
 events in their lives.
- I also thank the committee for including legislation 2025 that I helped lead, the Summer Barrow Prevention, Treatment, 2026 and Recovery Act, legislation which authorizes 11 SAMHSA 2027 programs that support mental health and substance use 2028 2029 disorder prevention, treatment, and recovery services. bold package includes substantial investments that will allow 2030 local and tribal leaders to put these funds to use in their 2031 2032 communities to provide support for those suffering from opioid dependency, providing services to pregnant and 2033 postpartum women in need of substance use treatment, funding 2034 to combat underage drinking, and funding to improve access to 2035 overdose medication. 2036

2037 Many local and regional non-profits take much of this work on themselves. For example, this package will help 2038 2039 ensure the homeless shelter like Flagstaff Shelter Services in Arizona will -- it will be able to provide important 2040 services to much of northern Arizona population. 2041 They are the actual on-the-ground providers providing this overdose 2042 2043 medication directly to individuals and treatment centers, saving lives and making our communities safer. 2044

- There is a much -- much I like in this package. But I
- 2046 do want to highlight the extensive focus on mental health and
- 2047 support for children in this package. The burdens of social
- 2048 media and the targeted harassment we see, particularly of
- 2049 younger women and girls, has caused a dramatic increase in
- 2050 mental health issues, including unfortunate suicides in
- 2051 teenagers. This is a tragedy. I look forward to continuing
- 2052 that work to hold them accountable through this committee.
- 2053 But I applaud the immediate focus on mental health for
- 2054 children.
- I will be proud to support this package, and look
- 2056 forward to continuing to work across the aisle to ensure that
- 2057 it becomes law.
- 2058 Thank you, Mr. Chair, and I yield.
- *The Chairman. Thank you, Mr. O'Halleran.
- So we are still on the underlying bill, if anyone wants
- 2061 to speak on that.
- 2062 Mrs. Fletcher?
- 2063 *Voice. No, Ms. Schrier.
- *The Chairman. Oh, I am sorry. Dr. Schrier?
- 2065 *Ms. Schrier. Thank you, Mr. Chairman. I move to
- 2066 strike the last word to speak on the underlying bill.
- 2067 *The Chairman. The gentlewoman is recognized.
- 2068 *Ms. Schrier. Thank you. I am so excited about this
- 2069 really important package on mental and behavioral health,

- 2070 especially as a pediatrician who has seen the growing
- 2071 challenges over the past 20 years with children's mental
- 2072 health, has seen the impact of so many features. Even since
- 2073 2007 there has been a dramatic rise in anxiety and
- 2074 depression, self-harm, eating disorders. And this just
- 2075 skyrocketed during the pandemic.
- 2076 And one of our challenges in addressing this is that we
- just don't have enough mental health specialists, and we can
- 2078 improve the pipeline, there is a lot that we can do, but we
- 2079 need help right now. And that is why I am so excited about
- 2080 this bill, because the pediatric mental health care access
- 2081 program is one of the ways that an on-call psychiatrist, for
- 2082 example, could support hundreds of pediatricians right there
- 2083 in the office to provide care while the patient is there at
- 2084 the right moment, sometimes staving off crises and sometimes
- 2085 being able to handle a crisis that normally would require a
- 2086 psychiatrist to manage. And so it is just such a great way
- to leverage the resources that we have, while working to
- 2088 increase the number of providers because we are in a crisis
- 2089 moment now.
- 2090 So I am proud to vote on this critical package that will
- 2091 fund the programs that families and kids need to stay safe
- 2092 and healthy now and in the future.
- I wanted to highlight one other element that I am
- 2094 concerned about with kids' mental health and development,

- 2095 which is that, as the only pediatrician in Congress, I have
- 2096 also been watching screen time and social media. And I want
- 2097 to -- I just want to highlight that we know -- you have heard
- 2098 from my colleagues, social media has impacts on the mental
- 2099 health of children.
- 2100 Sometimes it is helpful -- a child who would otherwise
- 2101 be ostracized, and is in a very -- in an area that does not
- 2102 support, you know, whatever their challenge is, and they need
- 2103 a community. But more often, it is very damaging, as we have
- 2104 heard, particularly with girls.
- 2105 And research exists in this space. We have been
- 2106 evaluating the impact of screen time and social media on kids
- 2107 for over a decade now. And I am worried. So we need to just
- 2108 be able to bring together the experts in this space --
- 2109 academia, pediatricians, the private sector, the agencies
- 2110 that have jurisdiction to provide some evidence-based
- 2111 solutions -- to keep our kids healthy and safe. And I will
- 2112 have a bill on this coming up soon.
- 2113 Thank you very much, and I yield back.
- *The Chairman. Thank you, Dr. Schrier.
- I think we also have -- Mrs. Fletcher is recognized.
- 2116 *Mrs. Fletcher. Thank you, Mr. Chairman. I move to
- 2117 strike the last word.
- 2118 *The Chairman. The gentlewoman is recognized for five
- 2119 minutes.

*Mrs. Fletcher. Thank you, Mr. Chairman. Thanks to you 2120 2121 and the ranking member of the full committee, as well as the chairwoman and ranking member of the Health Subcommittee for 2122 including my bill, H.R. 5218, the Collaborate in an Orderly 2123 2124 and Cohesive Manner bill, in H.R. 7666, the Restoring Hope for Mental Health and Well-Being Act of 2022. 2125 included in section 301. 2126 2127 And I also want to thank my co-lead, Representative Herrera Beutler, for partnering with me on this legislation. 2128 As several of our colleagues have noted, the United 2129 States is experiencing a mental health crisis, and the 2130 pandemic has exacerbated it as well as our awareness of its 2131 2132 many challenges. As Dr. Schrier just noted, Americans have experienced increased rates of anxiety, depression, and 2133 trauma. Approximately 4 in 10 adults are reporting symptoms 2134 of anxiety or depressive disorder. And recent census data 2135 shows that the number of Americans expressing the need for 2136 mental health assistance who did not receive it increased by 2137 one third last year. 2138 2139 Many people first display symptoms of a mental health condition or substance use disorder in the primary care 2140 setting. But often they can't access the necessary follow-up 2141 treatment, either because it is too expensive or too 2142 2143 difficult to find the necessary mental health professionals,

the appropriate professionals, or they face other obstacles,

2144

including stigma. 2145 2146 The collaborative care model addresses these issues by creating a team made up of a primary care physician, a 2147 psychiatric consultant, and a care manager that can meet the 2148 2149 needs of their patients in the primary care setting, which improves the ability to detect and treat mental illness as 2150 soon as symptoms begin. This model is one of the most 2151 rigorously studied approaches to integrate mental health and 2152 substance use disorder services to patients within the 2153 2154 primary care setting. It is already covered by Medicare, most private insurers, and many state Medicaid programs. 2155 And studies have shown that it is a cost saver. A cost 2156 2157 benefit analysis showed that the model has a 12-to-1 benefit to cost ratio for the treatment of depression in adults. 2158 I introduced in the legislative hearing a letter of 2159 support from 44 organizations supporting this legislation, 2160 including the Meadows Institute from my home state of Texas. 2161 And I would like to submit a recent statement from the 2162 Meadows Institute for the record in this markup, as well, 2163 2164 noting that this --2165 *The Chairman. Without objection, so ordered. [The information follows:] 2166 2167 2168

2169

- 2170 *Mrs. Fletcher. Thank you, Mr. Chairman. The letter
- 2171 reiterates its support for the model, and its estimate that,
- in their modeling, universal access to the collaborative care
- 2173 model could save more than 14,500 lives a year.
- Despite its success, despite the great promise, the
- 2175 uptake of this model remains low, mainly because many primary
- 2176 care practices operate on thin financial margins with limited
- 2177 support staff, making implementing a new delivery model
- 2178 difficult. This bill will address the issue by providing the
- 2179 necessary grant funding so that primary care physicians and
- 2180 practices looking to adopt the model have the resources they
- 2181 need.
- 2182 I am proud of the work we have done to address this
- 2183 important issue in this provision, as well as the other
- 2184 important mental health issues in the overall bill. And I
- 2185 will continue to work on these issues. I look forward to
- 2186 voting in favor of this bill today, and I urge my colleagues
- 2187 to do the same.
- Thank you, Mr. Chairman, and I yield back.
- 2189 *The Chairman. Thank you, Mrs. Fletcher. Next we are
- 2190 going to go to -- Mr. Curtis of Utah is recognized.
- *Mr. Curtis. Thank you, Mr. Chairman, Mr. Ranking
- 2192 Member. I move to strike the last word.
- 2193 *The Chairman. The gentleman is recognized for five
- 2194 minutes.

- 2195 *Mr. Curtis. Thank you. Thank you both to the chair
- 2196 and ranking member for including my legislation, the Helping
- 2197 Enable Access to Lifesaving Services Act, or the HEALS Act,
- in the mental health package today.
- 2199 This bill will help fund multiple programs that support
- 2200 education and training for mental and behavioral health and
- 2201 care professionals. Over the course of the pandemic, we have
- 2202 become acutely aware of the concerns within health care,
- 2203 including problematic workforce shortages, further COVID-
- 2204 exasperated and already troubled mental health crisis. This
- 2205 bill will help address both of these concerns.
- 2206 And Mr. Chairman, with 4 minutes and 30 seconds left, I
- 2207 yield my time back.
- 2208 *The Chairman. Thank you. Thank you. Next I go to --
- 2209 Mrs. Lesko is recognized.
- 2210 *Mrs. Lesko. Thank you, Mr. Chair. I move to strike
- 2211 the last word.
- 2212 *The Chairman. The gentlewoman is recognized for five
- 2213 minutes.
- 2214 *Mrs. Lesko. I think this is a very important issue
- 2215 because of the growing urgency of helping people with mental
- 2216 health.
- But I also am concerned about the extra cost in this
- 2218 bill that is an increase of over \$100 million. And I think
- 2219 we need to start balancing our needs of the American people

- 2220 with the cost that we are adding into our budget and,
- 2221 ultimately, our national debt and our interest.
- It is projected that, in 10 years from now, our interest
- 2223 payments in one year's time will be 1.2 trillion. And I
- 2224 think that estimate was done before interest rates started
- 2225 going up. \$1.2 trillion is more than I believe we spend on
- 2226 Medicare in a year. It is more than we spend on the health
- 2227 care for our veterans. I think it is 11 times more than
- 2228 that. It is more than we spend on a lot of things, and it is
- 2229 unsustainable.
- 2230 And so I know that you have committed to coming up with
- some pay-fors to help pay for the increased costs of this
- 2232 bill, and I look forward to hearing that.
- 2233 And with that, I yield back.
- 2234 *The Chairman. Thank you.
- I don't think we have any more opening statements, do
- 2236 we?
- No? So now we are going to go to the AINS, which -- I
- 2238 believe I have the AINS, so I will ask the clerk to report
- the amendment.
- *The Clerk. Amendment in the nature a substitutes H.R.
- 7666, offered by Mr. Pallone of New Jersey.
- 2242 Strike all --
- *The Chairman. So Madam Clerk, without objection, the
- reading of the amendment will be dispensed with.

2245	[The amendment	of The	Chairman	<pre>follows:]</pre>
2246				
2247	*********COMMITTEE	INSERT******		
2248				

- 2249 *The Chairman. And I will recognize myself for five 2250 minutes.
- The amendment in the nature of a substitute is to H.R.
- 2252 7666, the Mental Health and Well-Being Act, and the reason we
- 2253 are doing this underlying bill, as well as the amendment, is
- 2254 because Americans are facing mental health and substance use
- 2255 disorder increasingly, to the point where I would say it is a
- 2256 crisis.
- Today one in five adults battle a mental illness, while
- 2258 youth face staggering risk of suicide, and the lives lost in
- 2259 substance use disorders continue to climb, with more than
- 2260 100,000 deaths due to drug overdoses last year, which is why
- 2261 I am pleased that, after months of planning, drafting, and
- 2262 negotiations, this committee will consider a bipartisan
- 2263 mental health and substance use disorder package that I
- 2264 introduced alongside Ranking Member Rodgers. And I am
- 2265 grateful for Mrs. Rodgers's dedication to working together on
- 2266 this bill.
- The package represents a shared recognition that we must
- 2268 rise to the moment and provide support and resources to the
- 2269 American people with the final product balancing funding
- 2270 needs and integrating new initiatives into existing programs.
- 2271 So the bill incorporates both Democratic and Republican-led
- 2272 provisions that I think will bring meaningful support to
- 2273 millions of Americans in particularly vulnerable communities

- that are battling mental health and substance use disorders.
- 2275 It includes the five-year reauthorization of critical SAMHSA
- 2276 and HRSA public health programs, and key additional
- 2277 activities to support the mental health of people of all
- 2278 ages, especially young people, and support substance use
- 2279 disorder prevention, treatment, and recovery support
- 2280 services.
- In addition to continued investment and flexibility of
- 2282 the community mental health services and the substance abuse
- 2283 prevention, treatment, and recovery services block grants,
- 2284 the package extends the Maternal Mental Health Screening and
- 2285 Treatment Grant Program and reauthorizes grants to support
- 2286 American Indian and Alaska Native communities with mental
- 2287 health and substance use disorder prevention, treatment, and
- 2288 recovery services.
- The bill also expands access to treatment for opioid use
- 2290 disorders, directing SAMHSA to assess opioid treatment
- 2291 programs flexibilities provided during the COVID-19 pandemic,
- 2292 and reducing unnecessary and arbitrary barriers to care.
- The bill expands the integration of mental health and
- 2294 physical health care, and closes a loophole in current law
- that allows self-funded state and local government health
- insurance plans to opt out of mental health parity.
- The AINS changes -- or I should say further strengthens
- 2298 the bill. In addition to technical changes, the AINS

- 2299 includes provisions from Representative Hill and
- 2300 Representative Dingell's bill, the Preventing Overdoses and
- 2301 Saving Lives Act 2.0, that supports the development of
- 2302 strategic opioid crisis response plans, and requires health
- 2303 care practitioners to prescribe an opioid reversal drug when
- 2304 prescribing an opioid for certain patients.
- 2305 Further, it includes new provisions from the Triumph for
- New Moms Act of 2021, introduced by Representatives Barragan
- 2307 and Dr. Bucshon, which requires the Secretary of HHS to make
- 2308 recommendations to coordinate and improve Federal responses
- 2309 to maternal mental health conditions.
- But there are -- and I want to point out -- there are
- 2311 several additional policy changes that are in the AINS. For
- 2312 example, we will consider the MAT Act amendment, which
- 2313 eliminates the requirement for medical practitioners to apply
- 2314 for an additional DEA registration to prescribe Bup, a proven
- 2315 FDA-approved medication to treat opioid use disorders.
- 2316 And I want to thank -- I want to take a moment to thank
- 2317 Priscilla Robinson, Heather Shachter, and all of the New
- 2318 Jersey organizing project advocates who have fought
- 2319 tirelessly for the MAT Act, and know firsthand access to Bup
- 2320 -- how Bup has saved lives.
- 2321 Let me also thank my state senator, or state Senator
- 2322 Vitale in my district, who chairs the health subcommittee in
- the state senate. He has been calling me regularly about

- this, and is going to be happy that we have included MAT and
- 2325 MATE.
- 2326 We -- the MATE Act, which provides eligible
- 2327 practitioners with critical training and education on
- 2328 treating and identifying substance use disorders, is in here.
- 2329 And finally, we will consider an amendment to expand
- 2330 mental health peer support in-person and virtual services,
- and an amendment to strengthen mental health parity by
- 2332 providing funding to states to implement and enforce parity.
- So again, I look forward to strengthening this
- 2334 legislation with bipartisan support for the AINS and the
- 2335 amendments to follow together in advancing the Restoring Hope
- 2336 Act. I mean, it truly is what its name says, Restoring Hope,
- 2337 and I think that will support -- or do a lot more to support
- 2338 mental health and well-being for all Americans.
- 2339 And with that, I yield back.
- 2340 Does anyone else want to speak on the AINS?
- 2341 Dr. Bucshon?
- *Mr. Bucshon. Thank you, Mr. Chairman. I want to thank
- 2343 the chair and ranking member for including two bills I
- 2344 authored in H.R. 7666, the Restoring Hope for Mental Health
- 2345 and Well-Being Act.
- 2346 First, the Timely Treatment for Opioid Use Disorder Act
- 2347 would revise opioid treatment program criteria to remove the
- 2348 requirement that patients must have been addicted for at

- least one year before being admitted for treatment. Nearly 1
- 2350 in 12 Hoosiers meet the criteria for having a substance use
- 2351 disorder, and they are now more likely to die from a drug
- overdose than a car crash. We need to continue to make sure
- 2353 Americans have access to treatment early, and this bill is a
- 2354 great stride forward in that effort.
- Second, the TRIUMPH for New Moms Act would establish a
- 2356 no-cost inter-departmental task force to address the U.S.
- 2357 maternal mental health crisis by closing gaps in treatment,
- 2358 eliminating duplication, and coordinating Federal resources
- 2359 towards maternal mental health.
- 2360 Current Federal efforts to support women suffering from
- 2361 maternal mental health conditions lack coordinated action and
- 2362 organization. And as a result, 50 percent of these moms
- 2363 never receive treatment. This bill will increase mental
- 2364 health support for pregnant and new mothers by offering
- 2365 targeted solutions that have proven success. With Indiana
- 2366 having one of the worst maternal mortality rates in the
- 2367 country, this legislation is timely and important to help
- 2368 save lives.
- 2369 With an increase in mental health issues over the course
- of the COVID-19 pandemic, it is critical we pass legislation
- 2371 to help provide resources for those who need it most. I look
- forward to supporting the underlying bill and urge my
- 2373 colleagues to support this legislation.

- Thank you, and I yield back the balance of my time.
- 2375 *The Chairman. Thank you, Dr. Bucshon.
- The gentlewoman from California, Ms. Barragan.
- *Ms. Barragan. Thank you, Mr. Chairman, and I move to
- 2378 strike the last word.
- 2379 *The Chairman. The gentlewoman is recognized for five
- 2380 minutes.
- *Ms. Barragan. I want to thank and share my
- 2382 appreciation with you, Mr. Chairman and Ranking Member
- 2383 Rodgers, for including language for my bill, the TRIUMPH for
- New Moms Act, to H.R. 7666 in section 113 of the AINS.
- The amendment being offered includes a provision that
- 2386 would create a national maternal mental health strategy, and
- 2387 integrate maternal mental health into existing maternal
- 2388 infant and mental health activities at the Federal level.
- 2389 Tragically, suicide and overdose combined are the
- leading cause of death for new mothers. Maternal mental
- 2391 health disorders are the most common complications of
- 2392 pregnancy and childbirth, affecting one in five pregnant
- women or new mothers. Nearly 800,000 American families each
- year struggle with this, and only 25 percent of those
- 2395 impacted receive treatment. This is so critical because
- 2396 women of color experience maternal mental health conditions
- 2397 at nearly double the rate of White women.
- Now, section 113 enhances Federal collaboration between

- 2399 agencies and departments, closes the gaps in existing Federal
- 2400 maternal health programs, and generates recommendations to
- 2401 state governors, agencies, and committees to improve their
- 2402 maternal mental health work.
- 2403 Also, it recognizes the important work maternal mental
- 2404 health organizations are already doing, and gathers their
- 2405 input and engagement.
- I want to also thank my co-lead, Mr. Bucshon, for
- 2407 working with me on this important bipartisan policy on
- 2408 maternal mental health.
- I look forward to everyone supporting this bill, and I
- 2410 encourage my colleagues to support the amendment and the
- 2411 underlying bill.
- 2412 Thank you, and I yield back.
- *The Chairman. Thank you, Ms. Barragan.
- 2414 Mr. -- do we have anyone on the Republican side who
- 2415 wants to speak on the AINS?
- Mr. Cardenas, you are recognized.
- 2417 *Mr. Cardenas. Thank you very much, Mr. Chairman. I
- 2418 move to strike the last word.
- 2419 *The Chairman. The gentleman is recognized for five
- 2420 minutes.
- *Mr. Cardenas. Thank you, Mr. Chairman.
- I have spoken on the importance of funding 988 before,
- 2423 and today there is -- this is not an exception. We are just

- 2424 2 months away from 988 going live across the country, and the
- stakes couldn't be higher to get it right.
- 2426 If we are serious about mental health having equivalence
- 2427 with other physical health, then we are missing a fundamental
- 2428 infrastructure to address urgent mental health needs. If I
- break a bone, for example, I can call 911 and an ambulance
- 2430 will arrive. But if I am experiencing a mental health
- crisis, I can't rely on a trained mental health professional
- 2432 to be dispatched to me to help me in my time of need. It is
- 2433 time to walk the talk, and actually build out a system across
- 2434 our country that addresses mental health with the same care
- 2435 and response as physical health as we are accustomed with
- 2436 911.
- Now, I know some of my colleagues may believe that 988
- 2438 is already funded, but let me tell you that is not the
- 2439 reality on the ground. And the consequences of being wrong
- are too high. If 988 launches and we are ill-equipped to
- 2441 handle the volume of calls, it will be catastrophic and set
- 2442 back our ability to implement a robust continuum of care.
- In this package there are key provisions that will help
- 2444 to ensure that anyone who calls will get a timely response,
- 2445 and that the situation is adequately managed.
- I urge my colleagues to support these provisions of the
- 2447 bill and others that will find and support crisis care
- 2448 services throughout the country -- that will fund.

- Also, I would like to talk about -- with that, I also
 want to raise one other issue that is closely related to
 providing public health services to those experiencing mental
 health and related issues, and specifically substance use
 disorders.
- I am disappointed to see that my colleagues on the other side of the aisle have pushed to narrow funding for evidence-based harm reduction measures. We must utilize all of the tools in our arsenal to treat addiction and substance use disorders. To -- not to do so is a grave misstep. And the proof is all around us, as we see skyrocketing rates of addiction and overdose deaths, even in teenagers.
- There is a lot of misinformation out there about harm reduction, so I want to be clear: Harm reduction has been shown, time and time again, to decrease overdose, decrease disease outbreaks. It saves lives, and even saves taxpayer dollars.
- Just this Monday I read about the stark success of a

 safe injection site in New York City that has been -- has not

 seen a single fatal overdose over the course of over 17,000

 visits. This success is all the more astonishing when you

 consider that New York City saw a massive rise of about 30

 percent in overdose deaths in the first half of 2021.
- 2472 If we are serious about tackling the addiction crisis in 2473 the country, we need to utilize all of the tools available to

- 2474 us, and legislate on the evidence. And the evidence is clear
- 2475 that harm reduction works. I urge my colleagues to really
- 2476 make sure that their constituents have access to all of the
- 2477 harm reduction tools needed to reduce overdose deaths.
- So I thank you, and I yield back the balance of my time.
- *The Chairman. Thank you, Mr. Cardenas.
- 2480 Anyone else on the AINS?
- 2481 If not, we will move -- I think Mr. Tonko has an
- 2482 amendment to the AINS.
- 2483 *Mr. Tonko. Yes, sir. I have an amendment at the desk,
- 2484 Mr. Chair.
- 2485 *The Chairman. All right. The clerk has the Tonko
- 2486 amendment?
- 2487 All right, the clerk will report the amendment.
- 2488 *The Clerk. Amendment to the amendment in the nature of
- 2489 a substitute to H.R. 7666, offered by Mr. Tonko of New York.
- 2490 At the end --
- *The Chairman. Madam Clerk, without objection, the
- 2492 reading of the Tonko amendment will be dispensed with.
- [The amendment of Mr. Tonko follows:]

2494

2496

- *The Chairman. And the gentleman from New York is recognized for five minutes.
- *Mr. Tonko. Thank you, Mr. Chair. My amendment adds
 the text of my Mainstreaming Addiction Treatment Act to the
 underlying legislation.
- The Mainstreaming Addiction Treatment Act, which enjoys overwhelming bipartisan cosponsorship by members of this committee, would vastly expand access to safe and effective addiction treatment by eliminating the outdated and redundant requirement that health care providers obtain a special waiver from the DEA to prescribe buprenorphine for the treatment of addiction.
- Just last week we hit another grim record in what has
 been a decades-long losing battle against the scourge of drug
 addiction: 107,000 of our brothers and sisters, mothers and
 fathers were taken from us too early last year by drug
 overdoses.
- One all too common theme in these deaths is a lack of
 access to treatment. In our nation, the addicted -- only
 about 1 in 10 individuals with opioid use disorder receives
 medications like buprenorphine to treat their addiction,
 despite this being recognized as the gold standard of care
 that cuts the risk of overdose in half.
- Let me repeat that: we have a safe and effective
 medication that reduces mortality risk by 50 percent, yet we

- have a health care system that delivers it to only 1 in 10 eliqible patients. That is a glaring, systemic failure.
- One of the main reasons for this failure is the so-2524 called X waiver, which requires health care providers that 2525 2526 wish to offer buprenorphine for the treatment of addiction to submit to burdensome paperwork, record-keeping, and training 2527 2528 requirements to obtain a special waiver from the DEA, all of this despite the fact that at this very moment health care 2529 providers can prescribe that exact same drug for the 2530 2531 treatment of pain without a special waiver, and despite the fact that buprenorphine is less medically complex than 2532 2533 commonly prescribed medications such as insulin and blood
- Because of these current barriers, we live in a country
 where 40 percent of counties -- home to more than 20 million
 Americans -- lack even a single physician that can prescribe
 buprenorphine for addiction.

thinners.

2534

2539 We live in a country where Black Americans, who are disproportionately at risk for opioid overdose, are 2540 2541 significantly less likely to have health care providers in their neighborhoods who offer buprenorphine. Can you imagine 2542 2543 how quickly we would be acting if insulin wasn't available in more than 40 percent of counties or some of the most high-2544 2545 need neighborhoods? This is the life-or-death crisis that we 2546 are facing.

- In recognition of the absurdities of the existing 2547 2548 system, both the Trump and Biden Administrations took executive actions to reduce the burden of the X waiver and 2549 expand access to treatment, but were limited in their ability 2550 2551 to do so by existing statutory requirements. Just this week, Jim Carroll, head of the Office of Drug Control Policy under 2552 former President Trump, called on Congress to pass the MAT 2553 2554 Act and, once and for all, eliminate the X waiver. Today is our chance to answer that call, and to do so in a 2555 2556 resoundingly bipartisan fashion.
- In my conversations with members of this committee on
 the amendment before us, I have heard of two primary concerns
 that I wanted to preemptively address.
- 2560 First, some have raised the concern that this 2561 legislation would increase illicit diversion of buprenorphine. This is false. The Drug Enforcement Agency 2562 and everyone else who has looked at this issue has found that 2563 the primary reason for buprenorphine diversion is the failure 2564 to access legitimate treatment, and that increasing and not 2565 2566 limiting buprenorphine treatment may be an effective response to the diversion of buprenorphine. 2567
- To that end, we heard these exact same diversion
 arguments when this committee took decisive action to expand
 access to buprenorphine in both the 21st Century Cures Act
 and the SUPPORT Act. And as the Committee has taken these

- 2572 actions, illicit diversion of buprenorphine has fallen over
- 2573 the past five years. Increasing access to legitimate
- 2574 treatment decreases illicit diversion. Full stop.
- 2575 The diversion argument is nothing more than a red
- 2576 herring, which is why legislation has been supported by major
- 2577 law enforcement organizations, including the National
- 2578 Sheriffs Association and the National Association of
- 2579 Attorneys General.
- 2580 Second, I have heard concerns that eliminating the X
- 2581 waiver requirement will reduce the quality of addiction
- 2582 treatment by eliminating existing training requirements. To
- 2583 be clear, any health care provider who would be authorized to
- 2584 prescribe buprenorphine for opioid use disorder under this
- 2585 legislation can already prescribe the exact same medication
- 2586 for pain today, as well as the powerful opioids that got us
- 2587 into this crisis in the first place.
- 2588 Furthermore, under the MAT Act, health care providers
- 2589 will still have to meet state licensure requirements and
- obtain a standard controlled substance license from the DEA
- 2591 to prescribe the medication.
- 2592 Finally, in conjunction with the MATE Act, which
- 2593 Representative Trahan introduces -- we will also be
- 2594 considering that today, and we will actually expand addiction
- 2595 training requirements by ensuring that all, not just some,
- 2596 DEA-licensed prescribers have at least eight hours of

- 2597 training in treating and managing substance use disorders,
- which is the same standard for physicians under the current X
- 2599 waiver system.
- In closing, let me just say that I know this is a
- 2601 powerful issue in all of our communities, as it is in mine.
- 2602 I have grieved with too many families in my district, with
- 2603 neighbors and friends, and I am sick and tired of this pain.
- 2604 We have to do better. Today we have a chance to make a
- 2605 difference in so many people's lives. We have the chance to
- 2606 bring hope where there is despair.
- I urge all of my colleagues to support this critically
- 2608 needed legislation, and with that, Mr. Chair, I yield back.
- *The Chairman. All right, thank you.
- 2610 And now, anyone on the Republican side?
- 2611 Dr. Burgess?
- 2612 *Mr. Burgess. Mr. Chairman, I have an amendment to the
- 2613 amendment.
- *The Chairman. All right. We are going to proceed with
- 2615 this, although I am a little confused, because this is
- 2616 essentially a third-degree amendment. But I understand Dr.
- 2617 Burgess is going to offer and speak and withdraw. So let's
- 2618 -- I don't know, Madam Clerk, I --
- 2619 *Voice. Ask her to report the amendment.
- *The Chairman. We -- can you report the Burgess
- 2621 amendment?

```
*The Clerk. Amendment offered by Mr. Burgess of Texas
      to the amendment --
2623
           *Voice. I would like to reserve a point of order.
2624
           *The Clerk. -- offered by Mr. Tonko of New York.
2625
2626
           *The Chairman. You are raising a point of order?
           *Voice. Reserving.
2627
           *The Chairman. Reserving a point of order, okay.
2628
           *The Clerk. Page one, line --
2629
           *The Chairman. I am sorry.
2630
           Without objection, the gentlewoman's point of order
2631
      is --
2632
           *Voice. No, no. The reading of the amendment shall be
2633
2634
      dispensed with.
           *The Chairman. Oh, okay. So -- all right, go ahead,
2635
2636
      Madam Clerk.
           *The Clerk. Strike "two individuals,' and insert --
2637
           *The Chairman. All right. So, without objection, the
2638
2639
      reading of the Burgess amendment will be dispensed with.
           [The amendment of Mr. Burgess follows:]
2640
2641
      *********************************
2642
```

2622

- *The Chairman. And the gentleman from Texas is recognized for five minutes.
- 2646 *Mr. Burgess. Thank you, Mr. Chairman.

2659

2660

2661

2662

2663

- You know, under current law providers cannot prescribe
 buprenorphine to more than 275 patients for maintenance and
 detoxification treatment. This amendment to the MAT
 amendment would state that any provider who seeks to
 prescribe buprenorphine to over 275 patients would need to
 obtain separate registration to become an opiate treatment
 program.
- 2654 This will apply only to practitioners who do not
 2655 practice in an area within 30 miles of another practitioner
 2656 who dispenses narcotic drugs in schedule 2, 3 or 5 of the
 2657 section 202 of the Controlled Substance Act for individuals
 2658 for maintenance of detoxification and treatment.
 - We heard it said during the discussion on the underlying amendment that an all-too-common theme is the number of people that we are losing from drug overdose. But really, as I outlined in comments during the subcommittee markup, the all-too-common theme is the lack of control at the southern border that allows fentanyl to flood into this country.
- It is a different disease that we are facing today than
 we faced when we passed the SUPPORT Act. The SUPPORT Act was
 undertaken by this committee, by the Health Subcommittee, by
 the full committee to deal with the problem of opiate use

- 2669 disorder. Fentanyl opioid use disorder is indeed a different 2670 disease.
- So this amendment would ensure that the MAT Act would
- 2672 not go into effect -- or, in addition, this amendment would
- 2673 ensure that the MAT Act would not go into effect until the
- 2674 Secretary of Health and Human Services reports to the
- 2675 Committee on Energy and Commerce and the Committee on Health,
- 2676 Education, Labor, and Pensions in the Senate that the
- 2677 Substance Abuse and Mental Health Services Administration
- 2678 publishes science-based guidance on effective treatment for
- 2679 individuals with fentanyl opiate use disorder.
- In addition, practitioners must receive training on such
- 2681 guidance in order to prescribe opioids.
- 2682 As I mentioned in my opening statement, these are
- 2683 difficult and complicated patients. This cannot be a casual
- 2684 association with a treatment modality. This is a commitment
- 2685 to a patient who has a serious disease which, if not treated
- properly, will surely be lethal, as we have seen 107,000
- 2687 times in the last calendar year. The issue today is not only
- 2688 access to treatment. The issue is access to the right
- 2689 treatment for those individuals with fentanyl opiate use
- 2690 disorder.
- This committee, under Chairman Upton's tenure, spent a
- 2692 good deal of time dealing with the phenomenon known as pill
- 2693 mills. We certainly do not want to create another problem

- that we faced back in 2014 and 2015 with pill mills. So
- there needs to be significant oversight when we are
- 2696 discussing treatment options.
- Now, the chairman is very generous to have not started
- 2698 the clock yet, but I appreciate the concern over the
- 2699 technical and parliamentary difficulties of a second-order or
- 2700 a third-order amendment. I realize that this is complicated,
- 2701 but I thought it was important to get this out there and, in
- 2702 fact, do so in a way that there is legislative language to
- 2703 actually fix a problem that would actually help people who
- 2704 are suffering from fentanyl opioid use disorder.
- 2705 And I am prepared to ask unanimous consent to withdraw
- the second-order amendment, unless someone else would like to
- 2707 speak to that.
- 2708 So I will ask unanimous consent to withdraw the second-
- 2709 order amendment.
- 2710 *The Chairman. I certainly appreciate that, Dr.
- 2711 Burgess, particularly since he is a member of the Rules
- 2712 Committee. I don't want to be arguing with you over third-
- 2713 degree amendments, because I know, if I don't hear it here, I
- 2714 will hear it at rules.
- *Mr. Burgess. Yes, let's synchronize our watches.
- [Laughter.]
- *The Chairman. Right. So the gentleman has asked to
- 2718 withdraw the amendment.

- 2719 Without objection -- oh, I am sorry. The gentlewoman
- 2720 from -- the vice chair from Illinois, are you with -- oh, he
- 2721 withdrew the amendment, so you don't need to withdraw your
- 2722 reservation.
- You want to talk on this? On the next one, okay, so --
- 2724 huh? Oh, yes, no, we will get to that.
- 2725 So the -- Dr. Burgess has withdrawn his amendment, and
- 2726 we will go back to the Tonko amendment. And the next person
- 2727 who wants to speak is Ms. Kuster.
- Oh, do you want to talk, too?
- You already spoke. No?
- 2730 *Voice. Mr. Chairman?
- *The Chairman. All right, well, let's have Ms. Kuster -
- 2732 Kuster is recognized for five minutes.
- 2733 *Ms. Kuster. Thank you, Mr. Chairman. I move to strike
- 2734 the last word.
- 2735 *The Chairman. The gentlewoman is recognized for five
- 2736 minutes.
- *Ms. Kuster. In 2015 I founded the bipartisan Heroin
- 2738 Task Force that today has evolved into the bipartisan
- 2739 Addiction and Mental Health Task Force to better reflect the
- 2740 scope of this epidemic with my co-chairs David Trone, Brian
- 2741 Fitzpatrick, and Jamie Herrera Beutler.
- I would like to express my gratitude to the chair of the
- 2743 committee and the chair of the subcommittee for considering

- 2744 so many bills from our bipartisan Addiction and Mental Health
- 2745 Task Force legislative agenda. And I urge my colleagues to
- 2746 support the amendment offered by Congressman Tonko, and I
- thank him for his leadership.
- 2748 According to the CDC, more than one million Americans
- 2749 have died from overdoses during the last two decades. And
- 2750 2021 marked the deadliest year yet, with nearly 108,000
- overdose deaths just in the United States. Two-thirds of
- these overdose deaths involved fentanyl.
- We know that buprenorphine reduces heroin and fentanyl
- use, and can cut the risk of overdose death in half. In
- 2755 fact, the risk of overdose decreases immediately when a
- 2756 patient takes this medication. I know this from personal
- 2757 experience, with a relative of mine who relapsed during
- 2758 COVID, and now has returned to MAT treatment, likely saving
- 2759 his life. That is why the MAT Act is so important to today's
- 2760 discussion. It removes the outdated barriers that prevent
- 2761 health care providers from prescribing essential treatment
- 2762 for substance use disorder.
- 2763 We need this legislation now. In my state of New
- 2764 Hampshire overdose numbers rose by six percent, just from
- 2765 March to April of this year. And in the cities of Nashua and
- 2766 Manchester, our largest two cities, fatal overdoses doubled
- last month. We cannot delay common-sense legislation like
- this any longer, and I urge the members of this committee to

- 2769 support the legislation before us. We must increase access
- 2770 to treatment.
- 2771 Thank you, and I yield --
- *The Chairman. Could I ask you not to yield back, and
- 2773 yield to Mr. Tonko?
- *Ms. Kuster. I would be very grateful to yield to Mr.
- 2775 Tonko.
- *Mr. Tonko. Do I only have the two minutes left?
- *The Chairman. Yes, almost three.
- *Mr. Tonko. Mr. Doyle was going to yield five.
- *The Chairman. All right, then. We will wait. Okay,
- 2780 we will wait. Thank you.
- The gentlewoman yields back.
- 2782 *Ms. Kuster. I yield --
- *The Chairman. Does anyone want to -- yes, Dr. Bucshon?
- *Mr. Bucshon. Thank you, Mr. Chairman. I move to
- 2785 strike the last word and speak on the amendment.
- *The Chairman. The gentleman is recognized for five
- 2787 minutes.
- 2788 *Mr. Bucshon. Buprenorphine can be effective, if
- 2789 administered by properly educated and trained providers who
- 2790 counsel and educate the patient. However, the vast majority
- of individuals currently receive little or no counseling.
- 2792 Ongoing counseling is critical to success.
- I have been working with Congress to implement caps in

- 2794 the number of patients a practitioner can see at any one
- 2795 time, and increase prescriber education for buprenorphine.
- 2796 However, some of my friends in Congress continue to support
- 2797 expanding this -- the practice and scope to allow, in my
- 2798 opinion, almost anyone, regardless of their qualifications
- 2799 and/or training, to prescribe buprenorphine.
- In my opinion, that is exactly what this amendment does.
- 2801 It removes a needed requirement that ensures adequate
- 2802 training, and eliminates the existing caps on the number of
- 2803 patients practitioners could see at one time, making it
- 2804 easier to prescribe a medication known to be highly diverted
- 2805 and misused.
- 2806 Although very well intended, this is a huge mistake.
- 2807 This amendment will only expand access to an opioid used to
- 2808 treat opioid addiction, rather than focus on improving
- 2809 effective treatment for individuals with substance use
- 2810 disorder in a comprehensive way.
- I want to read from SAMHSA's website. "Buprenorphine is
- 2812 a medication approved by the Food and Drug Administration to
- treat opioid use disorder as a medication-assisted treatment,
- 2814 MAT. As with all medications used in MAT, buprenorphine
- should be prescribed as part of a comprehensive treatment
- 2816 plan that includes counseling and other behavioral therapies
- 2817 to provide patients with a whole-person approach.' '
- 2818 *Mr. Upton. Thank you.

- 2819 *Mr. Bucshon. In describing buprenorphine -- this is
- 2820 from Drugfree.org -- "It is a controlled substance, high risk
- for addiction and dependance, it can cause respiratory
- 2822 distress and death when taken in high doses or when combined
- 2823 with other substances, especially alcohol or other illicit
- 2824 drugs such as heroin or cocaine.' '
- 2825 At a time when practitioners are prescribing
- 2826 buprenorphine at record lows due to the lessons learned over
- 2827 the years of its diversion and misuse, the last thing
- 2828 Congress should do is lax the requirements for prescribing
- 2829 and dispensing narcotic drugs such as buprenorphine. We do
- 2830 need to expand access to addiction treatment, this just isn't
- the way to do it.
- 2832 For these reasons, and the medical concerns they bring,
- 2833 I will be voting no on this amendment, and I strongly urge my
- 2834 colleagues to join me in opposition.
- Thank you, and I yield back the balance of my time.
- *The Chairman. Thank you, Dr. Bucshon.
- I recognize Mr. Doyle for five minutes.
- 2838 *Mr. Doyle. Yes, I move to strike the last word, Mr.
- 2839 Chairman.
- *The Chairman. The gentleman is recognized.
- *Mr. Doyle. I would like to yield to Mr. Tonko.
- *The Chairman. Mr. Tonko?
- 2843 *Mr. Tonko. Thank you, Mr. Chair, and I appreciate the

- 2844 gentleman yielding.
- 2845 While I understand and appreciate that the gentleman has
- 2846 withdrawn his amendment, I would like to offer some brief
- thoughts on the underlying substance.
- The amendment attempted to limit the impact on the
- 2849 Mainstreaming Addiction Act (sic) only to places where there
- 2850 are currently severe issues with access to buprenorphine.
- From my vantage point, when you had a situation where
- 2852 only 1 in 10 struggling with opioid addiction is receiving a
- 2853 medication that can cut their risk of mortality from an
- overdose fully in half, it is indicative of an access crisis
- 2855 across our nation, not simply in select counties.
- The National Academy of Sciences, Engineering, and
- 2857 Medicine, which have studied the issue in depth, found that,
- 2858 even if all health care providers who currently have an X
- 2859 waiver prescribed up to their patient limits, only half of
- the nearly two million people who lack access to
- 2861 buprenorphine would receive the medication.
- I have already discussed that 40 percent of counties
- that lack a single waivered physician, the 20 million
- 2864 Americans who live in these counties, that Black and Latino
- 2865 Americans are seeing the biggest growth in overdose deaths --
- live neighborhoods with the least access to treatment, that
- our nation's veterans are 1.5 times more likely to die of an
- 2868 opioid overdose, that most pregnant women with opioid use

- disorder don't receive buprenorphine, despite being the gold standard of care in -- of care, as less than 1 in 100 OB-GYNs are rated providers.
- So, look, we all share the goal of preventing overdoses.

 Research demonstrates that the small amount of buprenorphine

 diversion that occurs today actually prevents overdoses and

 reduces heroin and fentanyl use. Buprenorphine has a ceiling

 effect, which protects against overdose from the medication,

 and buprenorphine also blocks the effect of other opioids,
- The National Academy of Sciences, Engineering, and
 Medicine has found that the risk of opioid overdose death
 declines immediately when patients with OUD initiate
 buprenorphine. And the DEA has noted that the small amount
 of diversion is a result of a lack of access to the
 medication through the health care system in a very
 disciplined fashion.

preventing overdoses from these drugs, as well.

- So the best way to expand access to buprenorphine and prevent overdoses is to pass the Mainstream Addiction and Treatment Act.
- 2889 We have had many law enforcement groups and the -2890 again, the Association of Attorneys General calling for this
 2891 legislation. We will destroy that black market if we provide
 2892 for a disciplined addressing of this issue with the
 2893 professional MDs that will assist in this effort. I think

- 2894 this is the way for us to really address the crisis in our
- 2895 midst.
- 2896 *Ms. Eshoo. Would the gentleman yield?
- 2897 *Mr. Tonko. Yes, I will
- 2898 *Ms. Eshoo. Would the gentleman yield?
- I think -- I just asked the committee staff about
- 2900 national medical organizations, if they -- if any have
- 2901 endorsed Mr. Tonko's effort. The American Medical
- 2902 Association supports the legislation. The Academy of Family
- 2903 Physicians have -- are in support of the legislation. And,
- 2904 as was just mentioned, and I think very importantly, law
- 2905 enforcement professionals.
- 2906 So I know that there is a different view held by Dr.
- 2907 Bucshon, but I think it is important to note for the record
- 2908 the national organizations that do support it.
- 2909 So I thank the gentleman for yielding, and I yield back
- 2910 to him.
- *Mr. Tonko. And thank you, and I yield back, Mr. Chair.
- 2912 *The Chairman. And Mr. Doyle?
- 2913 *Mr. Doyle. And I yield back my time.
- *The Chairman. Thank you. Now, I understand Dr. Dunn
- 2915 would like to speak next.
- You are recognized.
- *Mr. Dunn. Thank you very much, and I will move to
- 2918 strike the last word.

- 2919 *The Chairman. The gentleman is recognized for five
- 2920 minutes.
- I don't know what is going on with the clock, though.
- 2922 Hold on a second. I am going to restart it. Okay, we are
- 2923 all set. You are recognized.
- 2924 *Mr. Dunn. So I thank you.
- 2925 First I want to associate myself with the comments of my
- 2926 colleagues, Dr. Bucshon and Dr. Burgess. I too am very
- 2927 opposed to this bill. I think it is a shame that the short-
- 2928 sighted policy will be likely wrapped up in what is otherwise
- 2929 a commendable bipartisan mental health package that we are
- 2930 considering today.
- The opioid epidemic has hit every single one of our
- 2932 districts, and I mourn the loss of my members of my community
- 2933 who have succumbed to this terrible addiction. However,
- 2934 recently my office heard from opioid addiction centers in the
- 2935 district who are extremely concerned of the consequences of
- 2936 the bill. When the folks on the ground actively working to
- 2937 end the opioid epidemic say Congress is getting it wrong, I
- 2938 think we need to listen.
- There is over 120,000 doctors waivered to provide
- 2940 medication-assisted treatment to opioid addicts, and only
- 2941 half of them are engaged in treatment with patients. Ninety-
- 2942 nine percent of Americans live within thirty miles of X
- 2943 waivered provider. I think it is clear that the X waiver is

- 2944 not the barrier to treatment here. This legislation fails to
- 2945 move the needle on opioid addiction and, in fact, end the
- 2946 epidemic. In fact, I think it makes it worse.
- 2947 Today most opioid deaths are due to fentanyl and
- 2948 fentanyl analogs, not prescribed opioids or heroin, which
- 2949 was, just three years ago, the driver of this epidemic. If a
- 2950 provider wants to engage in medication-assisted treatment, I
- 2951 believe they should obtain a waiver from the DEA
- 2952 demonstrating they know the ins and outs of fentanyl
- 2953 treatment.
- 2954 Further, there is significant risk of buprenorphine
- 2955 misuse and diversion, a fact that is not at all addressed in
- 2956 this bill. Buprenorphine is a major cause of overdose deaths
- 2957 in Europe. When Congress passed the SUPPORT Act in 2018 -- a
- 2958 solid bipartisan bill, by the way -- we requested data
- 2959 regarding the impact of increased access to buprenorphine
- 2960 from HHS, but they failed to deliver on that requirement. So
- 2961 we remain in the dark regarding how opening access to
- 2962 buprenorphine has worked for the American people.
- 2963 And so I am concerned about my colleagues throwing
- 2964 another poorly considered policy at the wall just to see if
- 2965 it sticks, and see if it moves the needle, which I don't
- 2966 think it will, and I think it will be a disservice to the
- 2967 American people.
- 2968 You know, I am a doctor of 40 years. I am strongly

- 2969 opposed to this amendment. I encourage my colleagues to vote
- 2970 against it.
- 2971 Thank you, Mr. --
- 2972 *Ms. Eshoo. Would the gentleman yield?
- 2973 *Mr. Dunn. I do.
- *The Chairman. Ms. Eshoo asks if you would yield, Dr.
- 2975 Dunn.
- 2976 *Mr. Dunn. I do.
- 2977 *The Chairman. Dr. Dunn?
- 2978 *Mr. Dunn. Yes, I yield.
- 2979 *Ms. Eshoo. Oh, thank you --
- *The Chairman. He yields to you, Ms. Eshoo.
- *Ms. Eshoo. Well, I appreciate your yielding to me.
- 2982 I think that what is being spoken to is related to the
- 2983 methadone clinics in our country, and I think that it may be
- 2984 about some competition in the area of treatment. But it is a
- 2985 fact that methadone is far more dangerous than the drug that
- 2986 we are talking about, and access to it.
- 2987 So I just wanted to make those points. I appreciate
- 2988 your yielding time, and I yield back to you.
- 2989 *Mr. Dunn. Thank you. I will reclaim my time, and --
- 2990 *Mr. Bucshon. Will Dunn yield to Bucshon?
- 2991 *Mr. Dunn. -- say that I understand -- reclaiming my
- 2992 time, I understand the difference between methadone and
- 2993 buprenorphine very intimately. I mean, that is -- for

- 2994 physicians, that is a pretty obvious distinction.
- You know, this is not about methadone clinics. This is
- 2996 about people overdosing on buprenorphine that has been
- 2997 diverted. And that is the single largest cause of overdose
- 2998 deaths in northern Europe as we speak today.
- I think fentanyl and fentanyl analogs are a totally
- 3000 different problem, and I am not sure we are addressing that
- 3001 intelligently with this problem. It is like we are still
- 3002 stuck on heroin.
- 3003 With that, I will yield back, Mr. Chairman, the
- 3004 remainder [inaudible] --
- 3005 *The Chairman. The --
- *Mr. Bucshon. Will the gentleman yield to Bucshon?
- 3007 *Mr. Dunn. I will yield to Dr. Bucshon my remaining
- 3008 time.
- 3009 *The Chairman. Dr. Bucshon wants you to yield. You got
- 3010 30 seconds.
- 3011 *Mr. Bucshon. Yes, I just want to say my opposition to
- 3012 this is for medical reasons that has nothing to do with
- 3013 financial reasons or competition.
- The methadone clinics are highly regulated, as everyone
- 3015 knows. It is not comparable. It is apples and oranges. I
- 3016 remain opposed to this amendment.
- *The Chairman. All right, Dr. Dunn, do you yield back?
- 3018 *Mr. Dunn. I yield back to the chair.

- 3019 *The Chairman. We will go to the Democratic side.
- 3020 I realized, Mr. Welch, that I have to be careful about
- 3021 saying bad things about the Senate, because, you know, you
- 3022 may not let me back into the state to visit my alma mater.
- 3023 *Mr. Welch. Well --
- *The Chairman. But I will yield to you.
- 3025 *Mr. Welch. We all know, as long as we are in the
- 3026 House, the Senate is the enemy.
- *The Chairman. Okay, all right. I am glad you agree
- 3028 with that.
- 3029 *Mr. Welch. I am going to speak in support of this
- 3030 amendment.
- But first of all, I want to say that it has been such a
- 3032 pleasure on this committee, the bipartisan support we have
- 3033 had, to take serious measures to try to deal with this
- 3034 extraordinarily savage attack on our -- the well-being of our
- 3035 citizens.
- 3036 And I often think of our ranking member's comment that
- 3037 these opioid deaths are deaths of despair. And ultimately,
- 3038 we have to build resilient communities so people have
- 3039 support, and really have a lot of optimism about life.
- 3040 But in the meantime, treatment really matters, and the
- 3041 ease of access to treatment really, really matters. And I,
- obviously, respect the comments of Dr. Bucshon, who is a very
- 3043 qualified and compassionate medical provider.

- And I heard your comments as being really concerned
- 3045 about the well-being of the patients. So I can't dispute
- 3046 that. But the well-being of the patients also includes ease
- 3047 of access to this lifesaving treatment. And it is a tough
- 3048 balance. And I think that Mr. Tonko's bill strikes the right
- 3049 balance, and that is why I am so in support of this.
- 3050 You know, I am not going to tell you about the tragedies
- 3051 we have had in Vermont, because all the stories that I can
- 3052 tell you, you can tell me, and we share that. So I start out
- 3053 with that. But we did, in Vermont, reach the grim milestone
- of the highest number of fatal doses in 2021. So it is
- 3055 really serious.
- I believe that this Act, the MAT Act, will help our
- 3057 state and many states and communities that are struggling to
- 3058 equip our health care providers with a really key treatment
- option that can save lives and support the healing that is so
- desperately needed.
- 3061 With that, I yield back and thank my colleague, Mr.
- 3062 Tonko, for this very important legislation.
- *The Chairman. Thank you, Mr. Welch.
- Mr. Armstrong is recognized.
- 3065 *Mr. Armstrong. Thank you, Mr. Chairman. And I move to
- 3066 strike the last word.
- *The Chairman. The gentleman is recognized for five
- 3068 minutes.

- *Mr. Armstrong. The Mainstreaming Addiction Treatment

 Act would remove the burdensome requirements that a health

 care provider practitioner apply for a separate waiver, known

 as the X waiver, through the Drug Enforcement Agency to

 prescribe certain drugs such as buprenorphine for substance

 use treatment.
- The X waiver requirements limit access to lifesaving 3075 treatment, which is particularly painful considering the 3076 recent news that drug overdose deaths hit a record of over 3077 3078 107,000 in 2021. Just to highlight the arbitrary bureaucratic red tape involved with the X waiver, a health 3079 provider may prescribe buprenorphine for pain management, but 3080 must go through the process of acquiring the waiver to 3081 prescribe the same drug for substance abuse disorder. 3082
- Last year, SAMHSA took a -- the step in the right

 direction, exempting providers from X waiver training when

 they are treating 30 or less patients. However, more needs

 to be done to address the opioid epidemic, particularly in

 rural states and communities, which lack access to lifesaving

 treatment.

In much of North Dakota, primary care practices provide
a wide range of care, and these providers are often the only
nearby health provider maintaining a certain level of trust
and respect within their community. This amendment would
immediately benefit these local health providers by removing

- 3094 barriers to prescribing drugs to treat substance abuse
- 3095 disorders, and empower them to integrate more treatment
- 3096 options into their practice.
- Finally, I would like to address the concerns related to
- 3098 the illicit diversion of buprenorphine. When prescribing
- 3099 buprenorphine for substance use disorder, providers must
- 3100 monitor the patient throughout the treatment plan, and ensure
- 3101 they receive the counseling and behavioral guidance warranted
- 3102 by their condition. I trust our health care providers will
- 3103 exercise the necessary post-prescription monitoring, and
- 3104 prevent the diversion of buprenorphine.
- I do not want the potential risk of diversion to create
- 3106 barriers in accessing lifesaving treatments that could
- 3107 prevent thousands of overdoses we are seeing every year. We
- 3108 desperately need more providers with the ability to
- 3109 prescribe. Access to this treatment is necessary in rural
- 3110 communities, and I urge my colleagues on this committee to
- 3111 support the amendment.
- 3112 And with that, Mr. Chairman, I will yield back.
- *The Chairman. Thank you, Mr. Armstrong.
- 3114 Anyone on either side -- and we are still on the
- 3115 Tonko --
- 3116 *Voice. Ms. Matsui.
- *The Chairman. Ms. Matsui is recognized.
- 3118 *Ms. Matsui. Thank you, Mr. Chairman. I move to strike

- 3119 the last word.
- *The Chairman. The gentlewoman is recognized for five
- 3121 minutes.
- 3122 *Ms. Matsui. The MAT Act is a critical addition to the
- underlying mental health package, and I strongly support Mr.
- 3124 Tonko's amendment because it provides a common-sense solution
- that would prevent overdoses, increase access to treatment,
- 3126 and reduce stigmas.
- Now, outdated restrictions on prescribing safe,
- 3128 effective recovery medication have precluded far too many
- 3129 Americans struggling with an opioid use disorder from getting
- 3130 the treatment that they need. Like many communities across
- this country, increasing overdose deaths filled by fentanyl
- from counterfeit prescription pills are a serious problem in
- 3133 the Sacramento region. Fentanyl is more powerful, more
- 3134 addictive, and more dangerous than heroin. It has made the
- 3135 opioid epidemic even deadlier, and warrants sustained, bold
- 3136 responses from Congress.
- 3137 Including the Mainstreaming Addiction Treatment Act in
- 3138 this package is a step in the right direction, as it will
- 3139 enable millions of highly-trained health professionals to
- 3140 prescribe lifesaving addiction treatment. But we need to
- 3141 step up and do more for addiction and mental health. I want
- 3142 to echo Chairwoman Eshoo's opening remarks that our work on
- 3143 mental health in this committee is far from done, especially

- 3144 when it comes to youth mental health.
- Overdose can strike anyone and at any time, and even a
- 3146 small dose can be deadly. In my district, there are one-time
- 3147 casual users, including children, dying from an overdose.
- 3148 Adding to these tragedies is the bitter fact that overdose
- 3149 deaths are preventable.
- 3150 We must continue to work across the prevention
- 3151 continuum. A multi-pronged approach should include greater
- 3152 investment in harm reduction strategies and social support
- 3153 systems that will help educate kids and families, and ensure
- 3154 widespread distribution of naloxone.
- I look forward to continuing our work here to provide
- 3156 greater support to communities on the front lines of the
- 3157 fentanyl crisis.
- Thank you, Mr. Chairman. I yield back.
- *The Chairman. Thank you, Ms. Matsui.
- 3160 Anyone else on the Tonko amendment to the AINS?
- 3161 All right, then let's proceed to vote on that. Let's
- 3162 see. This is -- do they want a roll call? Dr. Bucshon, you
- 3163 want a -- okay, we are going to have a roll call. No? You
- 3164 don't -- you do want it, or you don't care?
- 3165 *Mr. Bucshon. Yes.
- *The Chairman. Okay. All right. So let's go to a
- 3167 recorded vote, as ordered on the Tonko amendment.
- Those in favor of the amendment will say aye, those

- opposed to the amendment will say no, and the clerk shall
- 3170 call the roll.
- 3171 *The Clerk. Mr. Rush?
- [No response.]
- *The Clerk. Ms. Eshoo?
- 3174 *Ms. Eshoo. Aye.
- *The Clerk. Ms. Eshoo votes aye.
- 3176 Ms. DeGette?
- 3177 [No response.]
- *The Clerk. Mr. Doyle?
- 3179 *Mr. Doyle. Yes.
- *The Clerk. Mr. Doyle votes aye.
- Ms. Schakowsky?
- 3182 *Ms. Schakowsky. Aye.
- *The Clerk. Ms. Schakowsky, can you please repeat your
- 3184 vote? I didn't see you on camera.
- *Ms. Schakowsky. I am on camera. See me?
- *The Clerk. Ms. Schakowsky votes aye.
- 3187 Mr. Butterfield?
- 3188 *Mr. Butterfield. Votes yes.
- *The Clerk. Mr. Butterfield votes aye.
- 3190 Ms. Matsui?
- 3191 *Ms. Matsui. Matsui votes aye.
- *The Clerk. Ms. Matsui votes aye.
- 3193 Ms. Castor?

- *Ms. Castor. Ms. Castor votes aye.
- *The Clerk. Ms. Castor votes aye.
- 3196 Mr. Sarbanes?
- 3197 *Mr. Sarbanes. Sarbanes votes aye.
- *The Clerk. Mr. Sarbanes votes aye.
- 3199 Mr. McNerney?
- 3200 *Mr. McNerney. McNerney votes aye.
- *The Clerk. Mr. McNerney votes aye.
- 3202 Mr. Welch?
- 3203 [No response.]
- 3204 *The Clerk. Mr. Tonko?
- 3205 *Mr. Tonko. Tonko of New York votes aye.
- *The Clerk. Mr. Tonko votes aye.
- 3207 Ms. Clarke?
- 3208 *Ms. Clarke. Ms. Clarke votes aye.
- *The Clerk. Ms. Clarke votes aye.
- 3210 Mr. Schrader?
- 3211 *Mr. Schrader. Schrader votes no.
- *The Clerk. Mr. Schrader votes no.
- 3213 Mr. Cardenas?
- *Mr. Cardenas. Cardenas from California votes aye.
- *The Clerk. Mr. Cardenas votes aye.
- 3216 Mr. Ruiz?
- 3217 *Mr. Ruiz. Ruiz votes aye.
- 3218 *The Clerk. Mr. Ruiz votes aye.

- 3219 Mr. Peters?
- 3220 *Mr. Peters. Peters votes aye.
- *The Clerk. Mr. Peters votes aye.
- 3222 Mrs. Dingell?
- 3223 *Mrs. Dingell. Dingell votes aye.
- *The Clerk. I am sorry, can you please repeat your
- 3225 vote?
- *Mrs. Dingell. Dingell votes aye. I am losing my
- 3227 voice.
- *The Clerk. Mrs. Dingell votes aye.
- 3229 Mr. Veasey?
- 3230 [No response.]
- 3231 *The Clerk. Mr. Veasey?
- 3232 *Mr. Veasey. [Inaudible.]
- *The Clerk. Mr. Veasey votes aye.
- 3234 Ms. Kuster?
- 3235 *Ms. Kuster. Kuster votes aye.
- *The Clerk. Ms. Kuster votes aye.
- 3237 Ms. Kelly?
- 3238 *Ms. Kelly. Kelly votes aye.
- *The Clerk. Ms. Kelly votes aye.
- 3240 Ms. Barragan?
- 3241 *Ms. Barragan. Barragan votes aye.
- *The Clerk. Ms. Barragan votes aye.
- 3243 Mr. McEachin?

- [No response.]
- 3245 *The Clerk. Mr. McEachin?
- 3246 *Mr. McEachin. McEachin votes aye.
- *The Clerk. Mr. McEachin votes --
- 3248 *Mr. McEachin. McEachin votes aye.
- 3249 *The Clerk. -- aye.
- 3250 Ms. Blunt Rochester?
- 3251 *Ms. Blunt Rochester. Blunt Rochester votes aye.
- *The Clerk. Ms. Blunt Rochester votes aye.
- 3253 Mr. Soto?
- 3254 *Mr. Soto. Aye.
- 3255 *The Clerk. Mr. Soto votes aye.
- 3256 Mr. O'Halleran?
- 3257 *Mr. O'Halleran. O'Halleran votes aye.
- 3258 [Pause.]
- 3259 *Mr. O'Halleran. O'Halleran votes aye.
- *The Clerk. Mr. O'Halleran votes aye.
- 3261 Miss Rice?
- 3262 *Miss Rice. Rice votes aye.
- 3263 *The Clerk. Miss Rice votes aye.
- 3264 Ms. Craig?
- *Ms. Craig. Craig of Minnesota votes aye.
- *The Clerk. Ms. Craig votes aye.
- 3267 Ms. Schrier?
- 3268 *Ms. Schrier. Schrier votes aye.

```
*The Clerk. Ms. Schrier votes aye.

Mrs. Trahan?
```

3271 *Mrs. Trahan. Trahan votes aye.

*The Clerk. Mrs. Trahan votes aye.

3273 Mrs. Fletcher?

*Mrs. Fletcher. Fletcher votes aye.

*The Clerk. Mrs. Fletcher votes aye.

3276 Mrs. Rodgers?

*Mrs. Rodgers. [Inaudible.]

*The Clerk. Mrs. Rodgers votes aye.

3279 Mr. Upton?

3280 *Mr. Upton. [Inaudible.]

3281 *The Clerk. Mr. Upton votes aye.

3282 Mr. Burgess?

3283 *Mr. Burgess. [Inaudible.]

*The Clerk. Mr. Burgess votes no.

3285 Mr. Scalise?

[No response.]

3287 *The Clerk. Mr. Latta?

3288 *Mr. Latta. [Inaudible.]

3289 *The Clerk. Mr. Latta votes aye.

3290 Mr. Guthrie?

3291 *Mr. Guthrie. [Inaudible.]

3292 *The Clerk. Mr. Guthrie votes no.

3293 Mr. McKinley?

```
*Mr. McKinley. [Inaudible.]
```

- *The Clerk. Mr. McKinley votes no.
- 3296 Mr. Kinzinger?
- [No response.]
- 3298 *The Clerk. Mr. Griffith?
- 3299 *Mr. Griffith. No.
- *The Clerk. Mr. Griffith votes no.
- 3301 Mr. Bilirakis?
- 3302 *Mr. Bilirakis. Mr. Bilirakis votes aye.
- *The Clerk. Mr. Bilirakis, can you please repeat your
- 3304 vote? I didn't see you on camera.
- *Mr. Bilirakis. Yes, votes aye.
- *The Clerk. Mr. Bilirakis votes aye.
- 3307 Mr. Johnson?
- 3308 *Mr. Johnson. [Inaudible.]
- *The Clerk. Mr. Johnson votes aye.
- 3310 Mr. Long?
- *Mr. Long. The only Long in Congress votes no.
- *The Clerk. Mr. Long votes no.
- 3313 Mr. Bucshon?
- *Mr. Bucshon. [Inaudible.]
- *The Clerk. Mr. Bucshon votes no.
- 3316 Mr. Mullin?
- 3317 *Mr. Mullin. No.
- *The Clerk. Mr. Mullin votes no.

Mr. Hudson? 3319 *Mr. Hudson. Yes. 3320 3321 *The Clerk. Mr. Hudson votes aye. Mr. Walberg? 3322 3323 *Mr. Walberg. Aye. *The Clerk. Mr. Walberg votes aye. 3324 Mr. Carter? 3325 3326 *Mr. Carter. Carter votes aye. 3327 *The Clerk. Mr. Carter votes aye. 3328 Mr. Duncan? *Mr. Duncan. Yes. 3329 *The Clerk. Mr. Duncan votes aye. 3330 Mr. Palmer? 3331 3332 *Mr. Palmer. [Inaudible.] *The Clerk. Mr. Palmer votes no. 3333 3334 Mr. Dunn? *Mr. Dunn. Dunn votes no. 3335 *The Clerk. Mr. Dunn votes no. 3336 3337 Mr. Curtis? 3338 *Mr. Curtis. [Inaudible.] *The Clerk. Mr. Curtis votes aye. 3339 Mrs. Lesko? 3340

*Mrs. Lesko. [Inaudible.]

Mr. Pence?

*The Clerk. Mrs. Lesko votes aye.

3341

3342

- 3344 *Mr. Pence. Aye.
- *The Clerk. Mr. Pence votes aye.
- 3346 Mr. Crenshaw?
- *Mr. Crenshaw. Votes aye.
- *The Clerk. Mr. Crenshaw votes aye.
- 3349 Mr. Joyce?
- 3350 *Mr. Joyce. Joyce votes aye.
- *The Clerk. Mr. Joyce votes aye.
- 3352 Mr. Armstrong?
- 3353 *Mr. Armstrong. Yes.
- *The Clerk. Mr. Armstrong votes aye.
- 3355 Chairman Pallone?
- 3356 *The Chairman. Votes aye.
- *The Clerk. Chairman Pallone votes aye.
- *Mr. Welch. Madam Clerk, how am I recorded?
- *The Chairman. We have members who haven't -- who was
- 3360 that?
- *Mr. Welch. Congressman Welch.
- *The Chairman. Mr. Welch?
- 3363 *Mr. Welch. Votes aye.
- *The Clerk. Mr. Welch votes aye.
- *The Chairman. Ms. DeGette is not --
- *Ms. DeGette. DeGette votes aye.
- *The Clerk. Ms. DeGette votes aye.
- *The Chairman. Anyone else who is not recorded and

- 3369 wants to be?
- *The Clerk. Mr. Rush is not recorded.
- *The Chairman. Mr. Rush going once, going twice.
- 3372 All right. Anyone else who wants to be recorded?
- Otherwise, the clerk will report the tally.
- *The Clerk. On that vote, Mr. Chairman, the yeas were
- 3375 45 and the nays were 10.
- *The Chairman. So the vote is 45 ayes and 10 noes, so
- 3377 the Tonko amendment is agreed to.
- 3378 Are there further amendments to the amendment in the
- 3379 nature of a substitute?
- *Mrs. Trahan. I have an amendment --
- *The Chairman. Mrs. Trahan --
- 3382 *Mrs. Trahan. -- at the desk.
- *The Chairman. -- has an amendment?
- *Mrs. Trahan. Yes, thank you, Mr. Chairman. I want to
- 3385 thank you and Ranking Member Rodgers for your commitment to
- 3386 investing in --
- *The Chairman. I am sorry, but I -- we have to report
- 3388 the amendment first. The clerk has it, and the clerk will
- 3389 report the amendment.
- *The Clerk. Amendment to the amendment in the nature of
- a substitute to H.R. 7666, authored by Mrs. Trahan of
- 3392 Massachusetts.
- 3393 At the end of title --

3394	*The Chairman. All right, Madam Clerk, without
3395	objection, the reading of the Trahan amendment will be
3396	dispensed with.
3397	[The amendment of Mrs. Trahan follows:]
3398	
3399	**************************************
3400	

- *The Chairman. And the gentlewoman from Massachusetts 3401 is recognized for five minutes. 3402
- *Mrs. Trahan. Well, I want to thank you, Mr. Chairman 3403 and Ranking Member Rodgers, for your commitment to investing 3404 3405 in mental health, wellness, and substance use disorder. amendment that I am offering today will simply give 3406 3407 prescribers of controlled substances the necessary tools to
- identify, treat, and manage their patients with a substance 3408 use disorder. 3409
- The lack of adequate education and the identification, 3410 treatment, and management of patients with SUD is 3411 particularly acute among prescribers of DEA-controlled 3412 medications. Across different clinical settings, these 3413 health care professionals often interact with and have 3414
- opportunities to provide effective interventions for 3415
- individuals with substance use disorder, critical opportunities to saving lives. But far too often, those 3417
- chances to help are missed. 3418

3416

3425

In fact, this point was brought up in this very 3419 3420 committee during a hearing in reference to a National Academies paper that found that most clinicians could not 3421 confidently diagnose and treat patients with substance use 3422 disorder. Stigma, discrimination, and lack of understanding 3423 3424 about addiction, including within the medical community, have

prevented far too many Americans from accessing evidence-

- 3426 based care for this chronical -- for this chronic, treatable disease.
- The idea for the MATE Act came to light when a physician
- in my home state of Massachusetts, Dr. Jim Baker, came to me
- 3430 with the tragic story of his son, Max. Dr. Baker was
- 3431 visiting his primary care physician one day when his PCP
- 3432 asked if there was anything he could help with. Dr. Baker
- 3433 pleaded with his PCP for help with Max's opioid addiction.
- 3434 To Dr. Baker's surprise, his PCP did not have adequate
- 3435 education or understanding of OUD to point Dr. Baker in the
- 3436 direction of appropriate treatment for Max. Tragically, Max
- 3437 Baker died from an overdose at just 23 years old.
- Now, every member sitting here today knows that Dr.
- 3439 Baker's story is not unique. In fact, each and every one of
- 3440 us have heard similar stories from our constituents, from
- 3441 families who are willing to do anything, everything to save
- the life of a loved one battling addiction. In almost every
- 3443 hearing in markup this committee has held, the opioid crisis
- 3444 and the hundreds of thousands of lives it has claimed is
- 3445 almost always mentioned. Remarks delivered about the
- 3446 addiction crisis, the need to save lives, and not wasting
- 3447 another moment to act.
- 3448 With this amendment and the underlying package we have
- 3449 the chance to put those words into action. We have the
- 3450 chance to advance a meaningful policy today that works for

- 3451 the patient by requiring prescribers of controlled substances
- 3452 to take a one-time, non-burdensome training on substance use
- 3453 disorder.
- I will repeat it, so it is clear: this is a one-time,
- 3455 non-additive, eight-hour training that can also be used for
- other CME purposes, like satisfying state licensing
- 3457 requirements.
- The burden on doctors is light, and the benefit is
- 3459 enormous: being trained to effectively spot signs of
- 3460 addiction in a patient; to treat them with compassion,
- 3461 dignity, and care that they deserve; and to direct them to
- 3462 the right services so that they can treat their addiction,
- 3463 like prescribing evidence-based treatment. There is simply
- 3464 no argument as to why doctors who prescribe strong pain
- 3465 medications should not know about substance use disorder, as
- 3466 well. We have the chance to make a real difference by making
- 3467 education on substance use disorder the standard, not the
- 3468 exception. And I implore my colleagues to join me in voting
- yes on this amendment today.
- 3470 Thank you, I yield back.
- *The Chairman. Thank you, Mrs. Trahan.
- Anyone on the Republican side? Dr. Burgess is
- 3473 recognized.
- *Mr. Burgess. I would like -- I seek recognition to
- 3475 speak on the amendment.

- *The Chairman. The gentleman is recognized for five
- 3477 minutes.
- 3478 *Mr. Burgess. And I am opposed to the amendment. I
- 3479 appreciate the gentlelady having spoken with me individually
- 3480 on this.
- Again, I cannot stress enough the problem here is not
- 3482 your physician. The problem is that -- the enormity of
- 3483 fentanyl coming across the southern border.
- Look, when this committee had the opportunity to work on
- 3485 the SUPPORT Act two or three Congresses ago, it was a
- 3486 different disease. It was predominantly opiates that were
- 3487 prescribed that were being improperly used. It has morphed.
- 3488 Now it is fentanyl produced in China by Chinese scientists,
- 3489 and it is flooding across our southern border unchecked. And
- 3490 guess what? It is going to get worse when title 42
- restrictions are suspended later this month.
- 3492 We need to focus our efforts on interrupting the supply
- 3493 of fentanyl that is coming into this country and further
- 3494 burdening physicians. We already have to do this for our
- 3495 state licenses. We already spend four years in medical
- 3496 school, many of us years in residency. The addictive nature
- of drugs is not something that is new to your physician or
- 3498 your physician community.
- I appreciate the reason that this was brought forward.
- 3500 But again, I think the focus is wrong, and we need to be

- focused on security at the southern border, not further
- 3502 burdening our physicians.
- And I will be happy to yield to anyone else who wants to
- 3504 speak on this.
- 3505 *Mr. Bucshon. Will the gentleman yield?
- *Mr. Burgess. I will be happy to yield, Dr. Bucshon.
- 3507 *Mr. Bucshon. Thank you for yielding.
- 3508 I -- the irony just strikes me of what we are talking
- about here, this amendment and the previous amendment. The
- 3510 previous amendment, we are making an argument that we should
- 3511 eliminate training requirements to prescribe one of the most
- 3512 diverted drugs, narcotics in America in the hope that this
- 3513 will expand treatment programs when, as Dr. Dunn pointed out,
- 3514 it is killing patients in Europe. And in the very next
- amendment, of course, it is the physician's fault, so what we
- 3516 need to do is we need to add training -- specific training
- 3517 requirements for physicians to be able to assess and evaluate
- 3518 whether someone is addicted to narcotics or not.
- Again, the irony of, one, we try to loosen the
- 3520 requirements, and in previous changes to the law -- that I
- 3521 also opposed -- we allowed nurse midwives and others to
- 3522 prescribe buprenorphine. But now, now we want to add the
- 3523 requirement, oh, well, the doctors, the physicians out there,
- 3524 they have to have another requirement, training requirement,
- 3525 because that is clearly what the problem is, that doctors in

- 3526 this country, after going through medical school and state
- 3527 requirements, still don't understand how to assess and
- evaluate patients who may be addicted to narcotics. I mean,
- 3529 it is just absurd.
- 3530 And I want to associate myself with Dr. Burgess's
- 3531 requirements. Why don't we address the pounds and pounds --
- 3532 well, tens of pounds -- or medication. Last year we caught
- 3533 enough fentanyl going across the southern border to kill
- 3534 billions of people. Not millions, not tens of thousands,
- 3535 billions of people. And yet we ignore that, right? We are
- 3536 not doing anything about it. The most people who are dying
- 3537 -- 107,000 people died last year in this country from drug
- 3538 overdoses. People in my district are dying from fentanyl.
- 3539 You know, people use a medication they got off the street one
- 3540 time, they die from it. We are ignoring that.
- But again, again, Congress at the Federal level wants to
- 3542 add another training requirement on top of the states for
- 3543 physicians to be just better educated, and that is the
- 3544 problem we have in America with addiction.
- I will be voting against this amendment. And I just
- 3546 think the irony between these two amendments can't be
- overstated.
- 3548 I yield back to Dr. Burgess.
- 3549 *Mr. Burgess. I thank the gentleman for his comments.
- 3550 Again, let me stress it is fentanyl produced by Chinese

- 3551 scientists in Chinese labs infiltrated into our country by
- 3552 drug cartels in Mexico. That is the problem, and that is
- 3553 where Congress should focus.
- 3554 I yield back.
- *The Chairman. Thanks, Dr. Burgess.
- 3556 And Chairwoman Eshoo is recognized.
- *Ms. Eshoo. I thank the chairman. I think there are a
- 3558 couple of points that are important to state for the record.
- First of all, in the previous debate on buprenorphine,
- 3560 that is a schedule 3 drug. That is not -- it is not the most
- 3561 dangerous drug. So we need to know where these drugs are
- 3562 classified. The pain medications are schedule 2, they are
- 3563 methadone, oxycodone, fentanyl. Those are schedule 2 drugs.
- 3564 What -- as I understand the gentlewoman's amendment,
- 3565 this is education for all controlled substances. What is
- 3566 wrong with that? What is wrong with that? Do we assume -- I
- 3567 can't assume that my primary care physician is schooled, is
- 3568 educated, comfortable relative to one of these controlled
- 3569 substances.
- 3570 So this is in no way to hammer physicians. I think it
- 3571 adds to their portfolio. Who is going to benefit from it?
- 3572 Patients. They are the people that we want to help. That is
- what this is designed to do.
- 3574 So I think that we -- look, schedule 1 are deadly. We
- 3575 know that. Schedule 2 are, you know, the pain medications --

- not to be fooled around with, I am not diminishing what they
- 3577 represent. Schedule 3 should not be elevated to the most
- 3578 dangerous, because it is not. It is listed as schedule 3.
- But across the board I think that education is very
- 3580 important. And when you have educated physicians on all
- 3581 controlled substances, then the access that someone has is,
- 3582 most frankly, that much richer.
- 3583 So I yield back, Mr. Chairman. Thank you.
- *The Chairman. Thank you, Chairwoman Eshoo.
- 3585 Mr. Carter is recognized.
- 3586 *Mr. Carter. I move to strike the last word.
- *The Chairman. The gentleman is recognized for five
- 3588 minutes.
- 3589 *Mr. Carter. Thank you, Mr. Chairman.
- And may I remind my colleague, Ms. Eshoo, she just made
- 3591 the comment that schedule 1 drugs are killers. Marijuana is
- a schedule 1 drug. So thank you for pointing that out. I
- 3593 appreciate it.
- Also, I want to express my due respect to the physicians
- on this committee for their opinion on this legislation. And
- 3596 I do respect them. And I do understand how they feel about
- 3597 this. But as a pharmacist for many years, I also have strong
- 3598 feelings about this, primarily because of the inconsistencies
- of the composite boards of medicine throughout the country.
- 3600 And I do believe that we need something to be more uniform.

- I have witnessed it in my state and in other states that

 I have practiced in, that they are inconsistent in how they

 apply the continuing ed on this particular -- on the use of

 opioids.
- So I want to thank Chairman Pallone and Leader Rodgers
 for including this Medication Access and Training Expansion
 Act in today's markup.
- Representative Trahan and I appreciate the engagement
 with our colleagues on the committee and stakeholders,
 including provider groups and patient advocates, which
 resulted in improvements to the language before us today.
 And there were improvements to the language, and I appreciate
 that.
- We do have a problem. The CDC released new data last 3614 week showing a record number of overdose deaths, 107,000 3615 lives lost in 2020 and 2021. And experts predict that the 3616 crisis will not stop in the next few years. In 2019 the 3617 national non-profit, Shatterproof, conducted a provider study 3618 which [inaudible] that only one in four of those providers 3619 3620 had received training on addiction during medical education. Less than one-third of surveyed emergency room OB/GYN or 3621 pediatric providers felt prepared to screen, diagnose, 3622 provide brief intervention for, or discuss and provide 3623 treatment for opioid use disorder. 3624
- 3625 This MATE Act would establish a one-time substance use

disorder education requirement tied to a provider's Federal 3626 3627 DEA registration, which is required to prescribe controlled substances. Most states have continuing education 3628 requirements in place, and the one-time training requirement 3629 3630 would not create any additional burden for those providers. As more and more individuals present with substance use 3631 disorders in a variety of settings, from primary care to the 3632 emergency room, all medical professionals need to be equipped 3633 to care for these patients in crisis. It is a matter of life 3634 3635 and death. And I ask that my colleagues support the MATE Act for every American in need of treatment for substance use 3636 disorders. 3637 Again, I want to thank my physician friends on this 3638 committee, and colleagues on this committee for their very 3639 valid points. I could not agree more about the problem with 3640 fentanyl, and the fentanyl that is coming across our border. 3641 3642 Yes, that is the problem. However, as a practicing 3643 pharmacist for many years, for over 30 years, I can tell you that at times I felt like a policeman, that I was supposed to 3644 3645 be making a decision on whether a physician's prescription was legitimate or not. And I don't think that is what we 3646 were -- I know that is not what we were trained for. 3647 That is why I think this is necessary. 3648 I am not

questioning anybody's training, and I understand that doctors

are some of the most well-trained professionals, the most

3649

- 3651 well-trained professionals, in my opinion, out there. I have
- 3652 an enormous amount of respect. But I do think this is
- necessary. I do think it is necessary because of the big
- 3654 problem that we have right now with addiction in our country.
- And because of my experience as a pharmacist, and seeing
- 3656 prescriptions being written by physicians in disciplines that
- 3657 -- they have no reason, no reason to be writing these
- 3658 prescriptions at all, and they should at least have some
- 3659 minimum training as a result of that.
- And with that, Mr. Chairman, again, I encourage people
- 3661 to vote for this, and I yield back.
- *The Chairman. Mr. Soto is recognized for five minutes.
- 3663 *Mr. Soto. Thank you, Mr. Chairman. We heard a lot
- about it already, the U.S. border. There has been 10,856
- 3665 pounds of fentanyl seized in 2021. Seized in 2021. Last
- 3666 time I checked, that is the Biden Administration and the
- 3667 Border Protection doing their job, seizing fentanyl from the
- 3668 border.
- 3669 And a little fact check moment. Border officials seized
- 3670 nearly as much fentanyl in the last nine months of Trump's
- 3671 presidency as had been seized in the first full month -- nine
- 3672 months of Biden's presidency. That means both
- 3673 administrations have been fighting to seize fentanyl from the
- 3674 border.
- 3675 This is an issue -- we all agree on that -- and that we

- 3676 need funding for. But that is not this committee's
- 3677 jurisdiction. That is Homeland Security. That is
- 3678 Appropriations. This committee is charged with dealing with
- 3679 the addiction itself, and that is why I applaud this
- 3680 bipartisan amendment. There is a stigma among some, and this
- 3681 training is going to help get over that stigma. And we do
- need to work together to continue to stop fentanyl from
- 3683 coming in.
- 3684 I yield back.
- *The Chairman. Dunn -- Mr. Dunn, and then we will go to
- 3686 -- after to Mrs. Lesko.
- 3687 Mr. Dunn?
- 3688 *Mr. Dunn. Thank you, Mr. --
- 3689 *The Chairman. You are recognized for five minutes.
- 3690 *Mr. Dunn. I move to strike the last word.
- 3691 *The Chairman. The gentleman is recognized for five
- 3692 minutes.
- 3693 *Mr. Dunn. Thank you. I would like to associate myself
- 3694 with the comments by Dr. Burgess and Dr. Bucshon.
- This committee voted favorably on an amendment to remove
- 3696 the X waiver requirement and educational requirement and its
- 3697 associated eight hours of training for providers who wish to
- 3698 engage in medication-assisted treatment of opioid use
- 3699 disorder. Now we are considering another amendment that will
- 3700 add an eight-hour training requirement for all prescribers of

- 3701 all drugs schedules 2 through 5. That is basically every
- 3702 prescription drug there is. Buprenorphine is a schedule 3
- 3703 drug included in this rule.
- 3704 This seems entirely inconsistent to me. Which is it?
- 3705 Do providers need more training, or is training the barrier
- 3706 to opioid treatment? Clearly we don't know.
- This committee should make informed decisions, but we
- 3708 don't have this critical data from HHS. This policy will not
- 3709 help those living with opioid use disorder and fentanyl
- addictions, especially the fentanyl overdoses.
- Not only are the requirements in this amendment
- 3712 duplicative, it is also extremely unclear how the extensive
- 3713 past training that essentially all physicians receive will be
- 3714 evaluated, or if it will satisfy the requirements. Bogging
- 3715 down doctors with additional training on information they
- 3716 already learned, not only in med school but regularly
- annually, or biennially through state CME requirements, isn't
- 3718 the answer here.
- This is a bad amendment. Providers don't support it, it
- 3720 doesn't belong in the mental health package. You know, I
- 3721 encourage my colleagues to vote against it.
- And with that, Mr. Chairman, I yield back to you.
- *The Chairman. Thank you, Dr. Dunn.
- Anyone else on the Democratic side?
- 3725 All right. I just want -- I will just --

- 3726 *Mr. Doyle. I do --
- *The Chairman. We do have someone?
- 3728 Mr. Doyle?
- *Mr. Doyle. May I strike the last word, Mr. Chairman?
- 3730 *The Chairman. The gentleman is recognized for five
- 3731 minutes.
- 3732 *Mr. Doyle. And I will yield to Mrs. Trahan.
- 3733 *Mrs. Trahan. Thank you, Mr. Doyle.
- You know, I have had many conversations with my
- 3735 colleagues on the other side, and I really do appreciate the
- 3736 openness by which Dr. Burgess and I have communicated. I
- 3737 wanted to -- just want to say a couple of things.
- 3738 Certainly, we need to do more to combat fentanyl and
- 3739 getting it off our streets, and we need to make sure that
- 3740 doctors are adequately trained.
- You know, despite the impact and the pervasiveness of
- 3742 the opioid epidemic, most clinicians cannot confidently
- 3743 diagnose and treat patients with SUD. A 2016 survey of
- 3744 general internists found that the majority felt unprepared to
- 3745 screen, diagnose, refer, or discuss treatment options with
- 3746 patients with SUD. So there is an urgent need to
- 3747 systematically increase the number of clinicians who are
- 3748 equipped to identify and treat OUD. Just like every time I
- 3749 go to the doctor's office and they ask me if I feel safe at
- 3750 home, we have to make that discussable at every point of

- 3751 contact with a doctor.
- And Dr. Bucshon, this is not blame here. This is us
- just answering the call for sufficient clinician training.
- And in terms of elimination of the X waiver, while we
- 3755 are giving tools to DEA prescribers to help patients, look,
- 3756 full elimination of the X waiver is aimed at removing
- 3757 barriers, taking the friction out of being able to prescribe
- 3758 a tried-and-true treatment in buprenorphine for treatment of
- 3759 OUD.
- The education requirement in MATE gives prescribers the
- 3761 tools they need to identify and then treat addiction. Many
- 3762 prescribers have said, as I mentioned previously, that they
- 3763 are just not comfortable with identifying addiction, and this
- 3764 is why MATE is so necessary.
- 3765 So while I so appreciate the debate back and forth, I
- just want to clarify, because we can't afford to miss any
- 3767 more opportunities because of a lack of training. And that
- 3768 is what this amendment is intended to do.
- 3769 Thank you. I yield back.
- 3770 *Mr. Doyle. Mr. Chairman, I yield back.
- *The Chairman. Okay, Mr. Doyle yields back.
- Mrs. Lesko is recognized for five minutes.
- 3773 *Mrs. Lesko. Thank you, Mr. Chairman. I move to strike
- 3774 the last word.
- *The Chairman. The gentlewoman is recognized.

- *Mrs. Lesko. I think all of us want to make sure that
 people that are addicted get help, and that doctors are
 educated on identifying these patients and what they can do
- 3779 about prescribing narcotics.
- I do think that Dr. Bucshon has a valid point. I
- 3781 believe doctors are educated on this issue, and I wanted to
- just share how some constituents have come to me and said
- 3783 that they are having a hard time getting their regular pain
- 3784 medication that they legitimately need for a chronic or -- or
- 3785 some type of pain issue.
- 3786 And I think sometimes we -- in our urge to help solve
- 3787 this problem, we over-regulate, and we do things that have
- 3788 unintended consequences, where doctors are now even a little
- 3789 bit nervous about prescribing narcotic drugs or pain
- 3790 medications, and so they refer the patient then to a
- 3791 psychiatrist, or someone else, and then the patient has to go
- 3792 to another doctor, which will add extra costs, or maybe they
- 3793 can't afford to go to that doctor.
- 3794 So I think I am going to vote no on this amendment, not
- 3795 because it is not a valid point, but just -- I think
- 3796 sometimes we regulate things too much that it has adverse
- 3797 effects. And with that, I yield back.
- 3798 *The Chairman. Thank you, Mrs. Lesko.
- I am just going to -- I don't want to prolong this, but
- 3800 I just want to strike the last word myself.

- *Mr. Ruiz. Mr. Chairman, I move to strike the last
- 3802 word, as well. I can speak after you, of course.
- *The Chairman. All right. I will yield to you, or
- 3804 whatever you want.
- I am very much supportive of the Trahan amendment. I --
- 3806 you know, I understand that no professional groups --
- 3807 lawyers, doctors, no one, accountants -- wants, you know,
- 3808 Federal mandates, you know, for their training. But I just
- 3809 think that, in this case, because of the overdose crisis,
- 3810 that we should step in and do this.
- I mean, there were over 100,000 Americans who died from
- overdoses last year. And I also -- my understanding -- and
- 3813 Mrs. Trahan, correct me if I am wrong, because I heard Dr.
- 3814 Dunn talk about state training -- but under your bill the
- 3815 state-required trainings would count towards the Federal
- 3816 requirement established by the bill, as with curriculum
- 3817 provided in most medical schools today. So if there is --
- 3818 for the majority of practitioners, no extra work is
- 3819 necessary. We are just trying to say that, if you don't get
- 3820 that training, you don't -- then it is -- we really think you
- 3821 should have it. And so I just wanted to add that point, as
- 3822 well.
- Did you want me to yield to you, Dr. Ruiz, or you want
- 3824 your own time?
- *Mr. Ruiz. Sure, I think -- no -- well, why don't you

- 3826 give --
- *The Chairman. I will yield to you.
- 3828 *Mr. Ruiz. I don't know if this is going to take more
- 3829 than the time allotted.
- *The Chairman. It is -- you have got four minutes. You
- 3831 might as well take my time, and then we will see.
- 3832 *Mr. Ruiz. Okay. So, Mr. Chairman, I understand the
- importance of provider training, and will vote for this
- 3834 amendment --
- *Voice. You can just say yes, or you could read it.
- *Mr. Ruiz. -- but I do have concerns about potential
- 3837 disruption for care, particularly --
- 3838 *Voice. At the --
- 3839 *Mr. Ruiz. -- amid severe health care workforce
- 3840 shortages.
- 3841 *Voice. About --
- 3842 *Mr. Ruiz. Giving rural, independent, or small
- 3843 practices more time to be aware of the requirement and to do
- 3844 the training will reduce the risk of them not being able to
- 3845 renew their DEA license and, as a result, not able to
- 3846 practice or care for patients.
- 3847 Specifically, I have concerns that medical providers
- 3848 will not have appropriate notice from the DEA for these new
- 3849 training requirements and enough time to fulfill them.
- I share Mrs. Trahan's goal of increasing provider

- 3851 education and patient access to substance use disorder
- 3852 treatment. But we should make sure providers are aware of
- 3853 new training requirements. This could be addressed by
- 3854 requiring DEA to provide all practitioners with the
- 3855 notification of these new requirements.
- So, Mr. Chairman, I feel strongly that these issues be
- resolved as we work towards final passage of the mental
- 3858 health package, and would like to ask for your commitment to
- 3859 work with me to address these concerns before full
- 3860 consideration on the House floor.
- *The Chairman. Yes, you yield to me -- oh, I guess it
- 3862 is my time. All right. I will take back my time.
- So, look, I appreciate your expressing your concern
- about administrative notification once the bill is enacted,
- and I discussed this with Ranking Member Rodgers, and
- 3866 Guthrie, and with Representative Trahan, and we agree to work
- 3867 on a proposal for an additional DEA notification. So I
- 3868 commit to working with you to address these concerns before
- 3869 final passage on the House floor.
- *Mr. Ruiz. Thank you, Mr. Chairman.
- *The Chairman. The gentleman --
- 3872 *Mr. Ruiz. Thank you, Mr. Chairman. I am just -- I
- just don't want to see patients not get the care, the
- 3874 legitimate care they need because the -- a physician wasn't
- 3875 able to get the DEA license renewed.

- And with that, Mr. Chairman, I thank you and yield back.
- 3877 *The Chairman. Thank you.
- 3878 Dr. Bucshon, I yield to you.
- 3879 *Mr. Bucshon. Yes, I would like to strike the last
- 3880 word. I will be brief.
- *The Chairman. Do you want to take my time, or do you
- 3882 want your own?
- 3883 *Mr. Bucshon. I will take my own. I am just going to
- 3884 be --
- *The Chairman. All right, all right. So I yield back.
- 3886 Has he already had time?
- 3887 Oh, so you want to --
- 3888 *Voice. Burgess did.
- *The Chairman. All right. Oh, you haven't had time?
- 3890 *Mr. Bucshon. No.
- *The Chairman. Okay, so I will recognize Dr. Bucshon
- 3892 for five minutes.
- *Mr. Bucshon. Yes, thank you, Mr. Chairman. I just
- want to point out that, under the buprenorphine expansion
- 3895 that we have been doing over the last three or four years,
- 3896 physicians, physician assistants, nurse practitioners,
- 3897 clinical nurse specialists, certified registered nurse
- 3898 anesthetists, and certified nurse midwives, and a couple of
- 3899 others can now prescribe buprenorphine.
- 3900 So we are making the argument in this amendment that the

physicians, specifically physicians, need specialized 3901 training to identify patients who have a narcotic addiction 3902 so that they can properly treat them. So on one hand, we are 3903 saying, well, all of these people here -- and nothing against 3904 3905 any of these professionals -- they can prescribe buprenorphine. Then we are eliminating -- in the current 3906 3907 amendment we are eliminating the extra training requirement for them to be trained to get -- to prescribe buprenorphine. 3908 But in this one we are just addressing physicians. 3909 3910 I mean, I would -- I think it would be more practical and less confusing of an amendment if it included everyone 3911 that is now eligible to prescribe buprenorphine should be 3912 required as part of their training and licensure if you are 3913 doing it the Federal level. 3914 First of all, I disagree with Federal-level licensure 3915 requirements. I think it should be -- continue to be state-3916 driven. But that said, if we are going to do something at 3917 the Federal level, then maybe we should have every class of 3918 individual that can -- is going to treat people who have 3919 3920 narcotic addiction with buprenorphine, maybe they should all have training for an extra eight hours so that they can 3921 adequately identify patients who need buprenorphine therapy. 3922 So I just think, you know, all of these things are well 3923 3924 intended, and I totally understand that, and I -- and all my

colleagues are doing what they think is right. And I get

- 3926 that. But it is just inconsistent. And I think we need more
- 3927 work on this.
- I mean, and again, if this amendment was requiring this
- 3929 training for everyone that currently we have authorized to
- 3930 prescribe buprenorphine or any medication-assisted treatment,
- 3931 I mean, I could see it would be more consistent. This is, in
- 3932 my -- this seems like this is singling out physicians, which
- 3933 would be MDs, DOs, for them to take this extra training, even
- 3934 though it is one time, but we are leaving behind nurse
- 3935 midwives, certified nurse anesthetists, clinical nurse
- 3936 specialists, nurse practitioners, physician assistants, and
- 3937 allowing them to prescribe buprenorphine with -- there is no
- 3938 extra training for them, I don't think, because the Tonko
- 3939 amendment is going to eliminate that.
- 3940 It just doesn't make sense --
- *Mrs. Trahan. Will the gentleman yield?
- *Mr. Bucshon. I am going to -- who is this?
- 3943 *Mrs. Trahan. It is --
- *Mr. Bucshon. Yes, I will -- Mrs. Trahan, sure.
- 3945 *Mrs. Trahan. No, I appreciate it. And so, just for
- 3946 clarification, it is the one-time sort of non-burdensome
- 3947 eight hours of training is for anyone who has a DEA license.
- 3948 So that includes non-physicians like nurse practitioners and
- 3949 physician assistants. So just -- we are not singling out
- 3950 physicians.

- 3951 *Mr. Bucshon. Great.
- 3952 *Mrs. Trahan. And I do want to keep sort of the
- 3953 buprenorphine and access and education -- the ability to
- 3954 prescribe that separate from, you know, all of the points of
- 3955 contact where somebody is coming in for care, whether that is
- in an emergency room, a primary care room, a specialty,
- 3957 whatnot, in -- with -- on every level --
- 3958 *Mr. Bucshon. Okay.
- 3959 *Mrs. Trahan. -- who they are meeting with. There
- 3960 could be an opportunity to have a conversation about
- 3961 addiction, and get the stigma right out of the providers --
- 3962 you know, right out of that room. And that is what this is
- 3963 trying --
- *Mr. Bucshon. Reclaiming my time, thanks for that
- 3965 clarification. I appreciate that. Anyone that has a DEA --
- 3966 is qualified to get a DEA licensure under their training,
- that makes more sense, because my impression was it was
- 3968 physicians for the training.
- 3969 So if that includes certified midwives, certified
- 3970 registered nurse anesthetists, which -- it would include them
- 3971 -- nurse practitioners, clinical nurse specialists, physician
- 3972 assistants, if all of those people want to apply and get a
- 3973 DEA license, and then they are covered under this extra
- 3974 training, then that makes sense to me.
- 3975 If they are -- but the reality is what we have done in

- 3976 the law, my understanding is, they can prescribe
- 3977 buprenorphine without -- under what we have done -- without a
- 3978 DEA. So hopefully, people will get their DEA. And if they
- 3979 do, then, I mean, this amendment would make a little more
- 3980 sense to me.
- 3981 So with that, I yield back.
- 3982 *The Chairman. All right. Dr. Bucshon -- so now we go
- 3983 to -- Ms. Eshoo is recognized.
- *Ms. Eshoo. Thank you, Mr. Chairman. I just -- I think
- 3985 it is important to state for the record that buprenorphine is
- 3986 schedule 3. That schedule requires training. This isn't
- 3987 something that is new. Isn't that correct? It is not?
- 3988 *Voice. It requires a DEA license.
- 3989 *Ms. Eshoo. It requires a DEA license, and -- that then
- 3990 requires --
- 3991 *Voice. Mrs. Trahan's amendment.
- 3992 *Ms. Eshoo. -- the training that this amendment has
- 3993 built into it.
- You are shaking your head no.
- 3995 *Mr. Bucshon. No, I mean, I would have to have
- 3996 clarification on that, but --
- 3997 *Ms. Eshoo. I would be happy to yield.
- 3998 *Mr. Bucshon. Oh, I am sorry.
- *Ms. Eshoo. Yes, we have to do that around here.
- 4000 *Mr. Bucshon. Yes, I know, sorry about that.

- 4001 [Laughter.]
- *Mr. Bucshon. Based on -- I thought you had asked me a
- 4003 question, so --
- 4004 *Ms. Eshoo. No.
- *Mr. Bucshon. Based on training, whoever is qualified
- 4006 can qualify to get a DEA number. That is what we are talking
- 4007 about here. Yes, and I --
- 4008 *Ms. Eshoo. Again, I --
- *Mr. Bucshon. -- off the top of my head, I don't know.
- 4010 I know --
- *Ms. Eshoo. Yes, reclaiming my time --
- *Mr. Bucshon. -- MDs, but I don't know --
- 4013 *Ms. Eshoo. Does the author of the amendment have any
- 4014 idea how many of those that are all covered, as you have
- 4015 stated to Dr. Bucshon -- an excellent clarification -- how
- 4016 many already have that training, you know, are required for
- 4017 the training?
- 4018 *Mrs. Trahan. Yes --
- *Ms. Eshoo. So we are not starting from scratch. Most
- 4020 of the covered professionals already take this training,
- 4021 correct?
- *Mrs. Trahan. Yes, so, like, I would not be able to
- 4023 give you exact numbers, Ms. Chair, Madam Chair. I -- look,
- 4024 one of the reasons why it is important, or it is incredibly
- 4025 complementary that MATE and MAT pass at the same time is, you

- know, requiring most controlled medication prescribers to 4026 attest on their initial registration or renewal of a DEA 4027 application that they are an addiction specialist physician, 4028 or have completed at least eight hours of education on 4029 4030 treating and managing patients with SUD from one or more accredited organizations or an accredited health professional 4031 4032 school or residency program, again, this would not prevent 4033 the use of this education both for purposes of satisfying the one-time DEA registration requirement and for other purposes 4034
- So eliminate the requirement that practitioners apply
 for a separate DEA waiver to prescribe buprenorphine for OUD,
 along with the X waivers --

such as satisfying state licensing requirements.

- *Ms. Eshoo. Right. But just reclaiming my time, we are doing nothing in the MAT Act that will allow a provider to prescribe the Bup without a DEA license. The X waiver was a requirement above the DEA license to describe (sic) the buprenorphine.
- So I think that the time that we have taken to clarify
 all of this is time well spent, but I am satisfied that we
 are on the right track here. And I want to thank the
 gentlewoman for the work, the time and the work that she has
 put into this and, you know, and the thoughtful comments of
 members on both sides of the issue and the aisle.

4050 I yield back.

```
*The Chairman. I thank the gentlewoman.
```

- Does any -- we are on the Trahan amendment to the AINS.
- 4053 Does anyone else want to address this?
- Hearing none, we will move to a vote. I assume this is
- 4055 a recorded vote. Okay. A recorded vote is ordered on the
- 4056 Trahan amendment. Those in favor of the amendment will say
- aye, those opposed to the amendment will say no, and the
- 4058 clerk shall call the roll.
- 4059 *The Clerk. Mr. Rush?
- [No response.]
- *The Clerk. Ms. Eshoo?
- *Ms. Eshoo. Eshoo votes aye.
- *The Clerk. Ms. Eshoo votes aye.
- 4064 Ms. DeGette?
- 4065 [No response.]
- *The Clerk. Mr. Doyle?
- 4067 *Mr. Doyle. Yes.
- *The Clerk. Mr. Doyle votes aye.
- 4069 Ms. Schakowsky?
- *Ms. Schakowsky. Schakowsky votes aye.
- *The Clerk. Ms. Schakowsky votes aye.
- 4072 Mr. Butterfield?
- [No response.]
- *The Clerk. Ms. Matsui?
- *Ms. Matsui. Matsui votes aye.

- *The Clerk. Ms. Matsui votes aye.
- 4077 Ms. Castor?
- *Ms. Castor. Ms. Castor votes aye.
- *The Clerk. Ms. Castor votes aye.
- 4080 Mr. Sarbanes?
- *Mr. Sarbanes. Sarbanes votes aye.
- *The Clerk. Mr. Sarbanes votes aye.
- 4083 Mr. McNerney?
- *Mr. McNerney. McNerney votes aye.
- *The Clerk. Mr. McNerney votes aye.
- 4086 Mr. Welch?
- *Mr. Welch. Aye, Welch votes aye.
- *The Clerk. Mr. Welch votes aye.
- 4089 Mr. Tonko?
- 4090 *Mr. Tonko. Tonko votes aye.
- *The Clerk. Mr. Tonko votes aye.
- 4092 Ms. Clarke?
- [No response.]
- *The Clerk. Mr. Schrader?
- *Ms. Clarke. Ms. Clarke votes aye.
- *The Clerk. Ms. Clarke votes aye.
- 4097 Mr. Schrader?
- *Mr. Schrader. Schrader votes aye.
- *The Clerk. Mr. Schrader votes aye.
- 4100 Mr. Cardenas?

- *Mr. Cardenas. Cardenas from California votes aye.
- *The Clerk. Mr. Cardenas votes aye.
- 4103 Mr. Ruiz?
- *Mr. Ruiz. Ruiz votes aye.
- *The Clerk. Mr. Ruiz votes aye.
- 4106 Mr. Peters?
- *Mr. Peters. Peters votes aye.
- *The Clerk. Mr. Peters votes aye.
- 4109 Mrs. Dingell?
- *Mrs. Dingell. Dingell votes aye.
- *The Clerk. Mrs. Dingell votes aye.
- 4112 Mr. Veasey?
- *Mr. Veasey. Veasey votes aye.
- *The Clerk. Mr. Veasey votes aye.
- 4115 Ms. Kuster?
- *Ms. Kuster. Kuster votes aye.
- *The Clerk. Ms. Kuster votes aye.
- 4118 Ms. Kelly?
- *Ms. Kelly. Kelly votes aye.
- *The Clerk. Ms. Kelly votes aye.
- 4121 Ms. Barragan?
- *Ms. Barragan. Barragan votes aye.
- *The Clerk. Ms. Barragan votes aye.
- 4124 Mr. McEachin?
- *Mr. McEachin. McEachin votes aye.

- *The Clerk. Mr. McEachin votes aye.
- 4127 Ms. Blunt Rochester?
- *Ms. Blunt Rochester. Blunt Rochester votes aye.
- *The Clerk. Ms. Blunt Rochester votes aye.
- 4130 Mr. Soto?
- *Mr. Soto. Soto votes aye.
- *The Clerk. Mr. Soto votes aye.
- 4133 Mr. O'Halleran?
- *Mr. O'Halleran. O'Halleran votes aye.
- *The Clerk. Mr. O'Halleran votes aye.
- 4136 Miss Rice?
- *Miss Rice. Miss Rice votes aye.
- *The Clerk. Miss Rice votes aye.
- 4139 Ms. Craiq?
- *Ms. Craig. Ms. Craig votes aye.
- *The Clerk. Ms. Craig votes aye.
- 4142 Ms. Schrier?
- *Ms. Schrier. Schrier votes aye.
- *The Clerk. Ms. Schrier votes aye.
- 4145 Mrs. Trahan?
- *Mrs. Trahan. Trahan votes aye.
- *The Clerk. Mrs. Trahan votes aye.
- 4148 Mrs. Fletcher?
- *Mrs. Fletcher. Fletcher votes aye.
- *The Clerk. Mrs. Fletcher votes aye.

- 4151 Mrs. Rodgers?
- *Mrs. Rodgers. Mrs. Rodgers votes aye.
- *The Clerk. Mrs. Rodgers votes aye.
- 4154 Mr. Upton?
- 4155 *Mr. Upton. Votes aye.
- *The Clerk. Mr. Upton votes aye.
- 4157 Mr. Burgess?
- *Mr. Burgess. Burgess votes no.
- *The Clerk. Mr. Burgess votes no.
- 4160 Mr. Scalise?
- [No response.]
- *The Clerk. Mr. Latta?
- 4163 *Mr. Latta. Aye.
- *The Clerk. Mr. Latta votes aye.
- 4165 Mr. Guthrie?
- 4166 *Mr. Guthrie. Aye.
- *The Clerk. Mr. Guthrie votes aye.
- 4168 Mr. McKinley?
- *Mr. McKinley. [Inaudible.]
- *The Clerk. Mr. McKinley votes aye.
- 4171 Mr. Kinzinger?
- [No response.]
- *The Clerk. Mr. Griffith?
- *Mr. Griffith. No.
- *The Clerk. Mr. Griffith votes no.

- 4176 Mr. Bilirakis?
- *Mr. Bilirakis. Bilirakis votes aye.
- *The Clerk. Mr. Bilirakis, can you please repeat your
- 4179 vote? I didn't see you on camera.
- *Mr. Bilirakis. Yes, I don't know why I am not on
- 4181 camera. Okay, now I think -- Bilirakis votes aye. Can you
- 4182 hear me? Do you see me?
- 4183 *The Clerk. Yes.
- 4184 *Mr. Bilirakis. Okay.
- *The Clerk. Mr. Bilirakis votes aye.
- 4186 Mr. Johnson?
- 4187 *Mr. Johnson. Aye.
- *The Clerk. Mr. Johnson votes aye.
- 4189 Mr. Long?
- 4190 *Mr. Long. No.
- *The Clerk. Mr. Long votes no.
- 4192 Mr. Bucshon?
- 4193 *Mr. Bucshon. No.
- *The Clerk. Mr. Bucshon votes no.
- 4195 Mr. Mullin?
- 4196 *Mr. Mullin. No.
- *The Clerk. Mr. Mullin votes no.
- 4198 Mr. Hudson?
- 4199 *Mr. Hudson. Aye.
- *The Clerk. Mr. Hudson votes aye.

- 4201 Mr. Walberg?
- 4202 *Mr. Walberg. Aye.
- *The Clerk. Mr. Walberg votes aye.
- 4204 Mr. Carter?
- *Mr. Carter. Carter votes aye.
- *The Clerk. Mr. Carter votes aye.
- 4207 Mr. Duncan?
- 4208 *Mr. Duncan. Aye.
- *The Clerk. Mr. Duncan votes aye.
- 4210 Mr. Palmer?
- 4211 *Mr. Palmer. Aye.
- *The Clerk. Mr. Palmer votes aye.
- 4213 Mr. Dunn?
- *Mr. Dunn. Dunn votes no.
- *The Clerk. Mr. Dunn votes no.
- 4216 Mr. Curtis?
- *Mr. Curtis. Aye.
- *The Clerk. Mr. Curtis votes aye.
- 4219 Mrs. Lesko?
- 4220 *Mrs. Lesko. No.
- *The Clerk. Mrs. Lesko votes no.
- 4222 Mr. Pence?
- 4223 *Mr. Pence. Aye.
- *The Clerk. Mr. Pence votes aye.
- 4225 Mr. Crenshaw?

- *Mr. Crenshaw. [Inaudible.]
- *The Clerk. Mr. Crenshaw votes aye.
- 4228 Mr. Joyce?
- *Mr. Joyce. [Inaudible.]
- *The Clerk. Mr. Joyce votes no.
- 4231 Mr. Armstrong?
- *Mr. Armstrong. [Inaudible.]
- *The Clerk. Mr. Armstrong votes aye.
- 4234 Chairman Pallone?
- *The Chairman. Pallone votes aye.
- *The Clerk. Chairman Pallone votes aye.
- *The Chairman. And yes, Ms. DeGette?
- *Ms. DeGette. DeGette votes aye.
- *The Clerk. Ms. DeGette votes aye.
- *The Chairman. Anybody else who hasn't voted and wants
- 4241 to be recorded?
- 4242 Mr. Butterfield?
- 4243 [Pause.]
- *The Chairman. Okay, I think that is everyone who seeks
- 4245 to be recorded.
- The clerk will call -- I mean, sorry, the clerk will
- 4247 report the tally.
- *The Clerk. On that vote, Mr. Chairman, the yeas were
- 4249 46 and the nays were 8.
- *The Chairman. Okay, so the vote on the Trahan

4251	amendment is 46 ayes to 8 noes. The amendment is agreed to.
4252	Do we have any further amendments to the AINS?
4253	*Mr. Upton. Mr. Chairman?
4254	*The Chairman. Yes?
4255	*Mr. Upton. I have an amendment at the desk.
4256	*The Chairman. The clerk will report the Upton
4257	amendment.
4258	*The Clerk. Amendment to the amendment in the nature of
4259	a substitute to H.R. 7666, offered by Mr. Upton of Michigan.
4260	At the end
4261	*The Chairman. Without objection, the reading of the
4262	Upton amendment would be dispensed with.
4263	[The amendment of Mr. Upton follows:]
4264	
4265	*********COMMTTTEE TNSERT******

- *The Chairman. And the gentleman from Michigan is recognized for five minutes.
- *Mr. Upton. Well, thank you, Mr. Chairman, and I thank

 you and your staff. I thank my leader, Mrs. Rodgers, and her
- 4271 staff, as well.

4278

This amendment is based on H.R. 2929, a bill that I

worked on with my -- our colleague, Susie Lee. It expands

upon the private-sector efforts to provide access to peer

support services, including virtual peer support, to help

folks with similar lived experiences, including veterans and

those who have experienced homelessness, connect with each

other and also offer support.

- We know that research and Real-World Evidence has shown 4279 that engaging with a trained mental health peer specialist in 4280 individual and group settings can offer needed support to 4281 maintain wellness, lead to better connectedness with mental 4282 health treatment, and assist individuals in crisis obtain 4283 4284 needed care, which is so important. This program is similar to one that was authorized under the SUPPORT Act for 4285 4286 individuals living with a substance use disorder.
- So the pandemic lockdowns demonstrated that access to
 mental health support and treatment is needed and can be
 delivered through virtual modalities. This amendment is
 going to help deliver much-needed access to support and care
 that individuals across the country are lacking, particularly

- 4292 in rural communities.
- One outcome of the amendment would be to help connect
- 4294 rural veterans and others who may not have individually --
- 4295 may not have individuals geographically nearby to each other.
- 4296 So the amendment also provides a provision placing priority
- on supporting efforts to engage rural communities. Access to
- 4298 these peer support groups improve individuals' relationships
- 4299 with their health care provider.
- For sure, it reduces expensive inpatient service use.
- 4301 It reduces recurrent psychiatric hospitalizations for
- 4302 patients at risk with re-admissions. It improves the
- 4303 individuals' relationships with their health care provider.
- 4304 It better engages individuals in care, and significantly
- 4305 increases individuals' abilities to manage their symptoms and
- 4306 reduce the reliance on formal services, while still achieving
- 4307 positive recovery outcomes.
- 4308 I would note that this amendment is supported by a whole
- 4309 slew of mental health advocacy groups, including the
- 4310 Depression and Bipolar Support Alliance, the National
- 4311 Association of Peer Supporters, the National Council for
- 4312 Mental Wellbeing, the National Alliance on Mental Illness,
- 4313 Mental Health America, the American Foundation for Suicide
- 4314 Prevention, the National Association of Behavioral Health,
- 4315 the National Association of County Behavioral Health and
- 4316 Development Disability Directors, and the National

- 4317 Association for Rural Mental Health.
- Thank you for the opportunity to offer this amendment.
- 4319 I would like to think that -- I know that it has strong
- 4320 bipartisan support, and it ought to be included as part of
- 4321 this.
- Those of us that return virtually every week to our
- 4323 districts know the need for this, as we sit down with many,
- 4324 many of our veterans who deserve this service. For all of
- us, I know veterans' votes are often the easiest ones that we
- 4326 ever cast. This ought to be an easy one, too.
- And with that, Mr. Chairman, I yield back the balance of
- 4328 my time.
- *The Chairman. Thank you, Mr. Upton. Ms. Kuster is
- 4330 recognized.
- *Ms. Kuster. Thank you, Chairman Pallone. I move to
- 4332 strike the last word.
- *The Chairman. The gentlewoman is recognized for five
- 4334 minutes.
- *Ms. Kuster. I would like to speak in support of this
- 4336 amendment, the Virtual Peer Support Act. I was proud to help
- 4337 introduce this legislation with my colleagues, Susie Lee and
- 4338 Congressman Fred Upton, and see it included in our bipartisan
- 4339 addiction and mental health task force legislative agenda.
- This amendment will increase access to peer support
- 4341 programing, an evidence-based, cost-effective way to expand

- 4342 affordable and accessible mental health care across the
- 4343 country.
- Peer support programs are programs where peer
- 4345 specialists use their own mental health and recovery
- 4346 experience and their state certified training to offer
- 4347 support, coping skills, and community to others living with
- 4348 mental health conditions. Peer support programs can be done
- 4349 via virtual settings or in person, allowing this in-demand
- 4350 care to reach at-risk populations such as rural areas,
- 4351 seniors, veterans, and adolescents.
- During the pandemic, organizations that host virtual
- 4353 peer support groups have seen registrations double, and the
- 4354 wait lists have grown by 166 percent. It is clear we are
- 4355 facing a national mental health crisis.
- This amendment is a timely, cost-effective, and common-
- 4357 sense way to meet our nation's need for affordable and
- 4358 accessible mental health care. I urge my colleagues to
- 4359 support this amendment, and I yield back.
- *The Chairman. Thank you. We are on the Upton
- amendment to the AINS. Does anyone else want to speak on
- 4362 this? It appears to be bipartisan.
- All right. Do we have a voice -- oh, Mrs. --
- 4364 *Voice. Mrs. Lesko.
- *The Chairman. Oh, Mrs. Lesko is recognized.
- 4366 *Mrs. Lesko. Thank you, Mr. Chair. I would move to

- 4367 strike the last word.
- *The Chairman. The gentlewoman is recognized for five
- 4369 minutes.
- *Mrs. Lesko. I guess I am going to make a statement
- 4371 which has a question in it. My understanding is this is a
- 4372 new program that will add \$12 million in cost. And I would
- 4373 like Mr. Upton or anyone else to tell me if that is not the
- 4374 case.
- 4375 My concern, as you can tell from my previous speaking,
- 4376 is about our cost and our budget. And I think we have to
- 4377 balance it out, even with worthy programs like this. So that
- 4378 is my question. Is this --
- *Mr. Upton. If the gentlelady is -- will yield --
- 4380 *Mrs. Lesko. I will yield.
- *Mr. Upton. The gentlelady is correct, it is a new
- 4382 program. And again, I would just note briefly that, as I
- 4383 have met with many of our returning vets to my district in
- 4384 southwest Michigan, this is -- and my mental health care
- 4385 providers -- this is a program that we ought to have, and
- 4386 that is why.
- But it is new, and you are right about the estimated
- 4388 cost.
- 4389 *Mrs. Lesko. Thank you --
- *Mr. Upton. Subject, of course, to appropriation.
- *Mrs. Lesko. Thank you, and I yield back.

- *The Chairman. Thank you.
- Anyone else want to speak on the Upton amendment?
- If not, we are going to go to -- a recorded vote has
- 4395 been requested. So a recorded vote is ordered.
- Those in favor of the Upton amendment will say aye,
- those opposed to the Upton amendment will say no, and the
- 4398 clerk shall call the roll.
- 4399 *The Clerk. Mr. Rush?
- *Mr. Rush. Rush votes aye.
- *The Clerk. Mr. Rush votes aye.
- 4402 Ms. Eshoo?
- *Ms. Eshoo. Eshoo votes aye.
- *The Clerk. Ms. Eshoo votes aye.
- 4405 Ms. DeGette?
- *Ms. DeGette. DeGette votes aye.
- *The Clerk. Ms. DeGette votes aye.
- 4408 Mr. Doyle?
- [No response.]
- *The Clerk. Ms. Schakowsky?
- *Ms. Schakowsky. Votes aye.
- *The Clerk. Schakowsky votes aye.
- 4413 Mr. Butterfield?
- [No response.]
- *The Clerk. Ms. Matsui?
- [No response.]

- *The Clerk. Ms. Matsui?
- *Mr. Butterfield. Votes yes. Butterfield votes yes.
- [Laughter.]
- *Voice. I was, like --
- *The Clerk. Mr. Butterfield votes aye.
- *Ms. Matsui. Matsui, yes.
- 4423 *Voice. Yes.
- *Ms. Matsui. Votes yes.
- *The Clerk. Ms. Matsui votes aye.
- 4426 Ms. Castor?
- [No response.]
- *The Clerk. Mr. Sarbanes?
- [No response.]
- *The Clerk. Mr. McNerney?
- *Mr. McNerney. McNerney votes aye.
- *The Clerk. Mr. McNerney votes aye.
- 4433 Mr. Welch?
- *Mr. Welch. Aye.
- *The Clerk. Mr. Welch votes aye.
- 4436 Mr. Tonko?
- *Mr. Tonko. Tonko from New York votes aye.
- *The Clerk. Mr. Tonko votes aye.
- 4439 Ms. Clarke?
- *Ms. Clarke. Ms. Clarke from New York votes aye.
- *The Clerk. Ms. Clarke votes aye.

- 4442 Mr. Schrader?
- *Mr. Schrader. Schrader votes aye.
- *The Clerk. Mr. Schrader votes aye.
- 4445 Mr. Cardenas?
- *Mr. Cardenas. Cardenas from California votes aye.
- *The Clerk. Mr. Cardenas votes aye.
- 4448 Mr. Ruiz?
- *Mr. Ruiz. Ruiz votes aye.
- *The Clerk. Mr. Ruiz votes aye.
- 4451 Mr. Peters?
- *Mr. Peters. Peters votes aye.
- *The Clerk. Mr. Peters votes aye.
- 4454 Mrs. Dingell?
- *Mrs. Dingell. Dingell votes aye.
- *The Clerk. Mrs. Dingell votes aye.
- 4457 Mr. Veasey?
- *Mr. Veasey. Veasey votes aye.
- *The Clerk. Mr. Veasey votes aye.
- 4460 Ms. Kuster?
- *Ms. Kuster. Kuster votes aye.
- *The Clerk. Ms. Kuster votes aye.
- 4463 Ms. Kelly?
- *Ms. Kelly. Kelly votes aye.
- *The Clerk. Ms. Kelly votes aye.
- 4466 Ms. Barragan?

- [No response.]
- *The Clerk. Mr. McEachin?
- *Mr. McEachin. McEachin votes aye.
- *The Clerk. Mr. McEachin votes aye.
- 4471 Ms. Blunt Rochester?
- *Ms. Blunt Rochester. Ms. Blunt Rochester votes aye.
- *The Clerk. Ms. Blunt Rochester votes aye.
- 4474 Mr. Soto?
- *Mr. Soto. Soto votes aye.
- *The Clerk. Mr. Soto votes aye.
- 4477 Mr. O'Halleran?
- *Mr. O'Halleran. O'Halleran votes aye.
- *The Clerk. Mr. O'Halleran votes aye.
- 4480 Miss Rice?
- *Miss Rice. Rice votes aye.
- *The Clerk. Miss Rice votes aye.
- 4483 Ms. Craig?
- *Ms. Craig. Craig of Minnesota votes aye.
- *The Clerk. Ms. Craig votes aye.
- 4486 Ms. Schrier?
- *Ms. Schrier. Schrier votes aye.
- *The Clerk. Ms. Schrier votes aye.
- 4489 Mrs. Trahan?
- *Mrs. Trahan. Trahan votes aye.
- *The Clerk. Mrs. Trahan votes aye.

```
4492
           Mrs. Fletcher?
            *Mrs. Fletcher. Fletcher votes aye.
4493
            *The Clerk. Mrs. Fletcher votes aye.
4494
4495
           Mrs. Rodgers?
4496
            *Mrs. Rodgers.
                            [Inaudible.]
            *The Clerk. Mrs. Rodgers votes aye.
4497
4498
           Mr. Upton?
4499
            *Mr. Upton.
                        Aye.
4500
            *The Clerk. Mr. Upton votes aye.
4501
           Mr. Burgess?
4502
            *Mr. Burgess. [Inaudible.]
            *The Clerk. Mr. Burgess votes aye.
4503
           Mr. Scalise?
4504
4505
           [No response.]
4506
           *The Clerk. Mr. Latta?
4507
            *Mr. Latta.
                        [Inaudible.]
            *The Clerk. Mr. Latta votes aye.
4508
           Mr. Guthrie?
4509
4510
            *Mr. Guthrie.
                           Aye.
4511
           *The Clerk. Mr. Guthrie votes aye.
           Mr. McKinley?
4512
4513
            *Mr. McKinley.
                            [Inaudible.]
            *The Clerk. Mr. McKinley votes aye.
4514
4515
           Mr. Kinzinger?
```

[No response.]

- *The Clerk. Mr. Griffith?
- *Mr. Griffith. [Inaudible.]
- *The Clerk. Mr. Griffith votes aye.
- 4520 Mr. Bilirakis?
- *Mr. Bilirakis. Bilirakis votes aye.
- *The Clerk. Mr. Bilirakis votes aye.
- 4523 Mr. Johnson?
- 4524 *Mr. Johnson. Aye.
- *The Clerk. Mr. Johnson votes aye.
- 4526 Mr. Long?
- *Mr. Long. Votes aye.
- *The Clerk. Mr. Long votes aye.
- 4529 Mr. Bucshon?
- 4530 *Mr. Bucshon. Aye.
- *The Clerk. Mr. Bucshon votes aye.
- 4532 Mr. Mullin?
- [No response.]
- *The Clerk. Mr. Hudson?
- 4535 *Mr. Hudson. Aye.
- *The Clerk. Mr. Hudson votes aye.
- 4537 Mr. Walberg?
- *Mr. Walberg. [Inaudible.]
- *The Clerk. Mr. Walberg votes aye.
- 4540 Mr. Carter?
- *Mr. Carter. Carter votes aye.

```
4542
           *The Clerk. Mr. Carter votes aye.
           Mr. Duncan?
4543
           *Mr. Duncan. [Inaudible.]
4544
           *The Clerk. Mr. Duncan votes aye.
4545
4546
           Mr. Palmer?
           *Mr. Palmer. [Inaudible.]
4547
4548
           *The Clerk. Mr. Palmer votes aye.
4549
           Mr. Dunn?
           *Mr. Dunn. Dunn votes aye.
4550
4551
           *The Clerk. Mr. Dunn votes aye.
           Mr. Curtis?
4552
           *Mr. Curtis. [Inaudible.]
4553
           *The Clerk. Mr. Curtis votes aye.
4554
           Mrs. Lesko?
4555
           *Mrs. Lesko. [Inaudible.]
4556
           *The Clerk. Mrs. Lesko votes no.
4557
           Mr. Pence?
4558
4559
           *Mr. Pence. Aye.
4560
           *The Clerk. Mr. Pence votes aye.
4561
           Mr. Crenshaw?
           *Mr. Crenshaw. [Inaudible.]
4562
4563
           *The Clerk. Mr. Crenshaw votes aye.
           Mr. Joyce?
4564
```

*Mr. Joyce. [Inaudible.]

*The Clerk. Mr. Joyce votes aye.

4565

- 4567 Mr. Armstrong?
- 4568 *Mr. Armstrong. Yes.
- *The Clerk. Mr. Armstrong votes aye.
- 4570 Chairman Pallone?
- *The Chairman. Pallone votes aye.
- *The Clerk. Chairman Pallone votes aye.
- *Mr. Doyle. Mr. Chairman, how am I --
- *The Chairman. Anyone who -- who is that?
- *Mr. Doyle. Mr. Chairman, this is Mr. Doyle. How am I
- 4576 recorded?
- *The Clerk. Mr. Doyle, you are not recorded.
- *Mr. Doyle. Doyle votes yes.
- *The Clerk. Mr. Doyle votes aye.
- *Ms. Castor. Mr. Chairman?
- *The Chairman. Ms. Castor?
- 4582 *Ms. Castor. Ms. Castor --
- *The Clerk. She is not recorded.
- *Ms. Castor. -- votes aye.
- *The Clerk. Ms. Castor votes aye.
- *Mr. Sarbanes. Mr. Chairman --
- *The Chairman. Mr. Sarbanes?
- *Mr. Sarbanes. -- [inaudible] recorded?
- *The Clerk. Mr. Sarbanes is not recorded.
- *Mr. Sarbanes. Sarbanes votes aye.
- *The Clerk. Mr. Sarbanes votes aye.

- 4592 *Mr. Mullin. How is Mr. Mullin --
- *The Chairman. Ms. Barragan?
- *Mr. Mullin. -- recorded?
- *The Chairman. Or Mr. Mullin?
- *The Clerk. Mr. Mullin is not recorded.
- 4597 *Mr. Mullin. Yes, aye.
- *The Clerk. Mr. Mullin votes aye.
- *Ms. Barragan. Mr. Chairman?
- *The Clerk. Ms. Barragan is not recorded.
- *Ms. Barragan. Barragan votes aye.
- *The Chairman. I think she is there.
- *The Clerk. Ms. Barragan votes aye.
- *The Chairman. Anyone else who is not recorded and
- 4605 wants to vote?
- *Ms. Clarke. Mr. Chairman, am I recorded?
- *The Chairman. Ms. Clarke?
- *The Clerk. I have Ms. Clarke as aye.
- *The Chairman. You are recorded as aye.
- 4610 Anyone else?
- All right, the clerk will report the tally.
- *The Clerk. On that vote, Mr. Chairman, the yeas were
- 4613 55 and the nays were 1.
- *The Chairman. All right. So the vote on the Upton
- amendment is 55 ayes to 1 no, the amendment is agreed to.
- 4616 Are there any further amendments to the AINS?

4617	Mr. Cardenas has an amendment.
4618	*Mr. Cardenas. Thank you. Yes, Mr. Chairman.
4619	*The Chairman. The clerk will report the Cardenas
4620	amendment.
4621	*The Clerk. Amendment to the amendment in the nature of
4622	a substitute to H.R. 7666, authored by Mr. Cardenas of
4623	California.
4624	At the end
4625	*The Chairman. Without objection, Madam Clerk, the
4626	reading of the Cardenas amendment will be dispensed with.
4627	[The amendment of Mr. Cardenas follows:]
4628	
4629	**************************************

- *The Chairman. And the gentleman from California is
- 4632 recognized for five minutes.
- *Mr. Cardenas. Thank you, Mr. Chairman. Thank you for
- 4634 recognizing me.
- It has been over a decade since Congress required by law
- 4636 that mental health must have parity with physical health in
- 4637 terms of insurance coverage. But just a few months ago, the
- 4638 U.S. Department of Labor, HHS, and the Department of Treasury
- 4639 issued a joint report which found, and I quote, "health plans
- 4640 and health insurance -- insurers are failing to deliver
- 4641 parity for mental health and substance use disorder benefits
- 4642 to those they cover.'
- To be even clearer about what this report found, of more
- than 1,000 parity analyses requested of health plans, the
- 4645 Department of Labor did not receive a single one. Not one.
- 4646 And that was insufficient. That is inappropriate.
- I bring this up not only because non-compliance at this
- 4648 stage -- well over a decade later -- is unacceptable, but
- 4649 also because the success of our response to the mental health
- 4650 epidemic that we are seeing in this country depends on it.
- 4651 Without adequate coverage for mental health services,
- 4652 patients delay care. This often times leads to them
- 4653 worsening without any relief, sometimes ending up in the
- 4654 hospital and, yes, sometimes even death.
- 4655 Studies have indicated a dramatic disparity in coverage

- 4656 for mental health services. For example, one study found
- 4657 that between 2013 and 2017, the use of out-of-network
- behavioral health visits were between 7 to 11-and-a-half
- 4659 times higher than for primary care visits in an analysis of
- 4660 over 11 states.
- This lack of coverage also impacts youth mental health,
- 4662 as well. The same study found that out-of-network visit
- rates are higher among children. In fact, a behavioral
- 4664 health visit for a child was just over 10 times more likely
- 4665 to be out of network than a primary care visit. These
- 4666 statistics revealed just one small piece of a complex series
- of barriers to accessing mental health care in America.
- 4668 It is critical to maintain mental health care, just as
- 4669 we emphasize maintaining physical health care. But without
- 4670 adequate financial support to ensure those services are
- 4671 affordable, people are simply unable to access the type of
- 4672 services they need. This amendment would offer grant funding
- 4673 to states to ensure that there are enough resources to
- 4674 oversee insurance compliance with the parity requirements.
- People need relief now, and my bill will be a step towards
- 4676 offering much-needed help.
- I urge my colleagues to support the amendment, and with
- 4678 that I yield back the balance of my time, Mr. Chairman.
- *The Chairman. Thank you, Mr. Cardenas.
- 4680 Does anyone want to speak in support of this?

- Mr. Hudson. Or either way.
- *Mr. Hudson. I move to strike the last word.
- *The Chairman. The gentleman is recognized for five
- 4684 minutes.
- *Mr. Hudson. Thank you, Mr. Chairman.
- While I believe every member of this committee would
- 4687 agree on the importance of ensuring mental health and
- 4688 substance use disorder parity and access, I have concerns
- 4689 with the need, the appropriateness, and the precedent of the
- 4690 amendment offered today.
- I do believe states need to ensure plans are working
- 4692 towards proper compliance with the current parity
- 4693 requirements and with the prevention of unnecessary denials.
- 4694 However, I question the necessity of authorizing additional
- 4695 funds for another grant program to the states at this time.
- 4696 Just earlier this week, in unveiling a massive \$300 billion
- 4697 spending package for the State of California, Governor Gavin
- 4698 Newsom revealed the state was swimming in a flush \$97.5
- 4699 billion budget surplus. Even the governor admitted this
- 4700 level of surplus is, "simply without precedent,' claiming
- "no other state in American history has ever experienced a
- 4702 surplus as large as this.' \ Wow. That is something.
- And it is not just the State of California. Recent
- 4704 reporting found that all 50 states have a budget surplus in
- 4705 the millions of dollars. Twenty-nine states have more than a

- 4706 billion dollars. These 29 states together equate to more
- 4707 than \$173.9 billion in additional funds at the states'
- 4708 disposal.
- While it would be nice to commend the governors for
- 4710 their work tightening their budget belts, these surpluses are
- 4711 not the result of strong fiscal restraint. Many states point
- 4712 directly to the American Rescue Plan funding.
- *The Chairman. That is what we should have. We should
- 4714 have a rainy day --
- *Mr. Hudson. States are already required to enforce
- 4716 mental health and substance abuse parity. Should Congress be
- 4717 indefinitely subsidizing what states are already supposed to
- 4718 be doing?
- 4719 And with that, I oppose this amendment and urge my
- 4720 colleagues to do so. I thank you, and I yield back.
- *The Chairman. I thank the gentleman. Ms. Eshoo is
- 4722 recognized.
- 4723 *Ms. Eshoo. I move to strike the last word, Mr.
- 4724 Chairman.
- 4725 *The Chairman. The gentlewoman is recognized for five
- 4726 minutes.
- *Ms. Eshoo. Thank you. I want to thank Congressman
- 4728 Cardenas for offering this amendment, and for his hard work
- in improving enforcement of the Federal mental health parity
- 4730 law.

- Many of the members that are now part of this committee 4731 4732 were not around in 2008, when the law was put into place. can tell you on both sides of the aisle there were massive 4733 celebrations, massive celebrations. Senator Domenici in the 4734 4735 Senate, in the House, our beloved Patrick Kennedy, they all helped to put in place the Mental Health Parity and Addiction 4736 Equity Act, and that was to ensure access to mental health 4737 services, that it would not be any more restrictive than 4738 access to any other health care. 4739 4740 We all know that mental health has been the stepchild of America's health care system. And it really pains me that, 4741 14 years later, after what we did, some insurance companies 4742 4743 are still denying care to people with mental illnesses. is not just my constituents, it is across the country in 4744 every single congressional district. This doesn't only have 4745 dire consequences for patients; it is also against the law. 4746 4747 This amendment helps right the wrong by providing states with the much-needed funding. And, you know, funding is in 4748 the eyes of the beholder. It is either an unfunded mandate 4749 4750 that members would speak up against, or they don't need the money because they have the money. So whatever lens people 4751 view this through, remember this, that the law we put in 4752 place and who is doing what to it is unlawful. 4753
- I think that these grants are a step in the right direction. Certainly, the appropriators are going to make

- 4756 that decision. I -- it is my hope that this committee -- and
- 4757 that legislation came out of this committee -- will continue
- 4758 to push forward any necessary legislation so that insurance
- 4759 companies can be accountable for their actions and no longer
- 4760 avoid their obligations under the law.
- I think it is time we finally end the unfair treatment
- 4762 of Americans that need mental health services. And I think
- 4763 that this is an important vote for each one of us to take. I
- 4764 hope that we send this to the full House with this amendment
- 4765 included, and I yield back.
- 4766 *Mr. Cardenas. Will the gentlewoman yield? This is
- 4767 Cardenas. Would the gentlewoman yield the balance of her
- 4768 time?
- 4769 *Ms. Eshoo. Sure, I am sorry, glad to. Glad to.
- *Mr. Cardenas. Yes, yes, thank you very much. I
- 4771 appreciate my colleagues voicing their concerns, et cetera,
- 4772 and it also gives me an opportunity to remind all of us that
- 4773 the State of California, the largest economy of any state in
- 4774 the nation, is a donor state to our Federal coffers.
- And there is nothing in this legislation that is going
- 4776 to -- in my amendment, that is going to contribute to the
- 4777 national debt. As a matter of fact, under this current
- 4778 President and this Administration and this Congress, we have
- 4779 actually been reducing the debt with the budget that we just
- 4780 passed, the appropriations that we just passed recently.

- So I just wanted to take the opportunity to remind all
- 4782 of us that, yes, this is something that needs to be
- 4783 corrected. These insurance companies throughout the country
- 4784 need to follow the law. It has been over a decade. It is
- 4785 high time that we get this in order, and mental health gets
- 4786 the attention it deserves. Because when it does, it will be
- 4787 lifesaving.
- So I just wanted to remind all of us that this is an
- 4789 opportunity for us to use the carrot and not the stick. And
- unfortunately, if we are not going to use grants, then we may
- 4791 have to look at other amendments in the future and other
- 4792 legislation in the future. So I think this is a great
- 4793 balance of opportunity for us to do the right thing and pass
- 4794 legislation to urge a well-overdue opportunity for mental
- 4795 health in America, for our American citizens, for our
- 4796 American taxpayers to finally get the law enacted in every
- 4797 community and every state in the nation.
- And with that, thank you. I thank the gentlewoman for
- 4799 yielding her time. I yield back.
- 4800 *Ms. Eshoo. Great. I yield back, Mr. Chairman.
- *The Chairman. I thank the gentlewoman.
- We are on the Cardenas amendment. Does anyone else want
- 4803 to speak about it?
- All right. We will go to a vote. Are we going to have
- 4805 a roll call --

```
*Mrs. Rodgers. Yes, we would like a recorded --
4806
           *The Chairman. Roll call? All right, there will be a
4807
      recorded vote on the Cardenas amendment, and a recorded vote
4808
4809
      is ordered. Those in favor of the amendment will say aye,
4810
      those opposed will say no, and the clerk shall call the roll.
           *The Clerk. Mr. Rush?
4811
4812
           *Mr. Rush.
                        Rush votes aye.
4813
           *The Clerk. Mr. Rush votes aye.
           Ms. Eshoo?
4814
4815
           *Ms. Eshoo.
                        [Inaudible.]
           *The Clerk. Ms. Eshoo votes aye.
4816
           Ms. DeGette?
4817
4818
           [No response.]
           *The Clerk. Mr. Doyle?
4819
           *Mr. Doyle. Doyle votes yes.
4820
           *The Clerk. Mr. Doyle votes aye.
4821
4822
           Ms. Schakowsky?
4823
           *Ms. Schakowsky. Schakowsky votes aye.
           *The Clerk. Ms. Schakowsky votes aye.
4824
4825
           Mr. Butterfield?
4826
           [No response.]
           *The Clerk. Ms. Matsui?
4827
4828
           *Ms. Matsui. Matsui votes aye.
           *The Clerk. Ms. Matsui votes aye.
4829
```

Ms. Castor?

- *Ms. Castor. Ms. Castor votes aye.
- *The Clerk. Ms. Castor votes aye.
- 4833 Mr. Sarbanes?
- *Mr. Sarbanes. Sarbanes votes aye.
- *The Clerk. Mr. Sarbanes votes aye.
- 4836 Mr. McNerney?
- *Mr. McNerney. McNerney, California, aye.
- *The Clerk. Mr. McNerney votes aye.
- 4839 Mr. Welch?
- [No response.]
- *The Clerk. Mr. Tonko?
- *Mr. Tonko. Tonko of New York votes aye.
- *The Clerk. Mr. Tonko votes aye.
- 4844 Ms. Clarke?
- 4845 *Ms. Clarke. Ms. Clarke of New York votes aye.
- *The Clerk. Ms. Clarke votes aye.
- 4847 Mr. Schrader?
- 4848 *Mr. Schrader. Schrader votes aye.
- *The Clerk. Mr. Schrader votes aye.
- 4850 Mr. Cardenas?
- *Mr. Cardenas. Cardenas from California votes aye.
- *The Clerk. Mr. Cardenas votes aye.
- 4853 Mr. Ruiz?
- 4854 *Mr. Ruiz. Ruiz votes aye.
- *The Clerk. Mr. Ruiz votes aye.

- 4856 Mr. Peters?
- *Mr. Peters. Peters votes aye.
- *The Clerk. Mr. Peters votes aye.
- 4859 Mrs. Dingell?
- 4860 *Mrs. Dingell. Dingell votes aye.
- *The Clerk. Mrs. Dingell votes aye.
- 4862 Mr. Veasey?
- 4863 *Mr. Veasey. Veasey votes aye.
- *The Clerk. Mr. Veasey votes aye.
- 4865 Ms. Kuster?
- *Ms. Kuster. Kuster votes aye.
- *The Clerk. Ms. Kuster votes aye.
- 4868 Ms. Kelly?
- *Ms. Kelly. Kelly votes aye.
- *The Clerk. Ms. Kelly votes aye.
- 4871 Ms. Barragan?
- [No response.]
- *The Clerk. Mr. McEachin?
- *Mr. McEachin. McEachin votes aye.
- *The Clerk. Mr. McEachin votes aye.
- 4876 Ms. Blunt Rochester?
- *Ms. Blunt Rochester. Ms. Blunt Rochester votes aye.
- *The Clerk. Ms. Blunt Rochester votes aye.
- 4879 Mr. Soto?
- 4880 *Mr. Soto. Soto votes aye.

```
*The Clerk. Mr. Soto votes aye.
4881
           Mr. O'Halleran?
4882
            *Mr. O'Halleran. O'Halleran votes aye.
4883
           *The Clerk. Mr. O'Halleran votes aye.
4884
4885
           Miss Rice?
           *Miss Rice. Miss Rice votes aye.
4886
4887
           *The Clerk. Miss Rice votes aye.
4888
           Ms. Craig?
            [No response.]
4889
4890
            *The Clerk. Ms. Schrier?
            *Ms. Schrier. Schrier votes aye.
4891
           *The Clerk. Ms. Schrier votes aye.
4892
           Mrs. Trahan?
4893
                           Trahan votes aye.
4894
            *Mrs. Trahan.
4895
           *The Clerk. Mrs. Trahan votes aye.
           Mrs. Fletcher?
4896
            *Mrs. Fletcher. Fletcher votes aye.
4897
            *The Clerk. Mrs. Fletcher votes aye.
4898
4899
           Mrs. Rodgers?
4900
           *Mrs. Rodgers. [Inaudible.]
           *The Clerk. Mrs. Rodgers votes no.
4901
```

4902

4903

4904

4905

Mr. Upton?

Mr. Burgess?

*Mr. Upton. [Inaudible.]

*The Clerk. Mr. Upton votes no.

```
*Mr. Burgess. Burgess votes no.
```

- *The Clerk. Mr. Burgess votes no.
- 4908 Mr. Scalise?
- [No response.]
- 4910 *The Clerk. Mr. Latta?
- 4911 *Mr. Latta. [Inaudible.]
- *The Clerk. Mr. Latta votes no.
- 4913 Mr. Guthrie?
- *Mr. Guthrie. [Inaudible.]
- *The Clerk. Mr. Guthrie votes no.
- 4916 Mr. McKinley?
- *Mr. McKinley. [Inaudible.]
- *The Clerk. Mr. McKinley votes no.
- 4919 Mr. Kinzinger?
- [No response.]
- 4921 *The Clerk. Mr. Griffith?
- 4922 *Mr. Griffith. No.
- *The Clerk. Mr. Griffith votes no.
- 4924 Mr. Bilirakis?
- 4925 *Mr. Bilirakis. Votes no.
- *The Clerk. Mr. Bilirakis votes no.
- 4927 Mr. Johnson?
- 4928 *Mr. Johnson. No.
- *The Clerk. Mr. Johnson votes no.
- 4930 Mr. Long?

- *Mr. Long. Long votes no.
- 4932 *The Clerk. Mr. Long votes no.
- 4933 Mr. Bucshon?
- 4934 *Mr. Bucshon. No.
- *The Clerk. Mr. Bucshon votes no.
- 4936 Mr. Mullin?
- 4937 *Mr. Mullin. No.
- 4938 *The Clerk. Mr. Mullin votes no.
- 4939 Mr. Hudson?
- 4940 *Mr. Hudson. No.
- *The Clerk. Mr. Hudson votes no.
- 4942 Mr. Walberg?
- 4943 *Mr. Walberg. [Inaudible.]
- *The Clerk. Mr. Walberg votes no.
- 4945 Mr. Carter?
- 4946 *Mr. Carter. Carter votes no.
- *The Clerk. Mr. Carter votes no.
- 4948 Mr. Duncan?
- 4949 *Mr. Duncan. No.
- *The Clerk. Mr. Duncan votes no.
- 4951 Mr. Palmer?
- 4952 *Mr. Palmer. [Inaudible.]
- *The Clerk. Mr. Palmer votes no.
- 4954 Mr. Dunn?
- 4955 *Mr. Dunn. Dunn votes no.

```
*The Clerk. Mr. Dunn votes no.
```

- 4957 Mr. Curtis?
- 4958 *Mr. Curtis. [Inaudible.]
- *The Clerk. Mr. Curtis votes no.
- 4960 Mrs. Lesko?
- 4961 *Mrs. Lesko. No.
- *The Clerk. Mrs. Lesko votes no.
- 4963 Mr. Pence?
- 4964 *Mr. Pence. No.
- 4965 *The Clerk. Mr. Pence votes no.
- 4966 Mr. Crenshaw?
- *Mr. Crenshaw. [Inaudible.]
- 4968 *The Clerk. Mr. Crenshaw votes no.
- 4969 Mr. Joyce?
- *Mr. Joyce. [Inaudible.]
- *The Clerk. Mr. Joyce votes no.
- 4972 Mr. Armstrong?
- *Mr. Armstrong. [Inaudible.]
- *The Clerk. Mr. Armstrong votes no.
- 4975 Chairman Pallone?
- *The Chairman. Pallone votes aye.
- *The Clerk. Chairman Pallone votes aye.
- *The Chairman. Ms. DeGette?
- 4979 *Ms. DeGette. DeGette votes aye.
- *The Clerk. Ms. DeGette votes aye.

- 4981 *Mr. Butterfield. Mr. Chairman?
- 4982 *The Chairman. Anyone else?
- 4983 *Ms. Craig. Madam Clerk, how am I recorded?
- *Mr. Butterfield. Butterfield.
- 4985 *The Chairman. Who speaks?
- 4986 *The Clerk. Mr. Butterfield --
- 4987 *Mr. Butterfield. Butterfield.
- 4988 *The Clerk. -- is not recorded.
- 4989 *The Chairman. Mr. Butterfield?
- 4990 *Mr. Butterfield. Butterfield votes aye.
- *The Clerk. Mr. Butterfield votes aye.
- *Mr. Welch. Madam Clerk, how am I recorded?
- 4993 *The Clerk. Mr. Welch is not recorded.
- 4994 *Mr. Welch. I vote aye.
- *The Clerk. Mr. Welch votes aye.
- 4996 *Ms. Craig. Madam Clerk, how am I recorded? Craig of
- 4997 Minnesota.
- *The Clerk. Ms. Craig is not recorded.
- 4999 *Ms. Craig. Craig votes aye.
- *The Clerk. Ms. Craig votes aye.
- *The Chairman. Is there anyone else who seeks to be
- 5002 recorded and is not?
- No? All right. The clerk will report the tally on the
- 5004 Upton amendment. I am sorry, not the Upton; on the Cardenas
- 5005 amendment.

5006	*The Clerk. On that vote, Mr. Chairman, the yeas were
5007	31 and the nays were 24.
5008	*The Chairman. Okay, so the vote is 31 ayes to 24 noes
5009	on the Cardenas amendment, and the amendment is agreed to.
5010	Are there further amendments to the AINS?
5011	*The Chairman. Does Mr. Curtis Mr. Curtis has an
5012	amendment at the desk.
5013	*Mr. Curtis. Yes.
5014	*The Chairman. Madam Clerk, will you report the Curtis
5015	amendment?
5016	*The Clerk. Amendment to H.R. 7666, authored by Mr.
5017	Curtis of Utah.
5018	Page 122
5019	*The Chairman. Without objection, Madam Clerk, the
5020	reading of the Curtis amendment will be dispensed with.
5021	[The amendment of Mr. Curtis follows:]
5022	
5023	**************************************

- *The Chairman. And the gentleman from Utah is recognized for five minutes.
- *Mr. Curtis. Thank you. I would like to thank you,
- 5028 Chair Pallone, and Ranking Member Rodgers, for holding this
- 5029 important hearing today. I intend to withdraw my amendment,
- 5030 but I want to raise awareness to a very important issue.
- My amendment is very simple. Everyone agrees mental
- 5032 health behavior health coverage is important. This is why
- 5033 Congress shouldn't place additional mandates on private
- 5034 businesses until the Administration provides guidance that
- 5035 Congress has requested for many years.
- 5036 Congress has expressed bipartisan support for this
- 5037 quidance. The last three times the House passed mental
- 5038 health parity standards, these bills included explicit
- 1039 language on illustrative examples of parity the Labor
- 5040 Department must provide: broad examples of compliance and
- 5041 non-compliance, specific examples of medical management
- 5042 standards, and network admissions standards. The language is
- 5043 very clear, very instructive, and very obvious as to what
- 5044 Congress is asking of the Labor Department with respect to
- 5045 issuing comprehensive, clear guidance. In fact, the latest
- 5046 version of the illustrative examples was cut and paste from a
- Joe Kennedy bill from last Congress.
- I support mental health parity, and I support additional
- 5049 guidance for plans to get this right. This language has been

- 5050 signed into law twice, and has cleared the chamber three
- 5051 times in less than a decade. Many of you have already voted
- 5052 to support illustrative compliance guidelines in committee
- 5053 and on the floor. The most recent time these guidelines --
- 5054 instructions passed four committees and two chambers, and
- 5055 agreed to the guidance in a bicameral, bipartisan fashion.
- 5056 Congress did not intend for compliance to be a mind-
- 5057 reading exercise. It is overdue to provide practical, real-
- 5058 life examples of how industry can comply with these
- 5059 standards. I urge members to support my bill.
- I am prepared to withdraw my amendment, but it is my
- 5061 hope we will work together in a bipartisan manner to find
- 5062 consensus before this package is enacted.
- 5063 And with that, Mr. Chairman, I withdraw my amendment and
- 5064 yield my time.
- *The Chairman. Thank you, Mr. Curtis. Yes, and we will
- 5066 work on it.
- 5067 *Mr. Curtis. Thank you.
- *The Chairman. So the Curtis amendment has been
- 5069 withdrawn. Do we have any other amendments to the AINS?
- Hearing none, we will go to the AINS.
- *Voice. The other way, the other way. Keep flipping,
- 5072 keep going, keep going.
- *The Chairman. Okay. Well, are you --
- 5074 *Voice. No, voice.

- *The Chairman. If there is no further discussion, we
- 5076 will proceed to a vote on the amendment in the nature of a
- 5077 substitute.
- All those in favor of the amendment in the nature of a
- substitute to H.R. 7666, as amended, will signify by saying
- 5080 aye.
- All those opposed will say no.
- In the opinion of the chair, the ayes have it, and the
- amendment in the nature of a substitute is adopted.
- Now we will go to the final passage of the bill, H.R.
- 5085 7666, to the House. The question now occurs on favorably
- reporting H.R. 7666, as amended, to the full House.
- All those in favor of reporting H.R. 7666, as amended,
- 5088 to the House will signify by saying aye.
- All those opposed will say no.
- In the opinion of the chair, the ayes have it and,
- therefore, H.R. 7666, as amended, is reported to the full
- 5092 House.
- All right. We have a few more bills. The chair now
- 5094 calls up H.R. 7233, the Keeping Incarceration Discharges
- 5095 Streamlined for Children and Accommodating Resources and
- 5096 Education Act, or the KIDS CARES Act, as forwarded by the
- 5097 Subcommittee on Health.
- And the clerk will report the title of this bill.
- *The Clerk. The committee print for H.R. 7233 to amend

5100	title 19
5101	*The Chairman. And without objection, Madam Clerk, the
5102	first reading of the bill will be dispensed with. The bill
5103	is now considered as read and open for amendment.
5104	[The bill follows:]
5105	
5106	********COMMITTEE INSERT******
5107	

*The Chairman. Is there anyone that wants to speak on 5108 5109 the underlying bill? Okay. Does anyone want to amend this bill? 5110 *Voice. Mr. Hudson. 5111 5112 *The Chairman. Mr. Hudson? Oh, the ranking member is recognized, Mrs. Rodgers. 5113 *Voice. Hold on, hold on. 5114 5115 *The Chairman. You spoke? 5116 *Voice. Is Mr. Hudson coming back? 5117 [Pause.] *The Chairman. Mr. Hudson, do you have an amendment in 5118 the nature of a substitute? 5119 *Mr. Hudson. Yes, Mr. Chairman. 5120 *The Chairman. All right. The clerk will report the 5121 5122 Hudson AINS. *The Clerk. Amendment in the nature of a substitute to 5123 H.R. 7233, offered by Mr. Hudson of North Carolina. 5124 Strike all --5125 5126 *The Chairman. And without objection, Madam Clerk, the 5127 reading of the Hudson AINS will be dispensed with. [The amendment of Mr. Hudson follows:] 5128

5131

5129

- *The Chairman. And the gentleman is recognized for five
- 5133 minutes.
- 5134 *Mr. Hudson. Thank you, Mr. Chairman. I would like to
- offer an amendment in the nature of a substitute on H.R.
- 5136 7233, the Keeping Incarceration Discharges Streamlined for
- 5137 Children and Accommodating Resources and Education Act, also
- 5138 known as the KIDS CARE Act.
- I am proud to lead H.R. 7233, along with Representative
- 5140 Ann Kuster and Ashley Hinson, and urge the full committee to
- 5141 consider favorably and adopt this AINS.
- 5142 This bill was reported favorably from our Health
- 5143 Subcommittee by a vote of 32 to 0, and I hope for a similar
- 5144 support today. The KIDS CARE Act would support kids as they
- 5145 transition out of incarceration by having state Medicaid
- 5146 programs establish a plan to conduct physical, mental, and
- 5147 behavioral health screenings for eligible children prior to
- 5148 release from prison. After the screenings, these children
- 5149 would then be offered a referral service to seek additional
- 5150 help, support, and services, based on their own specific
- 5151 needs.
- 5152 The bill also aims to improve school-based health
- 5153 services. Currently, elementary and high schools have the
- ability to provide and receive reimbursement for certain
- 5155 health services carried out within the school system.
- 5156 However, we have heard from school administrators that this

- submissions and claims process is burdensome, disjointed, and confusing, essentially making it unworkable.
- Our bill would direct the Centers for Medicare and
- 5160 Medicaid Services to update its school-based claims guide,
- including providing best practices for schools and school
- 5162 health centers. This would help schools cut red tape,
- decrease administrative burdens, and increase the
- 5164 availability of already existing services. This is
- 5165 especially important for small and rural school districts
- like those in my community, which are more likely unable to
- 5167 manage the bureaucratic burdens.
- In talking to our own North Carolina department of
- 5169 health and human services and the department of juvenile
- 5170 justice and delinquency prevention, we received much support
- and very helpful feedback on this legislation. Experts agree
- 5172 not only will the screenings and referral process help
- 5173 establish a landing spot for those recently released, but
- 5174 they will improve coordination of services, and greatly
- 5175 improve the overall well-being of our vulnerable kids.
- 5176 I would encourage other members of the committee, if you
- 5177 have not done so, to talk to your own state agencies on the
- 5178 impact this bill will bring to your states. For instance, we
- incorporated direct feedback from our state partners on the
- addition of a case management transition service for the 30
- 5181 days post release. This will help to coordinate the

- 5182 necessary referrals and next steps upon re-entry to society.
- 5183 During our Health Subcommittee we also incorporated
- amendments from Representative Eshoo as well as
- 5185 Representatives Blunt Rochester and Burgess that would
- 5186 continue the goal to ensure our kids have access to health
- 5187 care.
- 5188 With the addition of these amendments, this bill will
- 5189 help expand telehealth options for children by requiring the
- 5190 Centers for Medicare and Medicaid Services to provide updated
- 5191 guidance, strategies, and best practices to states on how to
- 5192 effectively overcome barriers and to increase access to
- 5193 telehealth within their Medicaid and their children's health
- insurance program populations.
- In addition, it will provide clarifying guidance and
- 5196 best practices to states to ensure they are providing
- 5197 appropriate and comprehensive access and coverage of
- 5198 available mental, emotional, and behavioral health services
- 5199 for children.
- 5200 This bill will also incorporate provisions of the Due
- 5201 Process Continuity of Care Act, led by Representative David
- 5202 Trone, Tom Emmer, Mike Turner, and Paul Tonko. This bill
- 5203 would remedy a gap in Medicaid services by ensuring children
- 5204 serving pre-trial detention are not kicked off Medicaid while
- 5205 awaiting adjudication. Currently, these kids are denied
- 5206 access to coverage, even when presumed innocent. This

- 5207 conflicts with our constitutional right to due process,
- 5208 particularly when it applies to kids, which is why this
- 5209 policy was endorsed by the Major County Sheriffs and National
- 5210 Sheriffs Association, among others.
- Taken together, these common-sense solutions in this
- 5212 bill will go a long way towards reducing recidivism in our
- 5213 youth population, increasing access to mental, physical,
- 5214 behavioral, and telehealth services for our children within
- 5215 schools and health care settings, and improving collaboration
- 5216 strategies and best practices for our states.
- I am proud of the strong bipartisan work that we have
- done on this bill, and urge my fellow committee members to
- 5219 consider it favorably, and adopt the AINS. And with that,
- 5220 Mr. Chairman, I am happy to yield back.
- *The Chairman. Thank you, Mr. Hudson.
- 5222 Ms. Kuster is recognized.
- *Ms. Kuster. Thank you, Chairman Pallone. I move to
- 5224 strike the last word.
- *The Chairman. The gentlewoman is recognized for five
- 5226 minutes.
- *Ms. Kuster. I am so proud to lead the KIDS CARES Act
- 5228 with Congressman Hudson and Hinson, and offer this amendment
- 5229 with him.
- 5230 The KIDS CARES Act is critical legislation to close the
- 5231 gap in health care that kids experience in the juvenile

- justice system. I have seen the difference that appropriate
 mental health care can mean for folks caught up in the
 judiciary -- judicial system. In Sullivan County in my
 district in New Hampshire, the recidivism rate dropped from
 for the percent to 18 percent when behavioral health and treatment
 services were brought inside the county jail. By ensuring
- that mental health and substance use treatment was
 accessible, we saw the cruel cycle of addiction and
- 5240 incarceration disrupted.
- 5241 The KIDS CARES Act would ensure that children in the 5242 justice system received a mental health screening prior to 5243 release, so that they can have a fair chance at staying out 5244 of the justice system entirely.
- The amendment I am offering today with Congressman 5245 Hudson to KIDS CARE further ensures that kids in our justice 5246 system have access to critical health care. This amendment 5247 is based on the Due Process Continuity of Care Act that I 5248 5249 introduced with my bipartisan addiction and mental health task force co-chair, Congressman David Trone. It would end 5250 5251 the antiquated Medicaid inmate exclusion policy for juvenile pre-trial detainees, as Mr. Hudson referenced, not even 5252 considered convicted of any crime in a pre-trial basis, so 5253 that they will not be kicked off of Medicaid before they are 5254 5255 ever found guilty of a crime.
- 5256 This means our youth will not be stripped of their

- 5257 health care while they await trial. They will have access to
- 5258 mental health care and existing treatments that they are
- 5259 already receiving.
- 5260 This legislation will help vulnerable youth all across
- 5261 this country, and save taxpayer dollars that currently foot
- 5262 the bill for inadequate health care in the justice system,
- 15263 leading to such a high rate of recidivism and cost to the
- 5264 taxpayers.
- I urge my colleagues to support this amendment, and I
- 5266 yield back.
- *The Chairman. Thank you, Ms. Kuster.
- Does anyone else want to speak on Hudson amendment in
- 5269 the nature of a substitute?
- 5270 All right. Hearing none --
- 5271 [Pause.]
- *The Chairman. -- or amendments, we will proceed to a
- 5273 vote on the Hudson amendment in the nature of a substitute.
- 5274 All those in favor of the amendment in the nature of a
- substitute to H.R. 7233, as amended, will signify by saying
- 5276 aye.
- 5277 All those opposed will say no.
- In the opinion of the chair, the ayes have it, and the
- 5279 -- oh, does that matter? Okay, all right, so the Hudson AINS
- is adopted. And I think we are going to go to final passage
- 5281 now.

```
So a recorded vote is ordered on H.R. 7233, and so those
```

- in favor of reporting H.R. 7233, as amended, to the full
- 5284 House will say aye, those opposed will say no, and the clerk
- 5285 shall call the roll.
- 5286 *The Clerk. Mr. Rush?
- *Mr. Rush. Rush votes aye.
- *The Clerk. Mr. Rush votes aye.
- 5289 Ms. Eshoo?
- 5290 *Ms. Eshoo. Votes aye.
- *The Clerk. Ms. Eshoo votes aye.
- 5292 Ms. DeGette?
- [No response.]
- *The Clerk. Mr. Doyle?
- 5295 *Mr. Doyle. Doyle votes yes.
- *The Clerk. Mr. Doyle votes aye.
- 5297 Ms. Schakowsky?
- [No response.]
- *The Clerk. Ms. Schakowsky?
- *Ms. Schakowsky. Schakowsky votes aye.
- *The Clerk. Ms. Schakowsky votes aye.
- 5302 Mr. Butterfield?
- [No response.]
- *The Clerk. Ms. Matsui?
- *Ms. Matsui. Matsui votes aye.
- *The Clerk. Ms. Matsui votes aye.

- 5307 Ms. Castor?
- *Ms. Castor. Ms. Castor votes aye.
- *The Clerk. Ms. Castor votes aye.
- 5310 Mr. Sarbanes?
- *Mr. Sarbanes. Sarbanes votes aye.
- *The Clerk. Mr. Sarbanes votes aye.
- 5313 Mr. McNerney?
- *Mr. McNerney. McNerney votes aye.
- *The Clerk. Mr. McNerney votes aye.
- 5316 Mr. Welch?
- *Mr. Welch. Mr. Welch votes aye.
- *The Clerk. Mr. Welch votes aye.
- 5319 Mr. Tonko?
- *Mr. Tonko. Tonko of New York votes aye.
- *The Clerk. Mr. Tonko votes aye.
- 5322 Ms. Clarke?
- *Ms. Clarke. Ms. Clarke of New York votes aye.
- *The Clerk. Ms. Clarke votes aye.
- 5325 Mr. Schrader?
- *Mr. Schrader. Schrader votes aye.
- *The Clerk. Mr. Schrader votes aye.
- 5328 Mr. Cardenas?
- *Mr. Cardenas. Cardenas from California votes aye.
- *The Clerk. Mr. Cardenas votes aye.
- 5331 Mr. Ruiz?

- 5332 *Mr. Ruiz. Ruiz votes aye.
- *The Clerk. Mr. Ruiz votes aye.
- 5334 Mr. Peters?
- 5335 *Mr. Peters. Peters votes aye.
- *The Clerk. Mr. Peters votes aye.
- 5337 Mrs. Dingell?
- *Mrs. Dingell. Dingell votes aye.
- *The Clerk. Mrs. Dingell votes aye.
- 5340 Mr. Veasey?
- *Mr. Veasey. Veasey votes aye.
- *The Clerk. Mr. Veasey votes aye.
- 5343 Ms. Kuster?
- *Ms. Kuster. Kuster votes aye.
- *The Clerk. Ms. Kuster votes aye.
- 5346 Ms. Kelly?
- *Ms. Kelly. Kelly votes aye.
- *The Clerk. Ms. Kelly votes aye.
- 5349 Ms. Barragan?
- *Ms. Barragan. Barragan votes aye.
- *The Clerk. Ms. Barragan votes aye.
- 5352 Mr. McEachin?
- *Mr. McEachin. McEachin votes aye.
- *The Clerk. Mr. McEachin votes aye.
- 5355 Ms. Blunt Rochester?
- *Ms. Blunt Rochester. Blunt Rochester votes aye.

- *The Clerk. Ms. Blunt Rochester votes aye.
- 5358 Mr. Soto?
- 5359 *Mr. Soto. Soto votes aye.
- *The Clerk. Mr. Soto votes aye.
- 5361 Mr. O'Halleran?
- *Mr. O'Halleran. O'Halleran votes aye.
- *The Clerk. Mr. O'Halleran votes aye.
- 5364 Miss Rice?
- *Miss Rice. Rice votes aye.
- *The Clerk. Miss Rice votes aye.
- 5367 Ms. Craiq?
- [No response.]
- *The Clerk. Ms. Schrier?
- *Ms. Schrier. Schrier votes aye.
- *The Clerk. Ms. Schrier votes aye.
- 5372 Mrs. Trahan?
- *Mrs. Trahan. Trahan votes aye.
- *The Clerk. Mrs. Trahan votes aye.
- 5375 Mrs. Fletcher?
- *Mrs. Fletcher. Fletcher votes aye.
- *The Clerk. Mrs. Fletcher votes aye.
- 5378 Mrs. Rodgers?
- *Mrs. Rodgers. Rodgers votes aye.
- *The Clerk. Mrs. Rodgers votes aye.
- 5381 Mr. Upton?

```
*Mr. Upton. Upton votes aye.
5382
            *The Clerk. Mr. Upton votes aye.
5383
           Mr. Burgess?
5384
            *Mr. Burgess. Burgess votes aye.
5385
5386
            *The Clerk. Mr. Burgess votes aye.
           Mr. Scalise?
5387
5388
           [No response.]
5389
            *The Clerk. Mr. Latta?
5390
            *Mr. Latta.
                         Aye.
            *The Clerk. Mr. Latta votes aye.
5391
           Mr. Guthrie?
5392
           *Mr. Guthrie.
5393
                           Aye.
           *The Clerk. Mr. Guthrie votes aye.
5394
           Mr. McKinley?
5395
5396
            *Mr. McKinley. Aye.
5397
            *The Clerk. Mr. McKinley votes aye.
           Mr. Kinzinger?
5398
5399
            [No response.]
5400
            *The Clerk. Mr. Griffith?
5401
            *Mr. Griffith. Aye.
            *The Clerk. Mr. Griffith votes aye.
5402
           Mr. Bilirakis?
5403
5404
            [No response.]
            *The Clerk. Mr. Johnson?
5405
```

[No response.]

- *The Clerk. Mr. Long?
- *Mr. Long. Long votes aye.
- *The Clerk. Mr. Long votes aye.
- 5410 Mr. Bucshon?
- *Mr. Bucshon. [Inaudible.]
- *The Clerk. Mr. Bucshon votes aye.
- 5413 Mr. Mullin?
- *Mr. Mullin. Aye.
- *The Clerk. Mr. Mullin votes aye.
- 5416 Mr. Hudson?
- 5417 *Mr. Hudson. Aye.
- *The Clerk. Mr. Hudson votes aye.
- 5419 Mr. Walberg?
- *Mr. Walberg. [Inaudible.]
- *The Clerk. Mr. Walberg votes aye.
- 5422 Mr. Carter?
- *Mr. Carter. Carter votes aye.
- *The Clerk. Mr. Carter votes aye.
- 5425 Mr. Duncan?
- [No response.]
- *The Clerk. Mr. Palmer?
- 5428 *Mr. Palmer. Aye.
- *The Clerk. Mr. Palmer votes aye.
- 5430 Mr. Dunn?
- 5431 *Mr. Dunn. Dunn votes aye.

- *The Clerk. Mr. Dunn votes aye.
- 5433 Mr. Curtis?
- 5434 *Mr. Curtis. Aye.
- *The Clerk. Mr. Curtis votes aye.
- 5436 Mrs. Lesko?
- 5437 *Mrs. Lesko. Aye.
- *The Clerk. Mrs. Lesko votes aye.
- 5439 Mr. Pence?
- [No response.]
- *The Clerk. Mr. Crenshaw?
- 5442 *Mr. Crenshaw. Aye.
- *The Clerk. Mr. Crenshaw votes aye.
- 5444 Mr. Joyce?
- *Mr. Joyce. Joyce votes aye.
- *The Clerk. Mr. Joyce votes aye.
- Mr. Armstrong?
- *Mr. Armstrong. [Inaudible.]
- *The Clerk. Mr. Armstrong votes aye.
- 5450 Chairman Pallone?
- *The Chairman. Pallone votes aye.
- *The Clerk. Chairman Pallone votes aye.
- *The Chairman. Ms. DeGette?
- *Ms. DeGette. DeGette votes aye.
- *The Clerk. Ms. DeGette votes aye.
- *Mr. Johnson. Mr. Chairman, how is Mr. Johnson

- 5457 recorded?
- 5458 *The Chairman. Mr. Johnson?
- *The Clerk. Mr. Johnson is not recorded.
- *Mr. Johnson. Johnson votes aye.
- *The Clerk. Mr. Johnson votes aye.
- *The Chairman. Mr. Pence?
- *Mr. Pence. Pence votes aye.
- *The Clerk. Mr. Pence votes aye.
- *The Chairman. Anyone else who is not recorded and
- 5466 wants to be?
- 5467 Who?
- 5468 [Pause.]
- *The Chairman. All right. The clerk will report the
- 5470 tally.
- *The Clerk. On that vote, Mr. Chairman, the yeas were
- 5472 52 and the nays were 0.
- *The Chairman. Fifty-two ayes and no -- zero noes?
- 5474 Okay. So the vote on H.R. 7233, as amended, is 52 ayes to 0
- noes, and so H.R. 7233, as amended, is reported to the full
- 5476 House.
- 5477 So the next bill we have, the chair calls up H.R. 623,
- 5478 the Gabriella Miller Kids First Research Act 2.0, as
- forwarded by the Subcommittee on Health, and the clerk will
- 5480 report that bill.
- *The Clerk. Committee print to H.R. 623, a bill to

5482	require certain civil penalties to be transferred to a
5483	fund
5484	*The Chairman. And Madam Clerk, without objection, the
5485	first reading of the bill will be dispensed with. The bill
5486	is now considered as read and, without objection, open to
5487	amendment.
5488	[The bill follows:]
5489	
5490	**************************************

- *The Chairman. Does anyone want to speak on the bill?
- No? Wow, okay. And are there any amendments? All
- 5494 right, we will go to a --
- *Mrs. Rodgers. Recorded vote.
- *The Chairman. -- recorded vote. Okay, let's skip to
- 5497 that. A recorded vote is ordered on 623. Those in favor of
- reporting H.R. 623, as amended, to the House will say aye,
- those opposed will say no, and the clerk shall call the roll.
- *The Clerk. Mr. Rush?
- *Mr. Rush. Rush votes aye.
- *The Clerk. Mr. Rush votes aye.
- 5503 Ms. Eshoo?
- *Ms. Eshoo. Eshoo votes aye.
- *The Clerk. Ms. Eshoo votes aye.
- 5506 Ms. DeGette?
- [No response.]
- *The Clerk. Mr. Doyle?
- 5509 *Mr. Doyle. Doyle votes aye.
- *The Clerk. Mr. Doyle votes aye.
- 5511 Ms. Schakowsky?
- *Ms. Schakowsky. Schakowsky votes aye.
- *The Clerk. Ms. Schakowsky votes aye.
- 5514 Mr. Butterfield?
- [No response.]
- *The Clerk. Ms. Matsui?

- *Ms. Matsui. Matsui votes aye.
- *The Clerk. Ms. Matsui votes aye.
- 5519 Ms. Castor?
- *Ms. Castor. Ms. Castor votes aye.
- *The Clerk. Ms. Castor votes aye.
- 5522 Mr. Sarbanes?
- *Mr. Sarbanes. Sarbanes votes aye.
- *The Clerk. Mr. Sarbanes votes aye.
- 5525 Mr. McNerney?
- *Mr. McNerney. McNerney votes aye.
- *The Clerk. Mr. McNerney votes aye.
- 5528 Mr. Welch?
- [No response.]
- *The Clerk. Mr. Tonko?
- *Mr. Tonko. Tonko of New York votes aye.
- *The Clerk. Mr. Tonko votes aye.
- 5533 Ms. Clarke?
- *Ms. Clarke. Clarke of New York votes aye.
- *The Clerk. Ms. Clarke votes aye.
- 5536 Mr. Schrader?
- *Mr. Schrader. Schrader votes aye.
- *The Clerk. Mr. Schrader votes aye.
- 5539 Mr. Cardenas?
- [No response.]
- *The Clerk. Mr. Ruiz?

- *Mr. Ruiz. Ruiz votes aye.
- *The Clerk. Mr. Ruiz votes aye.
- Mr. Peters?
- *Mr. Peters. Peters votes aye.
- *The Clerk. Mr. Peters votes aye.
- 5547 Mrs. Dingell?
- *Mrs. Dingell. Dingell votes aye.
- *The Clerk. Mrs. Dingell votes aye.
- 5550 Mr. Veasey?
- *Mr. Veasey. Votes aye.
- *The Clerk. Mr. Veasey votes aye.
- 5553 Ms. Kuster?
- *Ms. Kuster. Ms. Kuster votes aye.
- *The Clerk. Ms. Kuster votes aye.
- 5556 Ms. Kelly?
- *Ms. Kelly. Kelly votes aye.
- *The Clerk. Ms. Kelly votes aye.
- 5559 Ms. Barragan?
- *Ms. Barragan. Barragan votes aye.
- *The Clerk. Ms. Barragan votes aye.
- 5562 Mr. McEachin?
- *Mr. McEachin. McEachin votes aye.
- *The Clerk. Mr. McEachin votes aye.
- 5565 Ms. Blunt Rochester?
- *Ms. Blunt Rochester. Blunt Rochester votes aye.

- *The Clerk. Ms. Blunt Rochester votes aye.
- 5568 Mr. Soto?
- *Mr. Soto. Soto votes aye.
- *The Clerk. Mr. Soto votes aye.
- 5571 Mr. O'Halleran?
- *Mr. O'Halleran. O'Halleran votes aye.
- *The Clerk. Mr. O'Halleran votes aye.
- 5574 Miss Rice?
- *Miss Rice. Rice votes aye.
- *The Clerk. Miss Rice votes aye.
- 5577 Ms. Craig?
- *Ms. Craig. Craig of Minnesota votes yes.
- *The Clerk. Ms. Craig votes aye.
- 5580 Ms. Schrier?
- [No response.]
- *The Clerk. Mrs. Trahan?
- *Mr. Cardenas. Cardenas votes aye.
- *Mrs. Trahan. Trahan votes aye.
- *The Clerk. Mrs. Trahan votes aye.
- Mr. Cardenas votes aye.
- *Mr. Cardenas. Cardenas votes aye.
- *The Clerk. Mr. Cardenas votes aye.
- 5589 Mrs. Fletcher?
- *Mrs. Fletcher. Fletcher votes aye.
- *The Clerk. Mrs. Fletcher votes aye.

```
5592
           Mrs. Rodgers?
            *Mrs. Rodgers. Rodgers votes aye.
5593
5594
            *The Clerk. Mrs. Rodgers votes aye.
5595
           Mr. Upton?
5596
            *Mr. Upton. Upton votes aye.
            *The Clerk. Mr. Upton votes aye.
5597
5598
           Mr. Burgess?
5599
            *Mr. Burgess. [Inaudible.]
5600
            *The Clerk. Mr. Burgess votes aye.
5601
           Mr. Scalise?
5602
           [No response.]
           *The Clerk. Mr. Latta?
5603
5604
           *Mr. Latta.
                        Aye.
           *The Clerk. Mr. Latta votes aye.
5605
           Mr. Guthrie?
5606
5607
            *Mr. Guthrie.
                           Aye.
            *The Clerk. Mr. Guthrie votes aye.
5608
5609
           Mr. McKinley?
5610
            *Mr. McKinley. Aye.
5611
            *The Clerk. Mr. McKinley votes aye.
           Mr. Kinzinger?
5612
5613
           [No response.]
            *The Clerk. Mr. Griffith?
5614
```

*Mr. Griffith. Aye.

*The Clerk. Mr. Griffith votes aye.

5615

- 5617 Mr. Bilirakis?
- *Mr. Bilirakis. Bilirakis votes aye.
- *The Clerk. Mr. Bilirakis votes aye.
- 5620 Mr. Johnson?
- 5621 *Mr. Johnson. Aye.
- *The Clerk. Mr. Johnson votes aye.
- 5623 Mr. Long?
- *Mr. Long. Long votes yes.
- *The Clerk. Mr. Long votes aye.
- 5626 Mr. Bucshon?
- 5627 *Mr. Bucshon. Aye.
- *The Clerk. Mr. Bucshon votes aye.
- 5629 Mr. Mullin?
- 5630 *Mr. Mullin. Aye.
- *The Clerk. Mr. Mullin votes aye.
- 5632 Mr. Hudson?
- 5633 *Mr. Hudson. Aye.
- *The Clerk. Mr. Hudson votes aye.
- 5635 Mr. Walberg?
- 5636 *Mr. Walberg. Aye.
- *The Clerk. Mr. Walberg votes aye.
- 5638 Mr. Carter?
- 5639 *Mr. Carter. Carter votes aye.
- *The Clerk. Mr. Carter votes aye.
- 5641 Mr. Duncan?

```
[No response.]
5642
           *The Clerk. Mr. Palmer?
5643
            *Mr. Palmer. Aye.
5644
           *The Clerk. Mr. Palmer votes aye.
5645
5646
           Mr. Dunn?
5647
           *Mr. Dunn. Dunn votes aye.
5648
           *The Clerk. Mr. Dunn votes aye.
5649
           Mr. Curtis?
           *Mr. Curtis. [Inaudible.]
5650
5651
           *The Clerk. Mr. Curtis votes aye.
           Mrs. Lesko?
5652
           *Mrs. Lesko. [Inaudible.]
5653
           *The Clerk. Mrs. Lesko votes aye.
5654
           Mr. Pence?
5655
5656
           *Mr. Pence. Aye.
5657
           *The Clerk. Mr. Pence votes aye.
           Mr. Crenshaw?
5658
                            [Inaudible.]
5659
            *Mr. Crenshaw.
5660
           *The Clerk. Mr. Crenshaw votes aye.
5661
           Mr. Joyce?
           *Mr. Joyce. [Inaudible.]
5662
5663
           *The Clerk. Mr. Joyce votes aye.
5664
           Mr. Armstrong?
5665
           *Mr. Armstrong. [Inaudible.]
```

*The Clerk. Mr. Armstrong votes aye.

- 5667 Chairman Pallone?
- *The Chairman. Pallone votes aye.
- *The Clerk. Chairman Pallone votes aye.
- *The Chairman. Ms. DeGette?
- *Ms. DeGette. DeGette votes aye.
- *The Clerk. Ms. DeGette votes aye.
- *Ms. Schrier. How am I recorded?
- *Voice. Ms. Schrier, Dr. Schrier.
- *The Clerk. Ms. Schrier is not recorded.
- *Ms. Schrier. Schrier votes aye.
- *The Clerk. Ms. Schrier votes aye.
- *The Chairman. Any other member who seeks to be
- 5679 recorded?
- *Voice. We are missing some, but I don't --
- *The Chairman. All right. The clerk will report the
- 5682 tally.
- *The Clerk. On that vote, Mr. Chairman, the yeas were
- 5684 53 and the nays were 0.
- *The Chairman. Okay, so on H.R. 623 the vote is 53 ayes
- to 0 noes. And so H.R. 623, as amended, is reported to the
- 5687 full House.
- Next the chair calls up H.R. 3771, the South Asian Heart
- 5689 Health Awareness Act of 2021, as forwarded by the
- 5690 Subcommittee on Health, and the clerk will report the bill.
- *The Clerk. Committee print on H.R. 3771 to amend the

5692	Public Health Service Act
5693	*The Chairman. And Madam Clerk, without objection, the
5694	first reading of the bill will be dispensed with. The bill
5695	is now considered as read and open for amendment.
5696	[The bill follows:]
5697	
5698	*********COMMITTEE INSERT******
5699	

- 5700 *Ms. Schrier. Mr. Chairman?
- *The Chairman. Yes. Ms. Schrier, did you want to speak
- 5702 on the underlying bill?
- *Ms. Schrier. Yes, I would. Thank you very much.
- *The Chairman. All right.
- 5705 *Ms. Schrier. I wanted to speak in [inaudible] of H.R.
- 5706 3771, the South Asian Heart Health Awareness and [inaudible]
- 5707 Act. [Inaudible] of South Carolina.
- Asian Americans have experienced the fastest population
- 5709 growth rate among all racial and ethnic groups in the United
- 5710 States, and are projected to be the largest immigrant group
- in the U.S. by 2055. However, many programs and activities
- 5712 to date classify the South Asian population with other Asian
- 5713 groups as Asian American or Pacific Islander.
- We also know that heart disease is the leading cause of
- 5715 death for men, women, and people of most racial and ethnic
- 5716 groups in the United States. Specifically, the American
- 5717 Heart Association, though, has found that South Asian
- 5718 Americans are more likely to die of specifically coronary
- 5719 artery disease than other Asian Americans and non-Hispanic
- 5720 White Americans.
- 5721 So this legislation will provide grant funds to support
- 5722 cardiovascular health promotion and heart health research
- among the South Asian community, but also for other groups.
- 5724 And to say that this legislation is too targeted on a

- 5725 specific population is really not accurate, and also
- 5726 dismisses advances made when studies of disease in specific
- 5727 populations have led to medical advances for all races and
- 5728 ethnicities. For example, a study on high cholesterol in the
- 5729 Black community led to the discovery of a blockbuster
- 5730 cholesterol-lowering drug called Repatha, now taken by tens
- 5731 of millions of Americans.
- 5732 So lastly, let me just remind my colleagues that this
- 5733 bipartisan legislation is not new. Our committee considered
- 5734 this legislation in the 116th Congress, and it was passed in
- 5735 the House by voice vote.
- 5736 There is an urgent need for these grants and this
- 5737 research, and we simply can't ignore these communities, these
- 5738 growing communities, anymore in our research and programs.
- And I urge my colleagues to support this bill, and I
- 5740 yield back.
- *The Chairman. I thank the gentlewoman.
- 5742 Mr. Carter is recognized.
- 5743 *Mr. Carter. I move to strike the last word.
- *The Chairman. The gentleman is recognized for five
- 5745 minutes.
- 5746 *Mr. Carter. Mr. Chairman, I want to discuss the South
- 5747 Asian Heart Health Awareness and Research Act that Democrats
- 5748 have brought before us today.
- 5749 As a pharmacist and a lifelong health care professional,

- 5750 I support initiatives to improve our health care system,
- 5751 especially for those in ethnic and minority communities.
- 5752 However, I have concerns with South Asian Heart Health
- 5753 Awareness and Research Act that Democrats have brought before
- 5754 us today. Unfortunately, this bill will not help address the
- 5755 cardiovascular health issues that Americans face, and might I
- 5756 add that particularly those of us in the South, which is
- 5757 known as the Cardiac Belt.
- 5758 In providing technical feedback on the bill, the CDC
- 5759 expressed concerns that the grants authorized under the
- 5760 legislation would be duplicative to their current efforts to
- 5761 address cardiovascular disease in disproportionately impacted
- 5762 communities.
- 5763 In addition, the CDC expressed concerns that it would
- not be able to provide the data that the bill is mandating
- 5765 the agency report on.
- Now that my Public Health Infrastructure Modernization
- 5767 Act is now law, the CDC can work together with states so that
- 5768 they can better understand the burdens of heart disease in
- 5769 their own South Asian populations and other populations
- 5770 disproportionately impacted with poor health. As we have
- 5771 more data on the issue, we can better tailor our efforts to
- 5772 these populations.
- 5773 The South Asian Heart Health Awareness and Research Act
- 5774 should not move forward, and I urge my colleagues to oppose

- 5775 this piece of legislation.
- 5776 Thank you, Mr. Chairman, and I yield back.
- *The Chairman. I know you guys want a vote. Thank you,
- 5778 but I just wanted to say quickly, because I know that -- I
- just wanted to, if I could, express -- or respond to some of
- 5780 the concerns that Mr. Carter mentioned. So I move to strike
- 5781 the last word, but I will be brief.
- First, I do want to say this is bipartisan in the sense
- 5783 that the sponsors, Ms. Jayapal -- and Mr. Wilson of South
- 5784 Carolina, of course, is a Republican, so there are
- 5785 Republicans that support it.
- In addition to that, we broadened the bill in the last
- 5787 Congress because I know there was some concerns by some on
- 5788 the Republican side that it was too narrow. So the
- 5789 legislation states that it will support communities
- 5790 disproportionately affected by heart disease, such as South
- 5791 Asian communities in the U.S., and therefore it can be used
- 5792 to support any disproportionately affected community. And
- 5793 heart disease disproportionately affects many racial and
- 5794 ethnic groups in the U.S., and is the leading cause of death
- 5795 for African Americans, American Indians, Alaska Natives,
- 5796 Hispanic, and White men. So this legislation, you know,
- stands to benefit many of these groups, in my opinion.
- I just -- I know that some -- you know, I know -- I
- 5799 heard what Mr. Carter said, but I really think that we have

- done quite a bit here to broaden this, to make it, you know,
- not only what the sponsors wanted, but also to address some
- of the concerns of the CDC. So I didn't want you to think
- 5803 that we weren't trying. You may still oppose it, but we have
- 5804 tried to deal with some of your concerns.
- And I yield back. Does anyone else want to speak on
- 5806 this?
- If not, we will go to a vote. We are going to have a
- 5808 recorded vote. A recorded vote is ordered. Those in favor
- of reporting H.R. 3771, as amended, to the House will say
- 5810 aye, those opposed will say no, and the clerk shall call the
- 5811 roll.
- 5812 *The Clerk. Mr. Rush?
- 5813 *Mr. Rush. Rush votes aye.
- *The Clerk. Mr. Rush votes aye.
- 5815 Ms. Eshoo?
- *Ms. Eshoo. Eshoo votes aye.
- *The Clerk. Ms. Eshoo votes aye.
- 5818 Ms. DeGette?
- 5819 *Ms. DeGette. Aye.
- *The Clerk. Ms. DeGette votes aye.
- 5821 Mr. Doyle?
- [No response.]
- *The Clerk. Ms. Schakowsky?
- *Ms. Schakowsky. Schakowsky votes aye.

- *The Clerk. Ms. Schakowsky votes aye.
- 5826 Mr. Butterfield?
- *Mr. Butterfield. Butterfield votes aye.
- *The Clerk. Mr. Butterfield votes aye.
- 5829 Ms. Matsui?
- *Ms. Matsui. Matsui votes aye.
- *The Clerk. Ms. Matsui votes aye.
- 5832 Ms. Castor?
- *Ms. Castor. Ms. Castor votes aye.
- *The Clerk. Ms. Castor votes aye.
- 5835 Mr. Sarbanes?
- 5836 *Mr. Sarbanes. Sarbanes votes aye.
- *The Clerk. Mr. Sarbanes votes aye.
- 5838 Mr. McNerney?
- *Mr. McNerney. McNerney votes aye.
- *The Clerk. Mr. McNerney votes aye.
- 5841 Mr. Welch?
- [No response.]
- *The Clerk. Mr. Tonko?
- *Mr. Tonko. Tonko of New York votes aye.
- *The Clerk. Mr. Tonko votes aye.
- 5846 Ms. Clarke?
- *Ms. Clarke. Ms. Clarke of New York votes aye.
- *The Clerk. Ms. Clarke votes aye.
- 5849 Mr. Schrader?

```
5850 *Mr. Schrader. Schrader votes aye.
```

- *The Clerk. Mr. Schrader votes aye.
- 5852 Mr. Cardenas?
- *Mr. Cardenas. Cardenas votes aye.
- *The Clerk. Mr. Cardenas votes aye.
- 5855 Mr. Ruiz?
- 5856 *Mr. Ruiz. Ruiz votes aye.
- *The Clerk. Mr. Ruiz votes aye.
- 5858 Mr. Peters?
- 5859 *Mr. Peters. Peters votes aye.
- *The Clerk. Mr. Peters votes aye.
- 5861 Mrs. Dingell?
- 5862 *Mrs. Dingell. Dingell votes aye.
- *The Clerk. Mrs. Dingell votes aye.
- Mr. Veasey?
- *Mr. Veasey. Veasey votes aye.
- *The Clerk. Mr. Veasey votes aye.
- 5867 Ms. Kuster?
- *Ms. Kuster. Kuster votes aye.
- *The Clerk. Ms. Kuster votes aye.
- 5870 Ms. Kelly?
- *Ms. Kelly. Kelly votes aye.
- *The Clerk. Ms. Kelly votes aye.
- 5873 Ms. Barragan?
- [No response.]

- *The Clerk. Mr. McEachin?
- *Mr. McEachin. McEachin votes aye.
- *The Clerk. Mr. McEachin votes aye.
- 5878 Ms. Blunt Rochester?
- *Ms. Blunt Rochester. Blunt Rochester votes aye.
- *The Clerk. Ms. Blunt Rochester votes aye.
- 5881 Mr. Soto?
- 5882 *Mr. Soto. Soto votes aye.
- *The Clerk. Mr. Soto votes aye.
- Mr. O'Halleran?
- [No response.]
- *The Clerk. Mr. O'Halleran?
- *Mr. O'Halleran. O'Halleran votes aye.
- *The Clerk. Mr. O'Halleran votes aye.
- 5889 Miss Rice?
- *Miss Rice. Rice votes aye.
- *The Clerk. Miss Rice votes aye.
- 5892 Ms. Craig?
- *Ms. Craig. Craig votes aye.
- *The Clerk. Ms. Craig votes aye.
- 5895 Ms. Schrier?
- 5896 *Ms. Schrier. Schrier votes aye.
- *The Clerk. Ms. Schrier votes aye.
- 5898 Mrs. Trahan?
- 5899 *Mrs. Trahan. Trahan votes aye.

```
*The Clerk. Mrs. Trahan votes aye.
5900
           Mrs. Fletcher?
5901
            [No response.]
5902
            *The Clerk. Mrs. Fletcher?
5903
5904
            *Mrs. Fletcher. Fletcher votes aye.
            *The Clerk. Mrs. Fletcher votes aye.
5905
5906
           Mrs. Rodgers?
5907
            *Mrs. Rodgers.
                             [Inaudible.]
5908
            *The Clerk. Mrs. Rodgers votes no.
5909
           Mr. Upton?
5910
            *Mr. Upton. Votes no.
            *The Clerk. Mr. Upton votes nay.
5911
5912
           Mr. Burgess?
5913
            *Mr. Burgess. Votes no.
5914
            *The Clerk. Mr. Burgess votes nay.
5915
           Mr. Scalise?
5916
            [No response.]
            *The Clerk. Mr. Latta?
5917
5918
            *Mr. Latta.
                         No.
5919
           *The Clerk. Mr. Latta votes no.
           Mr. Guthrie?
5920
5921
           [No response.]
            *The Clerk. Mr. McKinley?
5922
5923
            *Mr. McKinley. No.
```

*The Clerk. Mr. McKinley votes no.

```
5925
           Mr. Kinzinger?
           [No response.]
5926
           *The Clerk. Mr. Griffith?
5927
           *Mr. Griffith. No.
5928
5929
           *The Clerk. Mr. Griffith votes no.
           Mr. Bilirakis?
5930
           *Mr. Bilirakis. Bilirakis votes no.
5931
           *The Clerk. Mr. Bilirakis votes no.
5932
5933
           Mr. Johnson?
5934
           [No response.]
           *The Clerk. Mr. Long?
5935
           *Mr. Long. Long votes no.
5936
           *The Clerk. Mr. Long votes no.
5937
5938
           *Voice. Hold on, guys.
           *The Clerk. Mr. Bucshon?
5939
5940
            *Mr. Bucshon. [Inaudible.]
           *The Clerk. Mr. Bucshon votes no.
5941
           Mr. Mullin?
5942
5943
           *Mr. Mullin. No.
           *The Clerk. Mr. Mullin votes no.
5944
           Mr. Hudson?
5945
           *Mr. Hudson. [Inaudible.]
5946
5947
           *The Clerk. Mr. Hudson votes no.
           Mr. Walberg?
5948
```

*Mr. Walberg. No.

- *The Clerk. Mr. Walberg votes no.
- 5951 Mr. Carter?
- 5952 *Mr. Carter. Carter votes no.
- *The Clerk. Mr. Carter votes no.
- 5954 Mr. Duncan?
- 5955 *Mr. Duncan. No.
- *The Clerk. Mr. Duncan votes no.
- 5957 Mr. Palmer?
- 5958 *Mr. Palmer. No.
- *The Clerk. Mr. Palmer votes no.
- 5960 Mr. Dunn?
- 5961 *Mr. Dunn. Dunn votes no.
- *The Clerk. Mr. Dunn votes no.
- 5963 Mr. Curtis?
- *Mr. Curtis. [Inaudible.]
- *The Clerk. Mr. Curtis votes no.
- 5966 Mrs. Lesko?
- 5967 *Mrs. Lesko. No.
- *The Clerk. Mrs. Lesko votes no.
- 5969 Mr. Pence?
- 5970 *Mr. Pence. No.
- *The Clerk. Mr. Pence votes no.
- 5972 Mr. Crenshaw?
- 5973 *Mr. Crenshaw. No.
- *The Clerk. Mr. Crenshaw votes no.

```
Mr. Joyce?
5975
           *Mr. Joyce. [Inaudible.]
5976
5977
           *The Clerk. Mr. Joyce votes no.
5978
           Mr. Armstrong?
5979
           *Mr. Armstrong.
                            No.
5980
           *The Clerk. Mr. Armstrong votes no.
           Chairman Pallone?
5981
5982
           *The Chairman. Pallone votes aye.
5983
           *The Clerk. Chairman Pallone votes aye.
5984
           *Mr. Welch. Madam Clerk, how am I --
           *Mr. Doyle. How am I recorded, Mr. Chairman?
5985
           *Mr. Welch. -- Welch.
5986
           *The Chairman. Mr. Johnson?
5987
5988
           *Mr. Doyle. Mr. Doyle.
           *Mr. Johnson. No.
5989
5990
           *The Clerk. Mr. Johnson votes no.
5991
           *The Chairman. Mr. Doyle?
           *Mr. Doyle. Mr. Doyle votes aye.
5992
5993
           *Mr. Welch. Mr. Welch.
5994
           *The Clerk. Mr. Doyle votes aye.
           *The Chairman. Mr. Welch?
5995
5996
           *Mr. Welch. Votes aye.
```

*The Clerk. Mr. Welch is -- Mr. Welch votes aye.

*Mr. Guthrie. Guthrie.

*The Chairman. Mr. Guthrie?

5997

5998

```
*Mr. Guthrie. Guthrie votes no.
6000
           *The Clerk. Mr. Guthrie votes no.
6001
           *The Chairman. Anyone else who is not recorded and
6002
6003
      wants to be?
6004
           Hearing none, the clerk will report the tally.
            *The Clerk. On that vote the yeas were 31 and the nays
6005
      were 24.
6006
6007
            *The Chairman. So the vote on H.R. 3771, as amended, is
      31 ayes to 24 noes. So H.R. 3771, as amended, is reported to
6008
6009
      the full House.
           And our last bill, the chair calls up H.R. 5585, the
6010
      Advanced Research Project Agency Health Act, or the ARPA-H
6011
      Act, last but certainly not least, Ms. Eshoo.
6012
           The clerk will report the title of the bill.
6013
            *The Clerk. H.R. 5585, a bill to establish the Advanced
6014
      Research Projects --
6015
            *The Chairman. Madam Clerk, without objection, the
6016
      first reading of the bill will be dispensed with. The bill
6017
      is now considered as read and open for amendment.
6018
6019
            [The bill follows:]
6020
```

6021

*The Chairman. Did you want to speak on the underlying 6023 bill? 6024 *Ms. Eshoo. Well, I appreciate your offering that, Mr. 6025 Chairman, but I think all of my colleagues have heard a lot 6026 6027 from me about ARPA-H, so I can't add to what I have said before, and I will just speak to the amendment in the nature 6028 of a substitute. 6029 6030 *The Chairman. Is that -- we can proceed to that. All right, let's go to the AINS. 6031 6032 I recognize Ms. Eshoo to offer an amendment in the nature of a substitute, and the clerk will report the 6033 amendment. 6034 *The Clerk. Amendment in the nature of a substitute to 6035 H.R. 5585, offered by Ms. Eshoo of California. 6036 Strike all --6037 *The Chairman. Madam Clerk, without objection, the 6038 reading of the amendment will be dispensed with. 6039 [The amendment of Ms. Eshoo follows:] 6040

*********COMMITTEE INSERT******

6043

6041

- *The Chairman. And Ms. Eshoo is recognized for five minutes.
- *Ms. Eshoo. Thank you, Mr. Chairman. Suffice it to say
 that each one of us, as a Member of Congress, have met with
 hundreds -- or, if our tenure is a long one in the Congress,
- 6049 literally thousands -- of constituents who have pleaded for
- 6050 Congress to do more to address diseases, especially in the
- area where a diagnosis is a death sentence: pancreatic
- 6052 cancer, glioblastoma, ALS, Alzheimer's.
- I introduced this legislation to take these deadly
 diseases head on by creating the Advanced Research Projects
 Agency for Health, ARPA-H. The bill and its amendment
 establishes ARPA-H as an independent agency within HHS, with
 a presidentially-appointed, Senate-confirmed director who
 would have the authority to approve and end project funding,
 establish milestones, and coordinate with other health
- nimble spirit of the highly regarded and successful DARPA to

agencies. ARPA-H will be outside of NIH, and will embody the

6062 pursue large-scale, high-risk projects.

6060

6068

I really can't thank the following enough for working

with me on this. To the Republican leader, Mrs. Rodgers,

certainly to you, Chairman Pallone -- from the beginning you

have supported this -- to Congresswoman DeGette, who has been

a partner, to Congressman Upton and to Congressman Burgess,

along the way each has leaned in and brought their critique

- 6069 to the legislation.
- And we are here today on this rework, and I think that
- it is a stronger bill, as amended. It is carefully written
- 6072 to define the clear authorities and mission so that it is an
- 6073 agency that will avoid duplication of effort in the Federal
- 6074 Government -- that was a concern that was raised some time
- ago -- or the private sector, as well as transparency
- 6076 requirements to ensure it responsibly spends the taxpayer
- 6077 funding.
- It breaks down the silos between Federal health programs
- 6079 by requiring both the FDA and CMS to closely coordinate with
- 6080 ARPA-H. And if the new agency creates a cutting-edge
- 6081 treatment, FDA should be ready to review it, and CMS should
- 6082 be ready to make a coverage determination.
- I am proud that the legislation has received widespread
- 6084 support from leading experts and organizations across the
- 6085 country, including bipartisan former officials from the NIH,
- 6086 CDC, the FDA, as well as respected research non-profits such
- 6087 as Friends of Cancer Research, UsAgainstAlzheimer's, and the
- 6088 Suzanne Wright Foundation.
- Two months ago the President signed into law the
- 6090 Bipartisan Consolidated Appropriations Act of 2022, which
- 6091 provided \$1 billion -- that is with a B -- to establish ARPA-
- 6092 H. Our committee now has the opportunity to pass this Act to
- 6093 provide the agency with the full authorities it needs to be

- 6094 successful from day one, and including ensuring that, again,
- 6095 that it will be a nimble, dynamic, and independent agency.
- So it is with a great deal of gratitude and more than a
- dose of humility that I urge my colleagues to vote for this
- 6098 important legislation.
- And I yield back, Mr. Chairman.
- *The Chairman. Thank you, Chairwoman Eshoo.
- The ranking member would like to speak on this. I
- 6102 recognize Mrs. Rodgers for five minutes.
- 6103 *Mrs. Rodgers. Thank you, Mr. Chairman. As I discussed
- at the last markup, I have been a long-time supporter of
- 6105 biomedical research and innovation, including projects like
- 6106 the BRAIN Initiative, intended to speed scientific research
- 6107 necessary to accelerate cures for neurologic diseases.
- When the concept of ARPA-H was first proposed to me, I
- 6109 expressed a healthy dose of skepticism.
- 6110 First, I did not see a clear and targeted strategic
- 6111 mission. An unfocused agenda, surely, is not a recipe for
- 6112 success.
- 6113 Second was the issue of duplication. The Federal
- 6114 Government has several agencies that advance biomedical
- 6115 innovation. Within the National Institutes for Health alone
- 6116 we already have the National Center for Advancing
- 6117 Translational Science, the Cures Acceleration Network, the
- 6118 Common Fund, and the Foundation of NIH's Accelerating

- 6119 Medicine's Partnership Program, to name a few.
- Third, I was concerned that the creation of a new agency
- 6121 would lack sufficient transparency and oversight. My
- 6122 questions to supporters of ARPA-H included how will projects
- 6123 be selected; how will the public be kept informed of projects
- and project funding; who will be assessing for duplication of
- 6125 Federal programs; and how will it be managed; what measure
- 6126 will be used to define success; what are the legislative
- 6127 guardrails to ensure that we are supporting American
- 6128 innovators?
- I am very pleased to say that, over the past few months,
- 6130 Chairwoman Eshoo and her team have listened, listened to my
- 6131 concerns. And we have had productive negotiations. And I
- 6132 believe that this amendment in the nature of a substitute
- 6133 sufficiently addresses those concerns.
- The amendment clearly defines the mission of ARPA-H as
- one that will foster the development of high-risk,
- 6136 transformative health technologies that are not being studied
- 6137 by existing public or private. ARPA-H is required to submit
- 6138 a strategic plan to Congress, and shall subject itself to an
- 6139 independent review to assess the degree of duplication and
- 6140 overlap between it and NIH, FDA, and BARDA.
- The new language requires the ARPA-H director to be
- 6142 Senate-confirmed, and ensures that funding will not go
- 6143 towards projects that do not meet the clear, specific goals

- of the agency.
- Importantly, this amendment requires ARPA-H to
- 6146 prioritize funding to domestic recipients conducting the
- 6147 research in the United States. Funding is prohibited from
- 6148 going to foreign recipients organized under the laws of
- 6149 adversarial nations, including China and the Russian
- 6150 Federation.
- And finally, the amendment provides a more sustainable
- 6152 authorization of funding that is in line with what has
- 6153 already been appropriated by Congress, and more closely
- 6154 resembles the funding level for ARPA-E.
- I am very pleased that we were able to come together.
- 6156 This amendment represents E&C's bipartisan record of success
- 6157 in moving legislation that enhances our biomedical research
- 6158 enterprise, and I urge its adoption.
- *Mr. Guthrie. Will the gentlelady yield?
- *Mrs. Rodgers. Yes, I would be happy to yield.
- *Mr. Guthrie. Just yield instead of taking additional
- 6162 time, just to say I agree with what you just said. I know we
- all worked together in agreement.
- I know we first met with -- all of us, several of us --
- 6165 with the President to try to see if we could get a pathway
- 6166 forward. And I wasn't sure we were going to get there, but
- 6167 everybody worked together, Ms. DeGette and Ms. Eshoo and Mr.
- 6168 Upton working on it originally, and all of us together. The

- 6169 staff has done -- so forth.
- So putting in the congressional oversight that you did,
- and really explicitly saying what can be researched with it,
- 6172 what can be part of this group and the other, ensuring that
- 6173 it is domestic, and if there is any international, that they
- 6174 have to work with domestic. This was well done, and good
- 6175 work, and I appreciate everybody and everybody's staff
- 6176 working together.
- 6177 And I yield back.
- *Mr. Upton. Will the gentlelady yield her time again?
- *Mrs. Rodgers. I am happy to.
- 6180 *Mr. Upton. I just want to say I really want to thank
- on both sides, getting this in the
- 6182 position where I would like to think all of us can support
- 6183 it. This is going to be a game-changer. It really is. We
- 6184 are going to be allowed -- and we have heard testimony from
- outside sources, this is going to be yet another avenue to
- find breakthrough drugs to solve these diseases.
- You know, it has already been funded. That debate is
- 6188 over. It was in the fiscal year 2022 appropriation bill, it
- 6189 will be in the CR, for sure, as it moves forward.
- But we want it to work. And I think that it did improve
- on the underlying legislation.
- I want to thank Chair Eshoo for what she did. I was a
- 6193 cosponsor with others on the original bill. But again, I

- 6194 think this is an improvement. And I just want to really
- 6195 thank everyone that was involved the last couple of months
- 6196 getting this ready so that, in fact, we could include this
- 6197 with a mighty strong vote, and signal particularly to the
- 6198 patient community that we are on their side.
- Thank you, I yield back.
- *The Chairman. And the ranking member yields back?
- *Ms. DeGette. Mr. Chairman?
- *The Chairman. Thank you.
- I recognize Ms. DeGette for five minutes.
- *Ms. DeGette. I thank the gentleman.
- I just want to echo this is what this committee does
- 6206 best, because when -- as Mr. Guthrie said, a number of us
- 6207 were in the White House -- Chair Eshoo, Mr. Guthrie, Mr.
- 6208 Upton, myself, other Senators, we were there talking about
- 6209 this unique potential of establishing a lean, mean research
- 6210 machine to address the intractable issues that face us with
- 6211 cancer, Alzheimer's, the brain, as all of the other members
- 6212 have mentioned.
- And Chairman -- and Mr. Upton and I, as all of you know,
- 6214 have been working on Cures 2.0 to try to update our
- 6215 successful 2016 bill, 21st Century Cures. So we, working
- 6216 with the White House, put an ARPA-H section in our bill. But
- 6217 then Chair Eshoo also took this idea, and ran with it in a
- 6218 parallel way.

- So we all then came together to work for the good of
 every patient in America, and we put together -- well, Chair
 Eshoo spent countless hours working on this bill, and we all
 put our input in on both sides of the dais, and we were able
 to come up with a structure that we think is really going to
 work to achieve the goal.
- So, you know, I say this all the time, and so does Fred.
- Disease doesn't just pick one political party or the other.
- 6227 Disease hits every family in America. And it is our
- 6228 obligation -- I think it is one of our most important
- obligations, with all of the advances in biomedical research
- 6230 that we see today -- that we grab that, and that we keep the
- 0231 U.S.'s position as the preeminent place to do research and
- 6232 find cures. And I think ARPA-H is going to be revelatory in
- 6233 that.
- So we are excited to work with the chair and with
- 6235 Chairman Pallone on this, and with the ranking member,
- 6236 because I think it really is going to be a new endeavor that
- is going to be exciting.
- I can't finish my remarks, though, without saying that,
- 6239 even though we have taken our -- or we intend to take our
- 6240 ARPA-H section out of Cures 2.0, this is very much an
- 6241 important bill in and of itself to update the way we deliver
- 6242 cures to the patients of America. And we continue -- Mr.
- 6243 Upton and I are continuing to work out some of the final

- 6244 details with the Administration and also with the majority
- 6245 and minority. We are working very closely with Chair Eshoo
- 6246 and -- oh, and also, as she says, with Chair Eshoo's full
- 6247 support that this bill will become law this Congress. So
- 6248 hold on to your seats, because Cures 2.0 is the next thing
- 6249 that we are teeing up.
- 6250 With that, Mr. Chairman, thank you, and I will yield
- 6251 back.
- 6252 *Mr. Cardenas. Will the gentlewoman yield? This is
- 6253 Cardenas --
- *Ms. DeGette. I would be happy to yield.
- *Mr. Cardenas. Thank you, Mr. --
- *The Chairman. Mr. Cardenas?
- *Ms. DeGette. It sounds like Mr. Cardenas.
- *The Chairman. Mr. Cardenas?
- *Mr. Cardenas. Yes. Thank you very, very much.
- I just wanted to memorialize this moment of bipartisan
- work on behalf of the elected officials on this committee.
- 6262 It is unfortunate that tonight you are probably going to see
- 6263 where we differ, or where we disagree on the nightly news or
- 6264 in the local papers, et cetera. And we are probably not
- 6265 going to hear a peep about this incredible bill, Advanced
- 6266 Research Project Agency Health Act, ARPA-H. And I just
- 6267 wanted to say thank you to all of the members who came
- 6268 together and insisted -- and insisted -- on the amendments

- 6269 that eventually became part of what this bill is in its final
- 6270 product on both sides of the aisle.
- And I also want to give a special thank you to
- 6272 Chairwoman Eshoo for her committed insistence on making sure
- 6273 that we not give up. There are many, many good things that
- 6274 have endured one, two, three, four, five congresses and more
- 6275 that have never come to fruition. So I just wanted to say
- 6276 thank you, Ms. Eshoo, for your tenacity.
- 6277 And this is going to save lives. This is truly going to
- 6278 be a continuance of how the United States of America can do
- 6279 things well, and we can actually lead the world. And this is
- 6280 going to be another chapter going forward of how we are going
- 6281 to do that. And it is not about pride, it is not about ego,
- 6282 it is just about doing the right thing as a country. And
- 6283 today we are doing the right thing as Democrats and
- 6284 Republicans.
- So I just wanted to say thank you to everybody who put
- 6286 their heart and soul into this effort.
- And I yield back.
- *Ms. DeGette. I yield back.
- *The Chairman. Thank you.
- And Mr. DeGette yields back. Is there anyone else?
- Dr. Burgess is recognized.
- *Mr. Burgess. Thank you, Mr. Chairman. I would like to
- 6293 be heard on the amendment.

- I do want to also thank Chairwoman Eshoo for her
- 6295 willingness to work on this. I was concerned originally,
- 6296 because the almost unreasonable reliance on the heads of
- 6297 Federal agencies that were going to comprise some part of a
- 6298 super-board to which this ARPA-H would be coupled, I thought
- 6299 that was a mistake, and I really appreciate the flexibility
- 6300 that is now built into the AINS.
- I also am still concerned about what Secretary Becerra
- 6302 said, that this would be on -- basically, collocated with
- 6303 NIH. That is a mistake. That is wrong. This needs to be
- 6304 freestanding.
- And look, it is not often that I agree with the Dallas
- 6306 Morning News, but an editorial a couple of weeks ago
- 6307 suggested that perhaps Texas would be a good location for
- 6308 ARPA-H, and even recommended that Colin Allred and Marc
- 6309 Veasey be champions for moving this to Texas.
- So I just wanted to be the first to say, in a bipartisan
- 6311 fashion, I want to support Congressman Veasey and Congressman
- 6312 Allred in locating the new ARPA-H in the State of Texas.
- I am happy to support this, and I am glad we got it to a
- 6314 good place.
- 6315 I will yield back.
- *The Chairman. Thank you, Dr. Burgess. I am not
- 6317 getting into that.
- 6318 And Mr. Peters is recognized for five minutes.

- *Mr. Peters. Thank you, Mr. Peters of California, by
- 6320 the way, for Dr. Burgess.
- I move to strike the last word.
- *The Chairman. The gentleman is recognized for five
- 6323 minutes.
- *Mr. Peters. Thank you.
- As we all know, President Biden proposed the
- 6326 establishment of ARPA-H in is fiscal year 2022 budget
- 6327 request. I would like now to thank Chair Eshoo for her
- 6328 leadership in introducing this Act, and helping to move the
- 6329 proposal through this legislative process in such a
- 6330 bipartisan way.
- There is no better recent example of the American
- 6332 biomedical sector's strength than its response to the
- 6333 COVID-19 pandemic through development of safe and highly
- 6334 effective vaccines, monoclonal antibody treatments, and other
- 6335 therapeutics. These, along with advances in immunology and
- 6336 across the scientific enterprises, are revolutionary, but
- 6337 they are also stepping stones toward preventing, treating,
- 6338 and curing cancer, Alzheimer's, ALS, and other rare diseases.
- ARPA-H will focus on building out high-risk, high-reward
- 6340 research with the goal of driving breakthroughs in health
- 6341 care to help identify treatments and cures for all patients.
- And the structure of the current biomedical ecosystem
- 6343 creates a few critical gaps that ARPA-H will be able to fill.

- ARPA-H will deliver on unmet needs by using -- use -- by 6344 6345 providing use-oriented pathways for the Federal Government to take on more risk in the high-cost process of developing 6346 drugs and therapies. This includes supporting research that 6347 6348 is too applied for academia and too broad for any company to fully realize its value. The missions will allow the agency 6349 to support projects that are so ambitious they would die in 6350 6351 commercial markets because of the incentive structures built
- And I am also particularly pleased that we are acting on
 ARPA-H today because the agency's work will complement San
 Diego's robust innovation ecosystem, and facilitate the
 robust investments the Federal Government has made in basic
 scientific research over the last decade.

into our biomedical innovation economy.

6352

- So I am proud that, when Congress authorizes ARPA-H as part of the final user fees package, we will begin the process of detecting, preventing, and treating cancers and diseases with the methods and platforms that might not otherwise reach patients.
- I would also like to make a quick note about the mental health package we just considered. I am excited to help pass the Restoring Hope for Mental Health and Well-Being Act of 2022. The New Democrat Coalition recently endorsed a slate of legislation to address mental health and substance use disorders, and I am proud to see some of those bills were

6369 included in the package.

And finally, I will speak on an exciting provision in the Food and Drug amendments that we just reported to the full House. The provision will allow applicants for new drug approval to use alternatives to animal testing as evidential support. Once enacted, applicants will be able to submit data collected through technologies like organ chips, cell-based assays, sophisticated computer modeling, along with other human biology-based testing methods to the FDA.

An organ chip, for example, is a tiny, 3D chip created from human cells that look and function like miniature human organs. Those chips can be used to determine how human systems respond to different chemicals, and to find out exactly what happens during infection or disease because other animals' bodies don't respond to medicines the same ways that ours do. Different organ chips representing heart, liver, lungs, or skin could be linked together to create an integrated human-on-a-chip model that allows researchers to test the impacts of a substance on the human body at large.

These technologies have revolutionized the speed at which we can test for the safety and efficacy of new treatments and therapeutics, and we know that there are methods more predictive of human safety than animal testing. We must strive to use them, because FDA should have access to the most thorough and accurate data when evaluating whether

- or not a drug meets the standards for approval.
- I am proud to say that researchers in San Diego are
- 6396 already using these methods to gain a better understanding of
- 6397 how the human body works, and how best to achieve positive
- 6398 treatment outcomes.
- I look forward to helping this legislation move us
- 6400 toward cures and away from animal testing, as these
- technologies become more widespread.
- And with that, Mr. Chairman, I thank you again for
- 6403 holding the markup and yield my time.
- *The Chairman. I thank the gentleman.
- Does anyone else want to speak on this?
- Mr. Soto is recognized.
- *Mr. Soto. Thank you, Mr. Chair. This is really a
- 6408 historic moment, the development of ARPA-H in a bipartisan
- 6409 fashion.
- 6410 It was 64 years ago that the Defense Advanced Research
- Project Agency was formed developing key military technology
- 6412 under President Eisenhower. The nation was -- just had World
- 6413 War II for a few years, and we knew we had to go to the next
- level to help protect the homeland.
- So now, with the Advanced Research Project Agency for
- 6416 Health Act, we get to do this for other key issues in
- 6417 President Biden's unity agenda that was outlaid in his State
- 6418 of the Union. He talked about the struggles with cancer,

- 6419 with Alzheimer's, with diabetes, many issues that central
- 6420 Florida families face every day, sadly.
- So this bill is going to accelerate innovation in health
- 6422 and medicine by investing in investing in high-risk, high-
- 6423 reward research projects. And we are putting our money where
- our mouth is with \$500 million annually for the next 5 years.
- 6425 Medical innovation has already been astounding over the last
- 6426 few years since I have been in Congress and in the state
- 6427 legislature: COVID-19 vaccines, immunology that is
- 6428 advancing, folks surviving cancer, emergency stroke
- 6429 surgeries, removing blood clots and allowing folks to get
- 6430 back to normal, improving quality of life, stability of
- 6431 families, and extending life spans.
- The lesson is, with an ample amount of funding, with
- 6433 time, and harnessing the power of the -- of American
- innovation, we can do many great things. We have the
- 6435 potential, we simply need the political will to get the job
- done. And with ARPA-H legislation, we have found it. And I
- remain hopeful that we will move forward on many medical
- 6438 miracles on the horizon.
- 6439 And I yield back.
- *The Chairman. Thank you, Mr. Soto.
- Anyone else?
- Okay, we are going to vote. Now, we are voting still on
- the AINS, not on the -- let me get to the final.

- 6444 [Pause.]
- *The Chairman. We are going to have a voice vote on the
- 6446 AINS. If there is no further debate, we will proceed to a
- 6447 vote.
- All those in favor of the Eshoo amendment in the nature
- of a substitute will signify by saying aye.
- Those opposed will say no.
- In the opinion of the chair the ayes have it, and the
- amendment in the nature of a substitute is agreed to.
- We are now going to go to a recorded vote on final
- 6454 passage. A recorded vote is ordered on H.R. -- sending H.R.
- 5585 to the full House.
- Those in favor of reporting H.R. 5585, as amended, to
- the House will say aye, those opposed will --
- *Voice. Aye.
- *The Chairman. No, this is going to be recorded.
- And those opposed will say no.
- The clerk shall call the roll.
- *The Clerk. Mr. Rush?
- *Mr. Rush. Rush votes aye.
- *The Clerk. Mr. Rush votes aye.
- Ms. Eshoo?
- *Ms. Eshoo. Aye.
- *The Clerk. Ms. Eshoo votes aye.
- Ms. DeGette?

- *Ms. DeGette. Aye.
- *The Clerk. Ms. DeGette votes aye.
- Mr. Doyle?
- *Mr. Doyle. Doyle votes yes.
- *The Clerk. Mr. Doyle votes aye.
- Ms. Schakowsky?
- *Ms. Schakowsky. Schakowsky votes aye.
- *The Clerk. Ms. Schakowsky votes aye.
- 6477 Mr. Butterfield?
- *Mr. Butterfield. Butterfield votes aye.
- *The Clerk. Mr. Butterfield votes aye.
- Ms. Matsui?
- *Ms. Matsui. Matsui votes aye.
- *The Clerk. Ms. Matsui votes aye.
- Ms. Castor?
- *Ms. Castor. Ms. Castor votes aye.
- *The Clerk. Ms. Castor votes aye.
- Mr. Sarbanes?
- *Mr. Sarbanes. Sarbanes votes aye.
- *The Clerk. Mr. Sarbanes votes aye.
- Mr. McNerney?
- *Mr. McNerney. McNerney votes aye.
- *The Clerk. Mr. McNerney votes aye.
- Mr. Welch?
- *Mr. Welch. Welch votes aye.

- *The Clerk. Mr. Welch votes aye.
- 6495 Mr. Tonko?
- *Mr. Tonko. Tonko votes aye.
- *The Clerk. Mr. Tonko votes aye.
- 6498 Ms. Clarke?
- [No response.]
- *The Clerk. Mr. Schrader?
- *Mr. Schrader. Schrader votes aye.
- *The Clerk. Mr. Schrader votes aye.
- Mr. Cardenas?
- *Mr. Cardenas. Cardenas of California votes aye.
- *The Clerk. Mr. Cardenas votes aye.
- 6506 Mr. Ruiz?
- *Mr. Ruiz. Ruiz votes aye.
- *The Clerk. Mr. Ruiz votes aye.
- Mr. Peters?
- [No response.]
- *The Clerk. Mrs. Dingell?
- *Mrs. Dingell. Dingell votes aye.
- *The Clerk. Mrs. Dingell votes aye.
- Mr. Veasey?
- *Mr. Veasey. Veasey votes aye.
- *The Clerk. Mr. Veasey votes aye.
- Ms. Kuster?
- *Ms. Kuster. Kuster votes aye.

- *The Clerk. Ms. Kuster votes aye.
- Ms. Kelly?
- *Ms. Kelly. Kelly votes aye.
- 6522 [Pause.]
- *Ms. Kelly. Kelly votes aye.
- *The Clerk. Ms. Kelly votes aye.
- Ms. Barragan?
- *Ms. Barragan. Barragan votes aye.
- *The Clerk. Ms. Barragan votes aye.
- Mr. McEachin?
- *Mr. McEachin. McEachin votes aye.
- *The Clerk. Mr. McEachin votes aye.
- Ms. Blunt Rochester?
- *Ms. Blunt Rochester. Blunt Rochester votes aye.
- *The Clerk. Ms. Blunt Rochester votes aye.
- 6534 Mr. Soto?
- *Mr. Soto. Soto votes aye.
- *The Clerk. Mr. Soto votes aye.
- Mr. O'Halleran?
- 6538 *Mr. O'Halleran. O'Halleran votes aye.
- *The Clerk. Mr. O'Halleran votes aye.
- 6540 Miss Rice?
- *Miss Rice. Rice votes yes.
- *The Clerk. Miss Rice votes aye.
- Ms. Craiq?

- *Ms. Craig. Craig votes yes.
- *The Clerk. Ms. Craig votes aye.
- Ms. Schrier?
- *Ms. Schrier. Schrier votes aye.
- *The Clerk. Ms. Schrier votes aye.
- Mrs. Trahan?
- *Mrs. Trahan. Trahan votes aye.
- *The Clerk. Mrs. Trahan votes aye.
- 6552 Mrs. Fletcher?
- *Mrs. Fletcher. Fletcher votes aye.
- *The Clerk. Mrs. Fletcher votes aye.
- 6555 Mrs. Rodgers?
- *Mrs. Rodgers. [Inaudible.]
- *The Clerk. Mrs. Rodgers votes aye.
- 6558 Mr. Upton?
- *Mr. Upton. Upton votes aye.
- *The Clerk. Mr. Upton votes aye.
- Mr. Burgess?
- *Mr. Burgess. Votes aye.
- *The Clerk. Mr. Burgess votes aye.
- Mr. Scalise?
- [No response.]
- *The Clerk. Mr. Latta?
- 6567 *Mr. Latta. Aye.
- *The Clerk. Mr. Latta votes aye.

- 6569 Mr. Guthrie?
- *Mr. Guthrie. Aye.
- *The Clerk. Mr. Guthrie votes aye.
- Mr. McKinley?
- *Mr. McKinley. [Inaudible.]
- *The Clerk. Mr. McKinley votes aye.
- 6575 Mr. Kinzinger?
- [No response.]
- *The Clerk. Mr. Griffith?
- 6578 *Mr. Griffith. Aye.
- *The Clerk. Mr. Griffith votes aye.
- 6580 Mr. Bilirakis?
- *Mr. Bilirakis. Bilirakis votes aye.
- *The Clerk. Mr. Bilirakis votes aye.
- 6583 Mr. Johnson?
- *Mr. Johnson. Aye.
- *The Clerk. Mr. Johnson votes aye.
- 6586 Mr. Long?
- *Mr. Long. [Inaudible.]
- *The Clerk. Mr. Long votes no.
- 6589 Mr. Bucshon?
- 6590 *Mr. Bucshon. Aye.
- *The Clerk. Mr. Bucshon votes aye.
- 6592 Mr. Mullin?
- 6593 *Mr. Mullin. Aye.

- *The Clerk. Mr. Mullin votes aye.
- 6595 Mr. Hudson?
- *Mr. Hudson. Aye.
- *The Clerk. Mr. Hudson votes aye.
- 6598 Mr. Walberg?
- 6599 *Mr. Walberg. Aye.
- *The Clerk. Mr. Walberg votes aye.
- Mr. Carter?
- *Mr. Carter. Carter votes aye.
- *The Clerk. Mr. Carter votes aye.
- Mr. Duncan?
- 6605 *Mr. Duncan. Aye.
- *The Clerk. Mr. Duncan votes aye.
- Mr. Palmer?
- 6608 *Mr. Palmer. Aye.
- *The Clerk. Mr. Palmer votes aye.
- Mr. Dunn?
- *Mr. Dunn. Mr. Dunn votes aye.
- *The Clerk. Mr. Dunn votes aye.
- 6613 Mr. Curtis?
- *Mr. Curtis. [Inaudible.]
- *The Clerk. Mr. Curtis votes no.
- 6616 Mrs. Lesko?
- *Mrs. Lesko. [Inaudible.]
- *The Clerk. Mrs. Lesko votes no.

- Mr. Pence?
- *Mr. Pence. Aye.
- *The Clerk. Mr. Pence votes aye.
- Mr. Crenshaw?
- 6623 *Mr. Crenshaw. Aye.
- *The Clerk. Mr. Crenshaw votes aye.
- Mr. Joyce?
- *Mr. Joyce. Joyce votes aye.
- *The Clerk. Mr. Joyce votes aye.
- Mr. Armstrong?
- *Mr. Armstrong. Yes.
- *The Clerk. Mr. Armstrong votes aye.
- 6631 Chairman Pallone?
- *The Chairman. Pallone votes aye.
- *The Clerk. Chairman Pallone votes aye.
- *Ms. Clarke. Mr. Chairman?
- *The Chairman. Anyone who is -- yes?
- *Ms. Clarke. Mr. Chairman?
- *The Chairman. Yes?
- *Ms. Clarke. This is Yvette Clarke. How am I recorded?
- *The Clerk. Ms. Clarke is not recorded.
- *Ms. Clarke. Mr. Chairman, Clarke of New York votes
- 6641 aye.
- *The Clerk. Ms. Clarke votes aye.
- *Mr. Schrader. How is Mr. --

- *The Chairman. Is there anyone else --
- *Mr. Schrader. -- [inaudible] recorded?
- *Voice. Great job, Anna.
- *Ms. Eshoo. Thank you.
- *Voice. That was --
- *The Chairman. Who was that?
- *Mr. Schrader. How is Mr. Schrader recorded?
- *The Chairman. Mr. --
- *The Clerk. Mr. Schrader is recorded as aye.
- *Mr. Schrader. Good.
- *The Chairman. You are an aye.
- *Mr. Schrader. Sounds good.
- *The Chairman. Anyone else? Anyone else who is not
- recorded and wants to be recorded?
- *Mr. Peters. Mr. Chairman, Peters, how is Peters
- 6659 recorded?
- *The Chairman. I don't think you are.
- *Mr. Peters. I am aye.
- *The Clerk. Mr. Peters votes aye.
- *The Chairman. Anyone else?
- I think we are -- I think we have got everybody. So the
- 6665 clerk will report the tally.
- *The Clerk. On that vote, Mr. Chairman, the yeas were
- 6667 53 and the nays were 3.
- *The Chairman. Okay, so on H.R. 5585, as amended, the

- vote is 53 ayes to 3 noes. H.R. 5585, as amended, is
- therefore reported to the full House.
- Now, before we adjourn, let me say, you know, when we
- 6672 have these wonderful markups and we all praise each other, it
- 6673 is wonderful. But I really have to say there was a lot of
- 6674 work that went into this over the last few months. And I
- 6675 want to thank not only the members and, of course, the
- 6676 ranking member, Mrs. Rodgers, and Chairwoman Eshoo, and
- 6677 Ranking Member Guthrie for all their hard work, but I also
- 6678 want to particularly pay attention to the staff.
- And I don't have to mention everybody by name, but I
- just want you all to know they spent a tremendous amount of
- 6681 time on weekends, during breaks, you know, during the
- 6682 holidays working to get us where we are today. And it is
- 6683 certainly a -- you know, I know we had a lot of compliments,
- 6684 but it really does show how well this committee works, not
- 6685 only works on a bipartisan basis, but everybody works
- 6686 together to try to accomplish the goal on an individual basis
- with their staff, as well.
- And, you know, somebody mentioned -- you know, made the
- 6689 contrast with the rest of the House and, you know, what goes
- on on the floor. I don't want to get into that, but I do
- 6691 think that we kind of serve as a shining example of not only
- 6692 working hard, but bipartisanship.
- 6693 So I do want to thank the staff and everybody before we

- adjourn.
- I don't know if --
- *Mrs. Rodgers. Yes, yes.
- *The Chairman. -- you would like to say something.
- I recognize the ranking member.
- *Mrs. Rodgers. Yes, yes, for sure.
- 6700 Well, thank you, Mr. Chairman. I want to associate
- 6701 myself with your comments about this markup, the important
- 6702 pieces of legislation that we were able to bring forward to
- 6703 today with strong votes, good debates.
- I join in just expressing gratitude to the members
- 6705 across the aisle for working in a -- working to find that
- 6706 common ground, and a big thank you to the staff also, the
- 6707 work that was done to answer every question, address every
- 6708 detail, late hours, weekends. You know, there is a lot that
- goes on to make this happen today, and it is a tribute to
- 6710 their commitment to addressing these issues that are so
- 6711 important to the people that we have the honor of
- 6712 representing.
- And I too want to just join in thanking the staff.
- 6714 Since you said you weren't going to list them by name, I
- 6715 won't either, but I will thank them.
- [Laughter.]
- *Mrs. Rodgers. Well, I know everyone wants to get out
- 6718 of here, but just a big thank you to all the members, all the

- staff that made this possible today. This is something that we can all be proud of.
- Thank you for your leadership, Mr. Chairman.
- [Applause.]
- *The Chairman. Thank you so much. Thank you, everyone.
- And without objection, the staff is authorized to make
- 6725 technical and conforming changes to the committee prints,
- 6726 consistent with the actions taken by the committee today.
- And with that, the committee stands adjourned.
- [Whereupon, at 3:20 p.m., the committee was adjourned.]